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VooRWooRd
Wat is een proefschrift? 
Volgens de via het wereldwijde web veelvuldig geraadpleegde encyclopedie “Wi-
kipedia” is het een boek, geschreven door een promovendus met daarin een originele 
wetenschappelijke verhandeling over een bepaald onderwerp. Mijn kinderen vroe-
gen mij of het een spannend boek was. De beoordeling daarvan laat ik graag aan de 
lezer, hoewel ik niet de illusie heb dat veel mensen het in het Engels geschreven deel 
van deze dissertatie daadwerkelijk zullen lezen. Toch ga ik een poging wagen u te 
verleiden een nadere blik te werpen op de in eerste instantie wellicht ontoegankelijke 
inhoud.
Aangezien dit verslag, grotendeels bestaande uit een samenvoeging van eerdere 
publicaties in medisch wetenschappelijke tijdschriften, bij ons thuis “papa’s boek” is 
gaan heten, leek een voorwoord mij op zijn plaats.
Hoe komt iemand ertoe een proefschrift te gaan schrijven?
In mijn geval was het de combinatie van behoefte aan verdieping van kennis en 
inzicht in de infectieziekten, de beantwoording van vele vragen betreffende immu-
nologie en een gedreven leermeester en toen nog aanstaand hoogleraar met meer 
ideeën dan ze zelf kan uitwerken. In essentie was het de drijfveer om de taal die 
wordt gesproken tussen mens en ziekteverwekker te kunnen begrijpen. De precieze 
invulling van die exercitie is het aloude verhaal gebleken van het leven dat je over-
komt terwijl je andere plannen maakt, ofwel serendipiteit.
Een hedendaags proefschrift is meestal geen klassieke monografie en dat geldt 
zeker in het onderhavige geval. Ik voel me dan ook bevoorrecht om als auteur van dit 
proefschrift op de voorzijde te mogen staan, terwijl het de vrucht is van vele handen. 
Op de eerste plaats is gebruik gemaakt van materialen en gegevens, geleverd door 
patiënten die hersenvliesontsteking hebben doorgemaakt. Dankzij hun genereuze 
bereidwilligheid is het mogelijk geweest enkele details te ontrafelen in het ingewik-
kelde proces van het verwerven van ziekteverwekkers, de reactie van de gastheer 
daarop en hoe dit samenspel het beloop van de ziekte beïnvloedt: werk voor en door 
patiënten dus! Daarnaast was er de sturende rol van mijn directe begeleiders, die 
me wegwijs hebben gemaakt in het formuleren van onderzoeksvragen, het adequaat 
analyseren van de verzamelde gegevens en die me van de nodige terugkoppeling 
hebben voorzien tijdens het schrijven van artikelen. Zoals u verderop kunt lezen zijn 
er diverse medeauteurs bij de in dit proefschrift samengevoegde artikelen betrokken. 
Ieder heeft zijn of haar bijdrage geleverd, veelal tot uiting komend in de volgorde van 
auteurs, met speciale aandacht voor de artikelen die een gedeeld eerste auteurschap 
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kennen. De onmisbare hulp achter de schermen dient hier ook genoemd te worden 
en de goede lezer vindt de dankbetuigingen daarvoor aan het einde van ieder artikel. 
Wie nog meer te danken? Dit zou ik willen samenvatten onder de noemer 
'inspiratie'. Voor een medicus betekent dit vaak simpelweg inademing en hoewel dit 
op zich de lading dekt, zie ik het toch iets breder. Het is iets dat mij vrijwel dagelijks 
overkomt, eigenlijk al vanaf jonge leeftijd en ik ben ijdel genoeg om te hopen dat 
ik anderen ook kan inspireren. Mijn grootste inspiratiebronnen zijn mijn kinderen 
en degenen aan wie ik dit proefschrift opdraag. Inspiratie komt verder van familie, 
(Maastrichtse en Amsterdamsche) vrienden, leermeesters, (jonge) collega’s en niet in 
de laatste plaatst van de kinderen die tegen wil en dank afhankelijk zijn van onze 
dagelijkse medische zorg.
Het proces dat uitmondt in een proefschrift is meer dan het schrijven van artike-
len of zelfs de pretentie een heus boek geschreven te hebben. Het is een oefening 
in verdieping, samenwerking, volharding en het steeds weer opnieuw uitgedaagd 
worden om buiten de veilige marge te treden van wat men gewend is of wat van 
nature makkelijk gaat. Degene die erin slaagt om van de ene naar de andere fout te 
gaan zonder daarbij zijn enthousiasme te verliezen is volgens de legendarische Britse 
staatsman Churchill succesvol te noemen. Het is ook mijn persoonlijke overtuiging 
dat de makkelijke weg meestal niet de beste is.
Maar welk doel dient dit proces? Wordt iemand een betere arts voor zijn patiënten 
na het afronden van een promotietraject? Dat is een vraag die een genuanceerde 
afweging verdient maar die ik niet zonder meer met een volmondig ‘ja’ kan beant-
woorden. Wordt iemand een betere leraar voor zijn studenten na het verkrijgen van 
de doctorstitel? Dat is niet ondenkbeeldig wanneer men nagaat dat onderzoeksre-
sultaten goed moet worden uitgelegd om voor publicatie in aanmerking te komen. 
Ook moet men zich daarvoor verplaatsen in het lezerspubliek van het betreffende 
tijdschrift. Hiermee worden twee belangrijke competenties van een docent ontwik-
keld. Wordt iemand een betere onderzoeker ten dienste van de maatschappij na 
het verwerven van de hoogste academische graad? Op zich kwalificeert men zich 
voor het zelfstandig opzetten en uitvoeren van wetenschappelijk onderzoek maar de 
praktijk blijkt vaak weerbarstiger en niet zelden gaat iemand na zijn promotie een 
geheel andere richting uit. Het is wel mijn intentie wetenschappelijk actief te blijven 
op het gebied van de pediatrische infectieziekten en immunologie maar dat is op zich 
nog geen garantie om daarin te excelleren. Om te kunnen excelleren wordt het in het 
algemeen van belang geacht te kiezen en kleur te bekennen. Geïnspireerd door de 
ouderwetse ‘uomo universale’, waarvan Leonardo Da Vinci wellicht de beroemdste 
belichaming was, bekwaam ik mij in het generalisme en hou er een holistische visie 
op na, getuige ook mijn keuzes in leven en werk tot nu toe. “Niets wil ik missen want 
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daar is het toch voor…” is een tekst van de Nederlandse zanger, dichter en acteur Van 
der Lubbe en mij op het niet geringe lijf geschreven. 
Wordt iemand dan een beter mens als hij gepromoveerd is? Dat waag ik ten stel-
ligste te betwijfelen en ik weet zeker dat dit niet het geval is in de afrondende fase 
van een dergelijk traject! 
Wat in de Angelsaksische nomenclatuur beter tot uiting komt dan in de Nederlandse, 
is dat het proces dat leidt tot promotie uitdaagt tot reflectie, nuance, relativering en 
bespiegeling, hetgeen iemand uiteindelijk een Philosophers Degree (PhD) oplevert, 
een graad in de filosofie. Dat is een competentie die wellicht van nut en dienst is 
tijdens leven en werk. 
Het spelen van diverse rollen in de spreekkamer, de collegezaal of het congrescen-
trum dan wel universiteitsaula, vormen tezamen het spectrum van de academische 
kinderarts en geven wellicht het begin van een antwoord op de vraag of een dokter 
nu het vak geneeskunde of geneeskunst beoefent. Naar mijn overtuiging zou iedere 
arts moeten ambiëren op kundige wijze kunst te bedrijven. Dit vergt kennis en erva-
ring en minstens zo belangrijk, inleving, betrokkenheid en volharding. Het is geen 
exercitie met duidelijke einddoelen, meer een motto. 
Ik wens u dezelfde competenties toe bij de eventuele lezing van dit manuscript.
Gijs van Well
Maastricht, maart 2012
Ich habe kein besondere Begabung, 
Ich bin nur leidenschaftlicht neugierig. 
 
(Einstein)
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InTRoducTIon
Bacterial meningitis (BM) is a severe and often life threatening infectious disease of 
the central nervous system (CNS) accounting for an estimated annual 170,000 deaths 
worldwide. It mostly affects people at the extremes of the age spectrum, infants and 
children on the one hand, and elderly on the other hand. The case fatality rate is 
estimated between 4 and 10% [1].
The etiology of BM is driven by the age of the affected patient. In neonates the most 
common etiologic pathogens are Group B Streptococcus, Listeria monocytogenes, 
Escherichia coli, and other Gram-negatives [1, 2]. In infants and young children 
worldwide, Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and 
Haemophilus influenzae type b (Hib) are the most common causes of BM. Among 
children older than 5 years of age and adolescents, SP and NM are the predominant 
causes of BM [1]. 
The epidemiology of BM has changed drastically over the last decades. Before 
routine childhood immunizations against Hib were introduced in the late 1980’s and 
early 1990’s, BM was primarily a disease of young children accounting for more than 
half of all BM cases [1, 3, 4]. Currently, the epidemiology of pneumococcal men-
ingitis (PM) is changing due to the introduction of conjugate vaccines against SP in 
most developed countries. Besides protection of young children, it also provides herd 
immunity in adults, although immunity wanes over time so the age distribution of 
BM is momentarily shifting to the older age groups [5]. Introduction of the serogroup 
C meningococcal conjugate vaccine in infancy has reduced disease caused by this 
specific serotype, but did not influence the incidence of BM caused by the serogroups 
A, B, Y and W-135 [1].
The highest risk of BM caused by SP is in infants younger than 2 years old and has 
an incidence of approximately 20 per 100,000 [1]. The incidence of meningococ-
cal meningitis (MM) is greatest in infants younger than 1 year old; a second peak 
incidence is observed at age 15 to 17 years [6]. Incidence rates vary between 1 and 
2 per 100,000. In sub-Saharan Africa, meningococcus serogroup A is a major cause 
of meningitis epidemics [7]. 
In developing countries, Mycobacterium tuberculosis (M. tub) is a common cause 
for BM besides the aforementioned pathogens. In South Africa, where tuberculosis 
(TB) is endemic with 998 cases per 100,000, the incidence of tuberculous meningitis 
(TBM) ranges from 31.5 per 100,000 in children under 1 year of age to 0.7 per 
100,000 in 10-14 year-olds [8].
This thesis consists of two parts and describes studies on the innate immune re-
ponse in (myco) bacterial meningitis. The fist part of this thesis focuses on TBM and 
describes a large retrospective cohort of children with TBM in South Africa, reviews 
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the available animal models to study TBM and presents a new animal model to study 
the immune response in TBM. The second part focuses on BM caused by either NM 
or SP and reviews the role of genetic variability in immune reponse genes in BM 
pathogenesis. It also presents several associations of polymorphisms in innate im-
mune response genes with susceptibility to or severity of BM.
clInIcal pResenTaTIon of BacTeRIal MenInGITIs
Infection of the meninges and cerebrospinal fluid (CSF) is called meningitis. Clini-
cally, meningitis presents as a severe febrile illness with signs of CNS involvement. 
Adults and older children often complain of severe headache and vomiting and pres-
ent with a stiff neck, representing meningeal irritation. Infants usually present with 
inconsolable crying and irritability upon handling and often have a bulging fontanel. 
Both may show signs of altered consciousness.
hIsToRy
These clinical signs are recognized as a disease entity since centuries. The first 
publications date from 1806 by the Swiss physician Viesseux who described a men-
ingitis outbreak in the Geneva area in 1805 [9]. In 1887 an Austrian pathologist 
and bacteriologist called Anton Weichselbaum was the first to isolate the causative 
agent of cerebrospinal meningitis, which he called Diplococcus intracellularis 
meningitidis [10]. Later the pathogen was renamed Neisseria meningitidis because it 
was his German colleague Albert Neisser who discovered Neisseria gonorrhoeae in 
1879, which retrospectively belonged to the same family. A trivial and amusing fact 
given the background of this thesis, is that Neisser also co-discovered the pathogen 
Mycobacterium leprae.
paThoGenesIs and TReaTMenT
In the period that pathogenesis was unclear, treatment of meningitis consisted of 
bed rest, excessive sweating and the application of spiritual liquids. In the tradition 
of phlebotomy, lumbar puncture was introduced in 1891. The American pharmacist 
and pathologist Simon flexner introduced meningococcal antiserum in 1913, which 
he applied intrathecally [11]. This therapy reduced the previous mortality of 100% 
to 31%. With increasing knowledge of disease causing pathogens but mostly by the 
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invention of antimicrobial drugs in the late 1930’s, antibiotic therapy became the 
cornerstone of meningitis therapy and still is today.
However, with increasing knowledge of the details of pathogenesis and the inflam-
matory response with its intriguing ambiguous role of both microbial clearance and 
tissue damage, immunomodulation became the new horizon in meningitis research. 
The first proper study on the use of corticosteroids in meningitis was reported in 1988 
[12]. Until today a lot of debate is going on the role of corticosteroids. A recent meta-
analysis by the Cochrane collaboration concluded that corticosteroids significantly 
reduced hearing loss and neurological sequelae, but did not reduce overall mortality. 
Data support the use of corticosteroids in patients with BM in high-income countries. 
They found no beneficial effect in low-income countries [13]. A Cochrane meta-
analysis of studies in TBM concluded that corticosteroids should be routinely used in 
HIV-negative people with TBM to reduce death and disabling residual neurological 
deficit amongst survivors. However, there is not enough evidence to support or refute 
a similar conclusion for those who are HIV positive [14].
Recently, Koedel et al. reviewed the current knowledge on pathogenesis of BM 
and focused on promising targeted approaches for adjunctive therapy, including 
limiting the release of toxic bacterial products (e.g. killing bacteria softly with non-
bacteriolytic antibiotics) and interfering in the generation of host-derived cytotoxins 
by inducing neutrophilic apoptosis [15]. 
hosT GeneTIcs of BacTeRIal MenInGITIs
The last decade, research on susceptibility and course of infectious diseases has 
shifted from a environmental and microbial point of view to the host and the identifi-
cation of specific genes linked to severity phenotypes of disease [16]. The next chal-
lenge will be to bring this knowledge from the proverbial laboratory bench to patient 
bedside. Data from host-pathogen genomic studies and molecular epidemiologic 
genome-wide association studies should be translated into clinical interventions and 
prevention programs, preferentially targeted to specific individuals at risk, based on 
their genetic profile (personalized healthcare). The field of Public Health Genomics is 
rapidly evolving and embraces the Bellagio statement (2005) which core aim is ‘‘the 
responsible and effective translation of genome-based knowledge and technologies 
into public policy and health services for the benefit of population health’’. In the last 
years this field has progressed enormously.
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aIMs and ouTlIne of ThIs ThesIs
The focus of this thesis is innate immune responses in (myco) bacterial meningitis.
Part one consists of studies on TBM. first, a retrospective cohort study of 554 chil-
dren with TBM in the Western Cape of South Africa is presented. Next, a review sum-
marizes animal models to study TBM. furthermore, an experimental study describing 
a murine model to study the pathogenesis of TBM is presented.
Part two consists of a review summarizing studies on genetic variation of innate 
immune response genes in invasive pneumococcal and meningococcal disease ap-
plied to the pathogenesis of meningitis. Next, four studies will be described focusing 
on the role of single nucleotide polymorphisms (SNPs) in a cohort of 472 survivors 
of BM caused by either NM or SP. The first study describes a SNP in the Toll-like 
receptor 9 gene (TLR9) affecting susceptibility to develop meningitis upon acquisition 
of NM. A second study focuses on TLR9 SNPs determining disease severity and the 
local inflammatory response inside the CNS in survivors of MM. Next, a study on 
BM susceptibility describes a set of SNPs in immune response genes for its respec-
tive potential to influence the development of meningitis upon infection with either 
meningococci or pneumococci. The last study summarizes the relation of SNPs in a 
set of immune response genes for its relation with disease severity in BM survivors, 
especially hearing loss.
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Bij twijfel, 
Altijd terug naar de bron. 
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aBsTRacT
Tuberculous meningitis (TBM) is the most severe extrapulmonary complication of 
tuberculosis, with high morbidity and mortality rates. The objective of this study was 
to assess the relationship between presenting clinical characteristics and outcome of 
pediatric TBM.
We present a retrospective cohort study of all of the children diagnosed with TBM 
in a large university hospital in South Africa between January 1985 and April 2005. 
We compared demographic, clinical, and diagnostic characteristics with clinical 
outcome after 6 months of treatment.
We included 554 patients. Common characteristics on admission were young age 
(82%; <5 years), stage II or III TBM (97%), nonspecific symptoms existing for > 1 
week (58%), poor weight gain or weight loss (91%), loss of consciousness (96%), 
motor deficit (63%), meningeal irritation (98%), raised intracranial pressure (23%), 
brainstem dysfunction (39%), and cranial nerve palsies (27%). Common features 
of TBM on computed tomography scan of the brain were hydrocephalus (82%), 
periventricular lucency (57%), infarctions (32%), and basal meningeal enhancement 
(75%). Clinical outcome after 6 months was as follows: normal (16%), mild sequelae 
(52%), severe sequelae (19%), and death (13%). All of the patients diagnosed with 
stage I TBM had normal outcome. factors associated with poor outcome in univariate 
analyses were as follows: African ethnicity, young age, HIV co-infection, stage III 
TBM, absence of headache and vomiting, convulsions, decreased level of conscious-
ness, motor deficits, cranial nerve palsies, raised intracranial pressure, brainstem 
dysfunction and radiographic evidence of hydrocephalus, periventricular lucency, 
and infarction. Ethnicity, stage of disease, headache, convulsions, motor function, 
brainstem dysfunction, and cerebral infarctions were independently associated with 
poor outcome in multivariate logistic regression analysis.
TBM starts with non-specific symptoms and is often only diagnosed when brain 
damage has already occurred. Earlier diagnosis will improve outcome significantly. 
We were able to identify presenting variables independently associated with poor 
clinical outcome.
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BackGRound
Two billion people are infected with Mycobacterium tuberculosis (M. tub), and each 
year 9 million people develop tuberculosis (TB) [1]. Although the incidence of TB is 
increasing, prevalence and mortality rates are declining. Annually, ∼2 million people 
die as a result of this disease [2]. 
Tuberculous meningitis (TBM) is the most severe complication of TB and frequently 
occurs in childhood. Lymphohematogenous spread from a primary pulmonary focus 
leads to the development of a Rich focus in the brain. Rupturing of this caseous 
granuloma into the subarachnoid space causes 3 features responsible for the clinical 
manifestations of TBM: development of further tuberculomas; basal inflammatory 
exudates that cause cranial nerve palsies and obstruct CSf pathways, resulting in 
hydrocephalus; and obliterative vasculitis, which leads to infarctions [3]. Once the 
Rich focus has ruptured, a prodromal period of nonspecific symptoms, such as fever, 
vomiting, and behavioral changes, develops. As the disease progresses, neck stiffness, 
loss of consciousness, motor deficits, and convulsions will follow. The diagnosis is 
often only considered once irreversible neurologic damage has already occurred [4]. 
The Western Cape Province has the highest incidence of TB in South Africa (998 
per 100 000) and a 1.9% prevalence of HIV. HIV coinfection increases the risk of 
developing TBM and leads to more complications and a higher case fatality rate [5,6]. 
Incidence rates of TBM are age specific and range from 31.5 per 100 000 (< 1 year) 
to 0.7 per 100 000 (10–14 years) in the Western Cape Province [7]. 
paTIenTs and MeThods
study design
The objective of this study was to assess the relationship between presenting clinical 
characteristics and outcome of pediatric TBM. All of the children diagnosed with 
TBM at Tygerberg Hospital, a large university hospital in Cape Town, between January 
1985 and April 2005, were included in this retrospective cohort study. We compared 
demographic, clinical, and diagnostic data on admission and clinical outcome after 
6 months of treatment.
demographic data
Demographic data include gender, race and age, HIV coinfection, Bacille Calmette-
Guerin (BCG) immunization, and possible TB contact. We used the Road-to-Health 
Card for data collection. This is a record of immunizations and growth rate, widely used 
in South Africa to monitor the development of the child until he or she is 5 years old [8]. 
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diagnostic criteria
A definite diagnosis of TBM is made when M. tub is isolated from CSf. In all other 
cases, the diagnosis is “probable TBM” based on clinical signs of meningitis in the 
presence of characteristic CSF findings (macroscopically clear, pleocytosis, elevated 
protein, and reduced glucose). In addition, ≥2 of the following criteria have to be 
present: (1) recent poor weight gain (crossing of percentiles on Road-to-Health 
Card); (2) household contact with sputum smear-positive TB patient; (3) computed 
tomography (CT) scan compatible with TBM; (4) chest radiography compatible with 
primary TB; (5) positive tuberculin skin test; and (6) other clinical specimens positive 
for acid-fast bacilli.
clinical data
We scored stage of disease, duration of symptoms before admission, type of present-
ing symptoms, nutritional state, Glasgow Coma Scale (GCS) score, motor function, 
and presence of other neurologic signs. TBM was staged using the modified criteria 
of the British Medical Research Council to determine the severity of TBM: stage I TBM 
(GCS 15 with no focal neurologic signs), stage II TBM (GCS 11–14 or GCS of 15 with 
focal neurologic deficit), and stage III TBM (GCS  < 11) [9]. 
Motor function was classified as normal, left hemiparesis, right hemiparesis, quadri-
paresis, or other deficits. Other neurologic signs were meningeal irritation, signs of 
raised intracranial pressure (bulging fontanel, sun setting sign, and papill edema), 
signs of brainstem dysfunction (unequal or nonreactive pupils, absent oculocephalic 
reflex, decerebration, or neurogenic hyperventilation), and cranial nerve palsies.
diagnostic data
Radiography
On CT scan images we scored hydrocephalus, expressed as the ratio between ven-
tricular and bi-parietal diameters of the cerebral ventricles (VP-ratio), periventricular 
lucency (white matter changes because of hydrocephalus), basal meningeal enhance-
ment, infarctions, and tuberculomas. Limited air encephalography was used to deter-
mine the level of CSf obstruction by injecting 5 to 10 mL of air into the lumbar CSf 
space during lumbar puncture. Air demonstrated in the ventricular system on a skull 
radiograph is indicative of communicating hydrocephalus (CH), whereas air trapped 
at the basal cisterns without entering the ventricles proves non-communicating 
hydrocephalus (NCH). Chest radiographic findings suggestive for TB include medias-
tinal lymphadenopathy, segmental infiltration and/or collapse, cavitation, or pleural 
effusion.
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Microbiology
Isolation of M. tub from CSF makes a definite diagnosis of TBM. Isolation of M. tub 
from gastric aspirate, bronchial aspirate, sputum, or lymph node, combined with 
clinical suspicion of TBM, adds strongly to the diagnosis.
Tuberculin skin test
The Mantoux skin test is regarded positive as defined by guidelines of the World 
Health Organization: in high-risk children (including HIV-infected children and 
severely malnourished children), ≥ 5 mm of induration, and in all other children 
(whether they have received a BCG vaccination or not), ≥ 10 mm of induration [10]. 
Treatment of tuberculous meningitis
Cornerstones of TBM treatment are antimycobacterial drugs, immunomodulation, 
and management of hydrocephalus. We used an intensive short-course regimen of 
daily isoniazid (20 mg/kg), rifampicin (20 mg/kg), pyrazinamide (40 mg/kg), and 
ethionamide (20 mg/kg) for 6 months. Prednisone (2 mg/kg per day) was given for the 
first month of treatment and then gradually discontinued over the next 2 weeks. We 
treat NCH with a ventriculoperitoneal shunt (VPS) and CH with diuretics (50 mg/kg 
per day of acetazolamide and 1 mg/kg per day of furosemide). CH not responding to 
diuretics within 4 weeks is treated with a VPS [11]. 
outcome of tuberculous meningitis
After completing 6 months of therapy, motor function, intelligence, vision, and hear-
ing was tested. The Bayley test, Griffiths test, or Junior South African Individual Scale, 
depending on the age of the child, was used to measure IQ. Patients were grouped as 
“normal” (IQ: > 80), “mild intellectual impairment” (IQ: 50–80), or “severe intellec-
tual impairment” (IQ: < 50). Vision and hearing were classified as normal, impaired 
vision or hearing, and blindness or deafness. We divided neurologic outcome into 
4 categories: (1) normal, including normal motor function, intelligence, vision, and 
hearing; (2) mild sequelae, including hemiparesis, mild intellectual impairment, and 
impaired vision and/or hearing; (3) severe sequelae, including quadriparesis, severe 
intellectual impairment, blindness, and/or deafness; and (4) death. Clinical outcome 
was defined as “good” in the case of mild neurologic sequelae or normal neurologic 
outcome and defined “poor” in the case of severe neurologic sequelae or death.
statistical analyses
SPSS 13.0 (SPSS Inc, Chicago, IL) has been used for statistical analyses. Statistical 
significance was determined at the 5% level. We used the χ2 test and relative risks in 
univariate analyses to determine which variables were associated with poor clinical 
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outcome. To study the independent effect of variables, we used multivariate logistic 
regression analysis. All of the variables with a P-value of < 0.2 were included one 
by one in a multivariate logistic regression model, starting with the variables with 
the smallest P-value. Different models were made, with and without variables, with 
high percentages of missing values. All of the variables with a P-value of < 0.2 were 
kept in the model. We calculated the area under the curve (AUC) as a measure of the 
discriminative ability to distinguish between patients with good and poor outcome. 
An AUC of ≥ 0.7 is generally considered to be adequate. The ethical committee of the 
University of Stellenbosch faculty of Health Sciences approved this study.
ResulTs
demographic data
Boys and girls were equally affected (Table 1). TBM has a higher incidence in the Af-
rican and Colored population of South Africa. Most of the children were very young 
(82% < 5 years of age).
clinical data
Most patients had stage II or III TBM and had nonspecific symptoms existing for 
> 1 week (Table 2). On admission, the majority of patients had poor weight gain, 
decreased level of consciousness, and any type of motor deficit. Meningeal irritation 
was present in 98% and signs of raised intracranial pressure in 23% of patients. 
Thirty-nine percent of patients had ≥ 1 sign of brainstem dysfunction. Cranial nerve 
palsies occurred in 27% of children.
diagnostic data
Hydrocephalus was often present, as indicated by abnormal VP-ratios (Tables 3 and 
4). Periventricular lucency and basal meningeal enhancement were found in > 50% 
of patients. Tuberculomas were found in a minority of patients. Eighty-three percent 
of patients underwent limited air encephalography, demonstrating that CH occurred 
twice as often as NCH. Chest radiography results often showed abnormalities suspect 
for TB. Culture for M. tub was from any type of origin was positive in 30%; in only 
12% of patients M. tub was isolated from the CSf. The tuberculin skin test was posi-
tive in 60% of patients. Lymphocyte counts and protein levels in CSf were elevated, 
and the CSF/blood glucose ratio was reduced.
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Table 1.  Demographic data
Variable data association With poor outcomeª
Gender n = 553b n = 412c
 Male, n, % 290, 52.4 RR: 1.0 (Cl:0.7-1.3); P = .96
 female, n, %d 263, 47.6
Race n = 552b n = 412c
 African, n, % 113, 20.5 RR:1.5 (Cl:1.1-2.0); P = .02
 Black (mixed), n, %d 439, 79.5
 European and Asian, n, % 0, 0.0
Age on admission n = 546b n = 409c
 Median and range 28 mo (2-180)
 0-1 y, n, % 108, 19.8 RR: 2.9 (Cl: 1.6-5.6); P <.001
 1-2 y, n, % 129, 23.6 RR: 3.0 (Cl: 1.6-5.5); P <.001
 2-5 y, n, % 209, 38.3 RR: 1.9 (Cl: 1.0-.6); P = .03
 >5 y, n, %d 100, 18.3
HIV infection n = 213b n = 188c
 Positive, n, % 8, 3.8 RR: 2.3 (Cl: 1.2-4.2); P = .05
 Negative, n, %d 205, 96.2
BCG documented n = 244b n = 199c
 Yes, n, %d 236, 96.7
 No, n, % 8, 3.3 RR: 1.4 (Cl:0.6-3.4); P = .50
BCG scar n = 488b n = 390c
 Yes, n, %d 136, 27.9
 No, n, % 352, 72.1 RR: 1.0 (Cl: 0.7-1.4); P = .94
TB contact n = 554b n = 412c 
 Known, n, % 295, 53.2 RR: 0.9 (Cl: 0.7-1.2); P = .57
 Unknown, n, %d 259, 46.8
RR indicates relative risk; Cl, 95% confidence interval; P, P value of X
2  test.
a Data indicate poor outcome: death or severe sequelae (quadriparesis, severe 
intellectual impairment, blindness, and/ or deafness).
b Variable is known for this number of patients. 
c  Variable and outcome are known for this number of patients.
d Data show the reference group.
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Table 2.  Clinical data on admission
Variable data association With poor outcomeª
TBM staging n = 548b n = 406c
 Stage I, n,% 14, 2.6 No poor outcome in stage I
 Stage II, n,%d 314, 57.3
 Stage III, n,% 220, 40.1 RR: 4.0 (Cl: 2.9-5.5); P < .001
Duration of symptoms n = 530b n = 395c
 Median and range, d 9 (1-122)
 0-7 d, n,% 225, 42.5 RR: 1.0 (Cl: 0.6-1.5); P = .84
 8-14 d, n,% 168, 31.7 RR: 0.9 (Cl: 0.6-1.4); P = .60
 15-21 d, n,% 78, 14.7 RR: 0.8 (Cl: 0.4-1.3); P = .34
 >21 d, n,%d 59, 11.1
Presenting symptoms n = 509b n = 385c
 Decreased consciousness, n,% 356, 69.9 RR: 1.3 (Cl: 0.9-2.0); P = .12
 fever, n,% 339, 66.6 RR: 0.9 (Cl: 0.6-1.2); P = .34
 Vomiting, n,% 269, 52.8 RR: 0.6 (Cl: 0.4-0.8); P = .001
 Malaise, n,% 263, 51.7 RR: 0.9 (Cl: 0.7-1.2); P = .54
 Convulsion, n,% 240, 47.2 RR: 1.8 (Cl: 1.3-2.4); P <.001
 Weight loss, n,% 236, 46.4 RR: 0.9 (Cl: 0.7-1.3); P = .70
 Cough, n,% 164, 32.2 RR: 1.1 (Cl: 0.8-1.6); P = .38
 Weakness, n,% 157, 30.8 RR: 1.2 (Cl: 0.9-1.7); P = .19
 Headache, n,% 128, 25.1 RR: 0.4 (Cl: 0.3-0.7); P <.001
 Nutritional state n = 232b n = 186c
 Consistent weight gain, n,%d 22, 9.5
 Poor weight gain, n,% 106, 45.7 RR: 3.0 (Cl: 0.8-11.2); P = .06
 Weight loss, n,% 104, 44.8 RR: 2.5 (Cl: 0.7-9.8); P = .13
GCS n = 553b n = 412c
 Median and range, n,% 10 (3-15)
 15, n,%d 22, 4.0
 12-14, n,% 217, 39.2 RR: 2.0 (Cl: 0.3-13.8); P = .48
 9-11, n,% 120, 21.7 RR: 5.0 (Cl: 0.7-34.2); P = .04
 ≤8, n,% 194, 35.1 RR: 10.0 (Cl: 1.5-67.0); P <.001
Motor function n = 554b n = 408c
 Normal, n,%d 204, 36.8
 Left hemiparesis, n,% 107, 19.3 RR: 1.6 (Cl: 0.8-3.1); P = .15
 Right hemiparesis, n,% 99, 17.9 RR: 3.9 (Cl: 2.3-6.6); P <.001
 Quadriparesis, n,% 138, 24.9 RR: 5.9 (Cl: 3.6-9.6); P <.001
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Treatment of tuberculous meningitis
All 554 of the children received antimycobacterial drugs, and 68% received cortico-
steroids (Table 5). The majority of children with CH were treated with diuretics only 
(75%). Patients with CH not responding to diuretic treatment within a month received 
a VPS (18%).
outcome
Only a small group of children (16%) was not affected by TBM (Table 6). Vision was 
affected in 14% and hearing in 16% of the children. A large group of children had 
motor deficits (44%) and intellectual impairment (77%). The deceased children died 
of cerebral herniation, infarction, cardio-respiratory arrest, shunt infection/obstruc-
tion, or pneumonia.
In a previous study, which described a subgroup of the current study population, 
we reported that we could not associate mycobacterial genotype with clinical char-
acteristics and outcome of TBM [12]. from other studies we know that there is no 
evidence for strain-specific central nervous system tropism in humans [13]. 
 Other (mono/paraparesis), n,% 6, 1.1 RR: 2.3 (Cl: 0.4-13.2); P = .38
Meningeal irritation n = 460b Too small number (n = 3) of patients followed up 
with absence of meningeal irritation on admission to 
test association with poor outcome
 Present, n,% 445, 98.1
 Absent, n,% 15, 1.9
Raised intracranial pressure n = 552b n = 412c
 Present, n,% 125, 22.6 RR: 1.7 (Cl: 1.2-2.2); P = .002
 Absent, n,%d 427, 77.4
Brainstem dysfunction n = 554b n = 412c
 Present, n,% 214, 38.6 RR: 3.0 (Cl: 2.2-4.1); P < .001
 Absent, n,%d 340, 61.4
Cranial nerve palsies n = 541b n = 400c
 Present, n,% 145, 26.8 RR: 1.5 (Cl: 1.1-2.0); P = .01
 Absent, n,%d 396, 73.2
RR indicates relative risk; Cl, 95% confidence interval; P, P value of X
2  test.
a Data indicate poor outcome: death or severe sequelae (quadriparesis, severe intellectual impairment, 
blindness, and/ or deafness).
b Variable is known for this number of patients. 
c  Variable and outcome are known for this number of patients.
d Data show the reference group. 
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Table 3.  Diagnostic data on admission
Variable data association With poor outcomeª
CT: VP ratio n = 237b n = 223c
 Mean and range 0.24 (0.08-0.53)
 Abnormal: VP ratio 165, 69.6 RR: 1.4 (Cl: 0.8-2.2); P = .19
  >0.200, n,%
 Normal: VP ratio ≥0.200, n,%d 72, 30.4
CT: periventricular lucency n = 515b n = 393c
 Present, n,% 292, 56.7 RR: 1.5 (Cl: 1.1-2.1); P = .01
 Absent, n,%d 223, 43.3
CT: infarctions n = 516b n = 394c
 Present, n,% 164, 31.8 RR: 2.2 (Cl: 1.6-2.9); P < .001
 Absent, n,%d 352, 68.2
CT: basal meningitis n = 517b n = 394c
 enhancement
 Present, n,% 387, 74.9 RR: 1.2 (Cl: 0.8-1.7); P = .40
 Absent, n,%d 130, 25.1
CT: tuberculomas n = 509b n = 386c
 Present, n,% 66, 13.0 RR: 1.1 (Cl: 0.7-1.6); P = .83
 Absent, n,%d 443, 87.0
Chest radiography n = 536b n = 404c
 Miliary tuberculosis, n,% 66, 12.3 RR: 1.4 (Cl: 0.9-2.1); P = .12
 Other abnormalities, n,% 249, 46.5 RR: 1.2 (Cl: 0.9-1.6); P = .32
 Normal, n,%d 221, 41.2
Air encephalography n = 553b n = 402c
 Communicating, n,% 310, 57.5 RR: 4.3 (Cl: 2.0-9.4); P < .001
 Noncommunicating, n,% 135, 25.0 RR: 3.5 (Cl: 1.6-8.0); P = .001
 No hydrocephalus, n,%d 94, 17.4
Culture n = 554b n = 412c
 Positive from CSf, n,% 64, 11.7 RR: 0.9 (Cl: 0.5-1.4); P = .57
 Positive from other origin, n,% 104, 18.6 RR: 1.1 (Cl: 0.8-1.6); P = .48
 Negative/not tested, n,%d 386, 69.7
Mantoux test n = 500b n = 380c
 Positive, n,% 304, 60.8 RR: 0.9 (Cl: 0.6-1.2); P = .39
 Negative, n,%d 196, 39.2
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legend to table 3
RR indicates relative risk; Cl, 95% confidence interval; P, P value of X
2  test, V, ventricular diameter at 
midportion of the lateral ventricles; P, biparietal diameter from inner table to inner table.
a Data indicate poor outcome: death or severe sequelae (quadriparesis, severe intellectual impairment, 
blindness, and/ or deafness).
b Variable is known for this number of patients. 
c  Variable and outcome are known for this number of patients.
d Data show the reference group. 
Table 4.  CSf findings on admission
Variable data association With poor outcomeª
Lymphocytes n = 514b n = 386c
 Median of range, cells per µL 97 (0-1213)
 Normal: 0-10 cells per µL, n,%d 50, 9.7
 Abnormal: >10 cells per µL, n,% 464, 90.3 RR: 0.9 (Cl: 0.5-1.3); P = .52
Polymorph leukocytes n = 512b
 Median of range, cells per µL 10 (0-684)
Protein n = 504b n = 377c
 Median of range 1.6 g/L (0.1-109.0)
 Normal: ≤0.8 g/L, n,%d 85, 16.9
 Abnormal: >0.8 g/L, n,% 419, 83.1 RR: 1.2 (Cl: 0.8-1.9); P = .45
Glucose in serum n = 171b n = 123c
 Median of range, mmol/L 6.2 (2.0-21.7)
 Normal: 3.3-7.8 mmol/L, n,%d 141, 81.5
 Abnormal: <3.3 mmol/L, n,% 2, 1.2 RR: 1.5 (Cl: 1.0-2.4); P = .34
 Abnormal: >7.8 mmol/L, n,% 30, 17.2 Abnormal groups are combined 
together 
Glucose in CSf n = 471b
 Median of range, mmol/L 1.7 (0.0-8.6)
 CSF/blood glucose ratio n = 172b n = 122c
 Median of range,% 26 (0-92)
 Normal: 60%-80% n,%d 10, 5.8
 Abnormal: <60%, n,% 159, 92.5 RR: 0.9 (Cl: 0.3-2.8); P = .83
 Abnormal: >80%, n,% 3, 1.7 Abnormal groups are combined 
together
RR indicates relative risk; Cl, 95% confidence interval; P, P value of X
2  test.
a Data indicate poor outcome: death or severe sequelae (quadriparesis, severe intellectual impairment, 
blindness, and/ or deafness).
b Variable is known for this number of patients. 
c  Variable and outcome are known for this number of patients.
34 Chapter 2
Table 5.  Treatment of TBM
Variable data association With poor/fatal 
outcomeª
Antimycobacterial drugs n = 554b
 Yes, n,% 554, 100.0
 No, n,% 0, 0.0
Treatment of hydrocephalus n = 409c
 Communicating n = 310b
  Diuretics, n,% 233, 75.3 RR: 3.3 (Cl: 1.5-7.3); P = .001
  Diuretics and shunt, n,% 56, 18.0 RR: 6.8 (Cl: 3.0-15.3); P <.001
  No treatment, n,%d 21, 6.8 RR: ∞; only poor outcome
 Non-communicating n = 135b
  Shunt, n,% 122, 90.4 RR: 3.5 (Cl: 1.6-8.0); P = .001
  Diuretics, n,%e 11, 8.1 RR: 1.6 (Cl: 0.2-11.6); P = .64
  No treatment, n,%d 2, 1.5 RR: ∞; only poor outcome
No hydrocephalus n = 94b
 No treatment, n,%f 94, 100.0
Corticosteroids n = 554b n = 412c
 Yes, n,%f 374, 67.5
 No, n,% 180, 32.5 Poor outcome: RR: 1.2 (Cl: 0.8-
1.6); P = .39
fatal outcome: RR: 2.5 (Cl: 1.7-
3.7; P <.001
RR indicates relative risk; Cl, 95% confidence interval; P, P value of X
2  test.
a Data indicate poor outcome: death or severe sequelae (quadriparesis, severe intellectual impairment, 
blindness, and/ or deafness).
b Variable is known for this number of patients. 
c  Variable and outcome are known for this number of patients.
d Data show children with severe brain damage on admission who did not receive treatment for their 
hydrocephalus because it would not improve their outcome.
e Data include 11 children with NCH, and open fontanelles were treated with diuretics because 
intracranial pressure [ICP] could be monitored clinically. five of these children received a shunt after 
1 month, because treatment with only diuretics was not successful..
f Data show the reference group. 
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Table 6.  Outcome at follow-up after 6 months of treatment
Variable data
Visiona n = 374b
 Normal, n,% 322, 86.1
 Loss of vision, n,% 20, 5.3
 Blindness, n,% 32, 8.6
Hearinga n = 348b
 Normal, n,% 292, 83.9
 Loss of hearing, n,% 55, 15.8
 Deafness, n,% 1, 0.3
Motor functionsa n = 450b
 Normal, n,% 254, 56.4
 Left hemiparesis, n,% 73, 16.3
 Right hemiparesis, n,% 59, 13.1
 Quadriparesis, n,% 60, 13.3
 Other deficits, n,% 4, 0.9
IQa n = 359b
 Mean and range 64 (2-116)
 Normal: <80, n,% 82, 22.8
 Mild impairment: 50-80, n,% 207, 57.7
 Severe impairment: <50, n,% 70, 19.5
Total outcome n = 359b
 Normal, n,% 65, 15.8
 Mild sequelae, n,% 217, 52.6
 Severe sequelae, n,% 77, 18.7
 Death, n,% 53, 12.9
Time admission to deathd n = 51b
 Median of range, days 23 (2-1466)
 0-7, d, n,% 14, 27.5
 8-30, d, n,% 15, 29.4
 30-90, d, n,% 10, 19.6
 >90, d, n,% 12, 23.5
a  After 6 months, 53 children died; the maximum amount of children at follow-up is 501.
b Variable is known for this number of patients.
c  The outcome is determined by the combination of motor functions, IQ scores, vision, and hearing 
(for 98 children, vision and/or hearing is unknown).
d At follow-up, 53 children died; 4 other children died after >6 months. For 51 children, the exact date 
of death is known. 
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prediction of poor outcome
Associated with poor outcome in the univariate analyses are African ethnicity, young 
age, HIV coinfection, stage III TBM, absence of headache, absence of vomiting, 
convulsions, decreased consciousness, motor deficits, raised intracranial pressure, 
brainstem dysfunction, cranial nerve palsies, periventricular lucency, cerebral infarc-
tions, and hydrocephalus (Tables 1–5 and 7). The absence of corticosteroids in TBM 
treatment was associated with fatal outcome in this study for all stages of disease. 
We did not find a threshold of days after which corticosteroids were no longer effec-
tive. However, we found lower mortality with corticosteroids but not a better clinical 
outcome: the patients survived but with severe neurologic sequelae.
In multivariate analyses, slightly different models were found depending on the 
variables that were entered first in the models and the inclusion or exclusion of 
variables with missing values. Seven variables entered all of the models and were 
included in the final model to predict poor clinical outcome. These were race, stage 
of disease, convulsions, headache, motor functions, brainstem dysfunction, and 
cerebral infarctions, as shown in Table 7. The AUC of the model was 0.84 (95% 
confidence interval: 0.80–0.89).
dIscussIon
This study confirms that TBM mainly affects young children, because 82% of our co-
hort was < 5 years of age. The mean age of 37 months is comparable to other studies, 
with mean ages ranging from 23 to 49 months [14-18]. Young age at presentation and 
the nonspecific nature of presenting symptoms partly explain the difficulty of early 
Table 7.  Multivariable Logistic Regression Analysis
Variable Odds Ratio, 95% Confidence 
Interval
P
Racea 2.6, 1.3-5.4 .008
Stageb 4.8, 2.7-8.7 <.001
Convulsion 1.5, 0.8-2.6 .07
Headache 2.0, 0.9-4.2 .18
Motor functionsc 1.8, 0.9-3.7 .10
Brainstem dysfunction 2.9, 1.6-5.1 <.001
Infarctions on CT scan 2.6, 1.4-4.6 .001
a Data show African versus Colored.
b Data show stage III versus stage I or II.
c Data show any type of motor deficit versus normal.
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diagnosis. Presentation is often subacute, and the early symptoms of stage I TBM, 
such as low-grade fever, cough, vomiting, and general apathy, are often wrongly 
interpreted [19]. This delay in diagnosis and start of TB treatment are supported by 
the finding that 57% of our cohort were unwell for > 7 days before admission. We 
demonstrated previously that missed opportunities for early diagnosis rather than 
late presentation or inaccessibility to medical care are the most common cause for 
delayed diagnosis of childhood TBM [20]. According to the literature, the duration of 
symptoms before diagnosis of TBM ranges between 13 and 42 days [16,18,21-23]. 
Recent poor weight gain is a valuable clue to early diagnosis of pediatric TBM in 
areas where TB is endemic [8]. This observation is confirmed by the present study, 
which showed that 90% of patients had either weight loss or poor weight gain for 
weeks to months before presentation.
Once TBM progresses to stage II and III disease, neck stiffness will almost always 
be present, as was the case in 98% of our patients. The CSf results in our patients 
emphasize that the majority of patients with TBM will have a low, predominantly 
lymphocyte CSf pleocytosis in the presence of a raised protein level and reduced 
CSF/blood glucose ratio. These CSF findings, especially if culture negative, are highly 
suggestive of TBM in areas with a high prevalence rate of TB. We have shown previ-
ously that as many as 11% of TBM patients are wrongly treated for bacterial meningitis 
on account of the results of the first lumbar puncture [20]. CSF changes in TBM take 
long to normalize, and serial CSF findings may, therefore, retrospectively differentiate 
TBM from other types of meningitis where the CSf normalizes much quicker [24]. 
The prevention of TBM is as important as early diagnosis. fifty-three percent of our 
patients had contact with a household adult with proven pulmonary TB, which is 
comparable with the 51% to 69% reported rates of other studies [14-18,23]. Undi-
agnosed and untreated TB is considered an important risk factor in the spread of the 
disease and the development of TBM. A history of close contact with a patient with 
proven TB is important in early diagnosis of TBM, especially at the stage when only 
nonspecific symptoms are present.
Delayed treatment of TBM because of missed diagnosis will result in progression 
to stage II and III disease with high morbidity and mortality rates. In our study, only 
16% of patients did not have sequelae, 71% had any type of sequelae, and 13% of 
the children died as a consequence of TBM. This agrees with other studies in the 
literature, which showed normal outcome in 11% to 61%, sequelae in 13% to 75%, 
and death in 7% to 57% [14-18,21-23]. The poor outcome found in TBM patients 
who were HIV coinfected (25% mortality and 25% severe sequelae) in this study is in 
agreement with the literature.
Corticosteroids reduce mortality but do not significantly alter the long-term se-
quelae of TBM. Children who would otherwise die without corticosteroids will now 
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survive with severe sequelae. The benefit of corticosteroids in TBM is proven by sev-
eral studies, but the mechanism is unknown. Corticosteroids do reduce brain edema 
and might reduce cytokine production and subsequent brainstem encephalopathy. 
The adjuvant treatment with corticosteroids in these studies led to improved survival 
but not to a decrease in motor deficits [25-27]. 
It is impossible to determine the role of possible multidrug-resistant (MDR) tuber-
culosis on the outcome of our patients, because only 12% were culture positive, 
and drug resistance testing was not routinely done. Selective drug resistance testing, 
however, showed that MDR in our hospital-based childhood population is ∼12% and 
has not changed significantly over the last decade [28]. 
The optimal length of therapy in TBM has not been established, because there are no 
data from randomized controlled trials. We treated patients with TBM for 6 months. 
The basis of our regimen is a prospective study published in 1998 [29]. We are aware 
of other recommendations advising treatment up to 9 or 12 months [30,31]. World 
Health Organization guidelines for national programs advise an intensive phase of 
treatment with isoniazid, rifampicin, pyrazinamide, and streptomycin for 2 months 
and a continuation phase with the first 2 drugs for 4 months. They consider our 
6-month regimen with ethionamide instead of streptomycin as an adequate alterna-
tive [10]. 
Hydrocephalus is a common complication of TBM, occurring in 57% to 99% of pa-
tients [15-18]. We found hydrocephalus, diagnosed as a VP ratio of > 0.2, in 70% of 
patients. Although modern neuroimaging has improved the diagnosis of tuberculous 
hydrocephalus significantly, the literature regarding its management is confusing. 
Over the past 20 years, we based the treatment on the level of CSf block determined 
by limited air encephalography, as described by Lorber [32]. We resorted to this 
technique because modern neuroimaging, including CT and magnetic resonance 
imaging (MRI) of the brain, does not differentiate between CH (basal cistern block) 
and NCH (fourth ventricular outlet obstruction), because both cause panventricular 
dilatation. This study confirms our previous observation that only ∼25% of patients 
with tuberculous hydrocephalus have NCH with a risk for herniation and are in need 
of an emergency VPS. The rest have CH, which generally responds well to a trial of 
diuretic therapy, as did 75% of patients in the present study. Hydrocephalus that does 
not become compensated within a month on medical treatment is treated with a 
VPS. This approach to the management of tuberculous hydrocephalus has many obvi-
ous advantages in a resource-poor setting. These not only include huge cost savings 
but also decreased patient morbidity and mortality. Shunt obstruction in a shunt-
dependent child may be fatal because of limited access to neurosurgical services 
in rural areas. We showed previously that clinical outcome in patients who were 
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immediately shunted for tuberculous hydrocephalus and those first treated medically 
did not differ significantly [11]. 
Our mortality rate of 13% is exceptionally low. This could be explained by a num-
ber of factors, including directly observed therapy, active treatment of hydrocephalus, 
and low rate of HIV coinfection and MDR TB in our population. However, the very 
high morbidity rate (only 16% had normal outcome) emphasizes the importance 
of stage of disease when treatment is begun. Most factors found to correlate with 
poor outcome in TBM can be directly traced to the degree of disease progression at 
the time of diagnosis. This applies to both clinical and radiologic characteristics of 
the disease. This dismal outcome of TBM will only improve when the diagnosis and 
initiation of treatment are made earlier. All of our patients with stage I disease had 
normal neurologic outcome, and deaths did not occur in this group.
conclusIons
TBM affects mainly children < 5 years of age. Presentation is often subacute, and 
early symptoms are non-specific. Recent poor weight gain, low-grade fever, vomit-
ing, and recent contact with a TB patient are important clues for an early diagnosis 
of TBM. Outcome is directly associated with the stage of TBM. Delayed treatment 
because of missed diagnosis will result in progression to stage II and III disease with 
high morbidity and mortality rates. In multivariate analyses, we could identify several 
presenting variables independently associated with poor clinical outcome of TBM.
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Alle grote dingen komen voort uit het onbelangrijke. 
Daarom streeft de wijze nooit naar het grote.  
Op die manier kan hij grote dingen bereiken. 
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aBsTRacT
Tuberculosis (TB) has the highest mortality of any bacterial pathogen in history. 
Tuberculous meningitis (TBM) is the most severe complication of this disease and 
frequently occurs in childhood. The interaction between mycobacteria and the host 
consists of pathogen recognition and subsequent specific inflammatory responses. 
The majority of our knowledge on pathogenesis of TB in general and specific local 
inflammatory responses in case of TBM derives from experimental studies in animals.
In this review animal models to study TBM are summarized, focusing on the patho-
genesis of this disease.
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InTRoducTIon
Worldwide 2 billion people are infected with Mycobacterium tuberculosis (M. tub). 
In 2009, more than nine million million people developed active TB and 1.7 million 
people died of the consequences of this disease [1]. TB is the world’s second largest 
killer among infectious agents behind HIV/AIDS. Besides, HIV infection increases the 
risk to develop active TB and results in more complications and a higher case fatality 
rate [2]. An emerging problem, especially in Eastern Europe, China and sub-Saharan 
Africa, is the development of (extensive) multidrug-resistant TB, which is very difficult 
to treat and indicates the failure of local TB control programs [3].
Tuberculous meningitis (TBM) is the most severe complication of TB and frequently 
occurs in childhood. TBM occurs in approximately 1% of all patients with active TB 
and has a high mortality rate. Survivors often develop severe neurological sequelae. 
TBM usually starts insidiously with non-specific symptoms, such as fever and vomit-
ing and the diagnosis is often only considered once irreversible neurological damage 
has already occurred [4].
The pathogenesis of TB and the development of TBM is a complicated interplay 
between mycobacteria and the specific host immune response. Granuloma formation 
is a very characteristic hallmark of mycobacterial infection [5]. In case of TBM, the 
local inflammatory response inside the central nervous system (CNS) is aimed at 
mycobacterial clearance but also creates a harmful environment for neuronal tissue. 
The majority of our knowledge about TB pathogenesis in general and specific 
immune responses inside the CNS in case of TBM originates from studying disease 
phenomena in animal models. These disease models have also been used to study 
antimicrobial and vaccine responses, as well as immunomodulating strategies.
We will focus on the pathogenesis of TBM and summarize animal models to study 
TBM in this perspective.
paThoGenesIs of TuBeRculous MenInGITIs
M. tub is an acid-fast, slow growing bacillus. The target cell for M. tub in mammalian 
species is the mononuclear phagocyte. After inhalation, M. tub enters the alveolar 
macrophage and survives inside. Phagocytosis also triggers innate immune recogni-
tion of M. tub inside these cells. The innate immune system is able to recognize 
highly conserved molecular motifs on pathogens that are not found on the cells of 
higher eukaryotes. These motifs are called pathogen-associated molecular patterns 
(PAMPs) and bind to pattern recognition receptors (PRRs). Activation of these recep-
tors on antigen-presenting cells induces a signaling cascade by the expression of 
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co-stimulatory molecules and cytokines and consecutive activation of the adaptive 
immune system [6]. Toll-like receptors (TLRs) are a group of cellular adaptor proteins 
that play a major role as PRRs in the initiation of innate immune responses. TLR acti-
vation results in various functional outcomes, including the secretion of inflammatory 
cytokines and chemokines, the regulation of phagocytosis and the induction of host 
defense mechanisms leading to direct antimicrobial activity but also responsible for 
local tissue damage [7].
Mycobacteria consist of several structures that act as PAMPs, which will be rec-
ognized by TLRs. The TLRs known to be involved in recognition of M. tub are TLR2, 
TLR4, TLR9, and possibly TLR8 [8]. TLR2 binds lipoarabinomannan of the mycobac-
terial cell wall. In experimental studies, triggering of TLR2 by mycobacteria leads to 
killing of intracellular M. tub in both murine and human macrophages [9]. Heat shock 
proteins, secreted by M. tub, activate TLR4. Mice lacking functional TLR4 were more 
susceptible to develop pulmonary TB and showed a reduced capacity to produce the 
protective type 1 cytokine interferon-gamma (IfN-γ) upon macrophage activation, 
indicating a protective role for TLR4 in host defense against pulmonary infection by 
M. tub [10]. TLR8 and TLR9 are intracellular PRRs, located in the endosome and very 
closely related to each other. M. tub is an intracellular pathogen that resides in char-
acteristic phagosomes, which interact with early endosomes [11]. Single-stranded 
RNA derived from pathogens such as M. tub has been proposed as a likely ligand 
of TLR8 [12]. TLR9 recognizes unmethylated Cytosine-phosphate-Guanine (CpG) 
oligodeoxynucleotides, highly frequent motifs in (myco-) bacterial DNA and rare in 
the mammalian genome [13]. TLR8 was recently reported to play a possible role in 
susceptibility to pulmonary TB in adults as shown by a genetic association of four 
TLR8 polymorphisms in two independent cohorts of TB patients compared to healthy 
controls. Expression levels of TLR8 transcripts and protein showed a marked increase 
during bacterial infection [14]. Experiments with TLR9 -/- mice infected with high 
doses of M. tub showed markedly enhanced susceptibility to infection in association 
with combined defects in proinflammatory cytokine production in vitro compared to 
wild type mice [15].
Figure 1 illustrates mycobacterial recognition receptors and their intracellular 
signaling pathways leading to an inflammatory response.
Cells inside the CNS also express TLRs, especially on astrocytes and microglia, 
antigen presenting and phagocytosing cells inside the CNS and key players in the 
immune response in this compartment [16]. Microglia are resident macrophages in 
the brain and are able to recruit and activate peripheral immune cells, such as mono-
cytes and T-lymphocytes, leading to leukocyte migration and cellular influx in the 
cerebrospinal fluid (CSF). Upon pathogen recognition TLRs activate a cell-signaling 
cascade, ultimately leading to the local production of pro-inflammatory cytokines 
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and chemokines such as TNf-α, IL-1, IL-6, IL-8, IL-10 and IL-18 by microglia [17]. 
These cytokines lead to activation and migration of more inflammatory cells and 
to lysis of invading pathogens in case of CNS inflammation but are also toxic and 
harmful for neuronal cells [18].
Our understanding of the pathogenesis of TBM originates from experiments in guin-
ea pigs and rabbits and post-mortem data of children described by Arnold Rich and 
Howard McCordock in 1933 [19]. They found that TBM results from hematogenous 
dissemination of M. tub to the CNS after primary pulmonary infection. However, 
TBM develops not directly by hematogenous spread of bacilli to the meninges but 
by release of bacilli into the CSf from focal granulomatous lesions, called Rich foci 
that are typically located subpial or subependymal. Recent studies show the dynamic 
interactions between mycobacteria and granuloma: infected macrophages attract 
uninfected macrophages and aggregate in an organized way to form granuloma, the 
hallmark of mycobacterial infection. These early granuloma contribute to mycobacte-
rial growth, contrary to the classical paradigm of being host-protective structures 
[20]. 
Once macrophages are infected, they are able to leave the granuloma and he-
matogenously form distant secondary foci of infection. The predominant location of 
Rich foci in the brain parenchyma, rather than the meninges, illustrates secondary 
granuloma formation during a preceding bacteremia. Bacteria remain dormant inside 
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figure 1. Pathogen-associated molecular patterns of Mycobacterium tuberculosis and its cell wall and 
the pathogen-recognition receptors of the mononuclear phagocyte, interacting via cytokines
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the granuloma for months or years and meningitis occurs only when bacteria are 
released into the subarachnoid space [21]. Entrance of bacteria into the CNS and the 
subsequent inflammatory response causes the three features responsible for the clini-
cal manifestations of TBM: 1) development of tuberculoma, 2) basal inflammatory 
exudates that cause cranial nerve palsies and obstruction of CSf pathways, resulting 
in hydrocephalus, and 3) obliterative vasculitis which leads to infarctions [19, 22].
Figure 2 summarizes the chain of events in TBM pathogenesis with the essential 
Rich focus.
droplet infection 
primary pulmonary focus bacteremia 
meninges & 
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figure 2. Schematic presentation of chain of events in TBM pathogenesis
anIMal Models of TuBeRculous MenInGITIs
Animal models have contributed substantially to our understanding of the patho-
genesis, pathology and immunology of TB and TBM throughout the years. In their 
thorough description of TBM in 1933, Rich and McCordock also used animal models. 
Next, we will describe which models have been designed to study TBM since the first 
descriptions in 1933. Available animal models will be summarized focusing on the 
understanding of host and bacterial factors in TBM. Primary purpose, advantages, and 
limitations of each model will be discussed.
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Guinea pig
The guinea pig (Cavia porcellus) has been used extensively in TB research in gen-
eral. Already in 1867 the first use of these rodents was reported in the literature by 
Sanderson and fox, describing inoculation of guinea pigs with human lesion exudate 
and subsequent development of progression, mimicking natural human disease [23, 
24]. Robert Koch used guinea pigs in his famous experiments to isolate and indentify 
the causative agent of human TB and also to test tuberculin as vaccine [25]. Guinea 
pigs are believed to be the most sensitive animals to TB, according to the classic 
experiments by Riley, showing that TB is an airborne infection [26]. He used guinea 
pigs as living air samplers for airborne tubercle bacilli generated by patients on an 
experimental TB ward. Because of the progressive nature of the pathology of TB in 
guinea pigs it replicates many aspects of TB, especially childhood TB and dissemi-
nated TB in immunocompromised hosts. Granuloma formation is well organized and 
the granulomas become necrotic, similar to human granuloma. It has also been a 
useful model to study dissemination and secondary granuloma formation [27].
Rich and McCordock used the guinea pig in their classical model to study the 
pathophysiology of TBM [19]. In a series of experiments they showed that both nor-
mal and hypersensitive guinea pigs showed clear meninges after direct injection of 
tubercle bacilli in the carotid artery, implying that TBM is not merely the simple result 
of direct meningeal infiltration from the bloodstream in miliary TB. The guinea pigs in 
their experiments indeed developed generalized miliary TB after mycobacterial injec-
tion in the carotid arteries but this did not result in diffuse inflammatory meningitis. 
TBM lesions could however be readily reproduced by introducing tubercle bacilli 
directly into the subarachnoid space. They also observed that the animals that had 
been injected with tubercle bacilli in the bloodstream developed a focal tubercle 
adjacent to the meninges. These lesions developed to the point of caseating and dis-
charging bacilli into the subarachnoid space with diffuse meningitis as a result [28].
The main advantage of the guinea pig model to study TB in general is that it displays 
well-structured granulomas and caseous necrosis. It has also proven to be a very 
effective model to test vaccines, especially BCG. Major limitation of the guinea pig 
model is the lack of available immunological reagents what makes it difficult to study 
the exact nature of the immune response in TBM in terms of receptor and protein 
expressions [29].
Rabbit
Classical experiments by Lurie et al. in 1952 described pulmonary TB pathogenesis in 
rabbits genetically inbred to be either susceptible or resistant to airborne human M. 
tub [30]. Most studies in rabbits however, use M. bovis because rabbits are extremely 
susceptible to M. tub and very rapidly succumb when infected. The pathology in 
rabbits infected with M. bovis is remarkably similar to human infection with M. tub, 
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showing pulmonary granulomas of similar organization as in human TB, including 
caseous necrosis.
The group of Kaplan et al. used the rabbit to model acute mycobacterial infection in 
the CNS. They injected 2 x 10e7 colony forming units (CfU) of M. bovis Ravenel di-
rectly in the cisterna magna of New Zealand White rabbits and collected CSf samples 
0, 2, 4, 6, and 24 h and every next 24h up to 8 days after inoculation [31]. These 
experiments induced leukocytosis (predominantly mononuclear cells), high protein 
levels, and release of tumor necrosis factor-alpha (TNf-α) into the cerebrospinal fluid 
within 1 day. Histologically, severe meningitis with thickening of the leptomenin-
ges, prominent vasculitis, and encephalitis was apparent, and mortality was 75% 
by day 8. This model was also used to describe the potential therapeutic effect of 
thalidomide in TBM. Adding thalidomide to antituberculous drugs in TB infected 
rabbits substantially reduced TNf-α concentrations in CNS and plasma and 100% 
of animals survived compared to 50% mortality in rabbits not additionally treated 
with thalidomide [32]. Using the same stereotactic rabbit model they also described 
the therapeutic effect of IMiD3, a thalidomide analog showing limited pathological 
neurologic changes and improved survival of experimental animals [33].
Although very useful to specifically study TBM and closely mimicking well-
structured granulomas and caseaous necrosis and moderate range of immunolical 
reagents, rabbits are costlier to maintain and have larger laboratory space require-
ments [29, 34]. 
Mouse
Mice are generally resistant to pulmonary TB compared to guinea pigs, rabbits and 
humans. They develop non-caseating granulomas in the lung and manifest a chronic 
inflammatory disease. On the other hand, parallels exist between murine and human 
innate immune responses in terms of pathogen recognition and cytokine responses. 
Another advantage of this experimental to study the pathogenesis of TB is the avail-
ability of inbred and targeted genetic knockout strains of mice that help to elucidate 
the role of specific cytokines, cells and surface markers in response to mycobacterial 
infection. Mice are also the most common available experimental animals with the 
obvious advantage of low cost in housing and feeding and a wide spectrum of avail-
able immunological reagents.
Mazzolla et al. inoculated susceptible Balb/c mice and resistant DBA2 mice with 
M. bovis by intracranial injection. Natural differences in systemic inflammation 
susceptibility in these mice strains were determined by the presence or absence of 
natural resistance-associated protein 1 (Nramp1). After direct intracisternal inocula-
tion with 1 x 10e5 M. bovis BCG mycobacterial growth in the CNS was very different 
for both mouse strains on day 14: DBA/2 mice showed low colonization that reached 
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the maximal peak of 22 x 10e3 CFU/brain on day 14. In contrast, at the same time 
point, BALB/c mice showed as much as 134 x 10e3 CFU/brain. Both strains cleared 
the infection completely after 28-35 days. They also observed different patterns of 
local immune responses between the two mouse strains (time-dependent differences 
were observed between Balb/c and DBA/2 mice for macrophage inflammatory protein 
(MIP)-2, interleukin (IL)-12, IL-1β, interferon (IfN)-γ, IL-6 and TNf-α and concluded 
that Nramp1 is important in anti-mycobacterial defenses. In both strains of mice, 
infection did not result in granuloma formation, giant-cell formation or necrotic areas 
[35].
More recently, we described a C57Bl/6 murine model to study the pathogenesis of 
TBM. We found perivascular leukocyte infiltration in the meninges after intracerebral 
inoculation with 1 x 10e5 CfU M. tub H37Rv. We cultured up to 1 x 10e5 CfU of 
mycobacteria from brain homogenates after 3, 7, 12, 18 and 24 weeks after inocula-
tion, reflecting intracerebral growth of mycobacteria. Besides, in the CSF we could 
measure concentrations of cytokine-induced neutrophil chemoattracktant (KC) (mean 
concentrations of 123 ± 16 pg/mL 3 weeks after infection) and MIP-2 (mean concen-
trations of 695 ± 97 pg/mL 24 weeks after infection), chemokines that were absent in 
uninfected mice, reflecting chronic infection by attraction and activation of phago-
cytic cells inside the CNS. However, we did not observe brain exudate or infarction, 
characteristic for human TBM, we did not find the characteristic pro-inflammatory 
cytokine responses (TNf-α IL-6 and IfN-γ) upon our first measurements 3 weeks after 
infection and we found no infection related mortality in the experimental animals 
[36]. Because of the availability of a wide variety of genetically inbred mice, this 
model seems promising for future research to unravel the details of the inflamma-
tory response to TBM in terms of immune cells, cell surface receptors and cytokine 
production.
In order to study a crucial step in the pathogenesis of TBM, which is entering the 
CNS after primary pulmonary infection upon bacteremia, Be et al. developed a 
murine model based on their in vitro experience with cell cultures mimicking the 
blood-brain barrier. They used BALB/c mice and infected them intravenously with 1 x 
10e6 CfU M. tub H37Rv to mimic hematological dissemination. Gross pathological 
examination of the brain did not show any granulomas or infectious lesions in the 
brain at any time point. Significantly higher numbers of M. tub were found in the 
brain than in the whole-blood volume in the mouse, indicating that CfU counts from 
the brain were not due to contamination from the blood. CfU count of mycobacteria 
in brain tissue peaked at day 14. They also observed cytokine responses inside the 
CNS. TNf-α (300-400 pg/mL) and IL-10 (1000 pg/mL) were found in brain tissue 
of infected mice compared to mice injected with saline. The model was developed 
to identify genetic determinants for CNS invasion. By means of a pooled infection 
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with genotypically defined M. tub mutants, bacterial genes required for invasion or 
survival were determined in the CNS. They identified mutants for 5 M. tub genes 
(Rv0311, Rv0805, Rv0931c, Rv0986, and MT3280) with CNS-specific phenotypes 
[37].
Lee et al. described the specific immune response in the CNS after direct intracere-
bral infection of C57Bl/6 mice with 1 x 10e5 CFU M. bovis BCG. At 3 and 5 weeks 
post infection, BCG bacilli were detected not only in the CNS but also at a low level 
in the periphery, which suggests systemic dissemination of BCG. The bacterial load 
declined from 3 to 5 weeks post infection in all tissues tested, but the reduction was 
most significant in the brain and the lymph nodes draining the CNS. The significant 
decline in the number of CfU in the brain implies that immunity within the CNS is as 
efficient at controlling bacterial growth as it is in the periphery. Histopathology was 
evaluated 3 and 5 weeks post infection by assessing infiltrating mononuclear cells 
in H&E stained brain sections. In the infected mice, infiltrating mononuclear cells 
were found in the perivascular areas, ventricles, and parenchyma. They found IfN-γ 
producing CD4+ T-cells in the brain, similar as in peripheral blood but also a subset 
of activated T-cells (IfN-γ IL-17 producing double-positive CD4+ T-cells) unique to 
the CNS. These cells originate from microglial and dendritic sources indicating a 
specific local inflammatory response inside the CNS [38]. 
Limitations of the murine model to study TB in general are the loosely organized 
granulomas. Compared to the rabbit model to study TBM, the murine model is limited 
in pinpointing the optimal location to infect the animals intracerebrally.
swine
In order to develop a TB model that better mimics human disease Bolin et al. devel-
oped a swine model in 1997. In a sub-experiment the infected swines were divided 
in two groups and infected with 1 x 10e4 and 1 x 10e8 M. bovis intrathecally. These 
pigs showed less signs of respiratory distress compared to swine that were infected 
intravenously or inside the lymph nodes. Mycobacteria were cultured from brains, 
lungs and lymph nodes in the three different groups of inoculation indicating dis-
semination. The granuloma found in lungs and lymph nodes were very similar in 
architecture details when compared to human granulomas [39]. They concluded that 
swine are an excellent model to study pulmonary and disseminated TB. To study TBM 
they later switched to murine models.
non-human primate
The obvious advantage of non-human primates, such as the cynomologous macaque, 
is the similarity of disease compared to humans, both clinically and pathologically. 
Another advantage is that most human reagents can be used in primates. Because 
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of cost and space requirements and ethical issues, research on primates should be 
reserved for those questions that cannot be answered with in vitro techniques or 
with unvertebrated species or rodents. They mainly concern vaccine and drug testing 
and the issue of reactivation as well as the interaction with HIV. We are not aware 
of primate models that were primarily designed to study TBM. However, we did find 
a communication on a primate model that also described granuloma formation in 
the CNS [40]. In 1996 a cynomologous macaque model to study TB was decribed, 
closely resembling human disease. Three groups of four monkeys were described 
and infected with 10e5, 10e4, and 10e2 CfU M. tub Erdman strain respectively. In 
a second experiment three groups of four animals were infected with 10e3, 10e2, 
and 10e1 CfU. All infected animals were compared to healthy animals. In this study, 
the authors describe that two animals developed TBM. They displayed weakness of 
the extremities, loss of coordination, and irritable behavior. At necropsy, military 
tubercles were observed on the meninges.
Zebra fish
The zebra fish is relative new animal used to study TB, especially pathogenesis, host-
pathogen interactions and granuloma formation. Ramakrishnan et al. described in 
2002 the real-time visualization of mycobacterium-macrophage interactions leading 
to initiation of granuloma formation in zebrafish embryos using M. marinum [41]. 
No zebra fish model has been published that studies central nervous system TB or 
neuronal granuloma formation. Currently our group is developing such a model. The 
zebra fish model is excellent for imaging early pathology and ideal to study innate 
immunity and also suitable for making mutants [29].
conclusIons
Evaluating the available animal models to study TBM, the rabbit model seems to 
most closely mimic human TBM. The murine model however, is superior in terms of 
studying the immunological response. The non-human primates are irreplaceable for 
drug and vaccine testing. Animal models in general have been and continue to be 
crucial to our understanding of both host and bacterial factors in TB and TBM. Still 
unresolved questions range from the genetics of host defense and microbial virulence 
to drug therapy and vaccination. Animal models promise to be useful immunologic, 
genetic, molecular and pharmacological tools in future research of TBM.
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aBsTRacT
Tuberculous meningitis (TBM) is a severe complication of tuberculosis that mainly 
occurs during childhood. No murine models are available to study this disease. 
The purpose of the present study was to develop a murine model to investigate the 
pathogenesis of TBM. 
Mice were intracerebrally injected with Mycobacterium tuberculosis. Bacilli could 
be cultured from brain homogenates, and, on histopathological examination, all 
mice were found to have meningeal cellular infiltration. 
We found elevated levels of chemoattractants for mononuclear phagocytes and 
neutrophilic granulocytes. 
This is the first murine model for TM that can be used for research on the host 
response to TM, in particular the innate immune response.
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BackGRound
Tuberculosis (TB) remains a global threat to mankind. One third of the world’s popu-
lation is infected with Mycobacterium tuberculosis (M. tub), and 1.7 million people 
die each year as a consequence of TB [1]. Tuberculous meningitis (TBM), which 
mainly occurs during childhood, is considered to be the most severe extrapulmonary 
complication of TB [2]. Its fatality rate is ∼30%, and 25% of survivors develop severe 
neurological sequelae [3]. The aim of the present study was to develop an in vivo 
model for TBM to investigate the inflammatory response.
We examined brain tissue samples and measured local cytokine and chemokine 
production. These mediators orchestrate the host defense to TB in the brain but are 
also responsible for neuronal damage [4].
MaTeRIals and MeThods
Pathogen-free 6-week-old female C57Bl/6 mice were obtained from Harlan Sprague 
Dawley and were maintained in biosafety level 3 facilities. The Animal Care and Use 
Committee of the University of Amsterdam approved all experiments.
H37Rv (American type culture collection), a virulent laboratory strain of M. tub, 
was grown for 4 days in liquid Dubos medium containing 0.01% Tween 80. A rep-
licate culture was incubated at 37 degrees Celsius, harvested at mid-log phase, and 
stored in aliquots at -70 degrees Celsius. for the experiment, a vial was thawed and 
washed twice with sterile 0.9% NaCl.
Mice were anesthesized by inhalation with isoflurane (Abbott Laboratories) and 
infected intracerebrally with 1 x 10e5 colony forming units (CfU) of M. tub in 50 mL 
of saline, as determined by viable counts on Middlebrook 7H11 (M7H11) agar plates. 
To inoculate bacteria in or close to the cisterna magna, we used a mouse cadaver to 
determine a standardized puncture location. We also determined the standard length 
of the needle to reach the subarachnoidal space and used a stopping mechanism 
to prevent overshoot of the needle. Afterward, we histologically checked the site of 
inoculation.
Groups of 8 mice were killed 3, 7, 12, 18, and 24 weeks after infection. Mice were 
anesthetized with Hypnorm (Janssen Pharmaceuticals) and Midazolam (Roche). Blood 
was obtained by cardiac puncture, and cerebrospinal fluid (CSF) was collected by 
puncture of the cisterna magna. Brain, lungs, and spleen were removed. Half of each 
organ was fixed in 10% buffered formaline for 24 h; after paraffin embedding, 4-mm 
sections were stained with hematoxylin-eosin. The other half was homogenized in 5 
volumes of sterile 0.9% NaCl by use of a tissue homogenizer (Biospec Products), and 
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10-fold serial dilutions were plated on M7H11 agar plates to determine the numbers 
of CfU. CSf was also plated on M7H11 agar plates. CfU were counted after 21 
days of incubation at 37 degrees Celsius and are provided as the total number per 
microliters of organ homogenate or of CSf.
for cytokine and chemokine measurements, organ homogenates were diluted 1:1 
in lysis buffer (150 mmol/L NaCl, 15 mmol/L Tris, 1 mmol/L MgCl, 1 mmol/L CaCl, 
1% Triton, and 100 mg/mL pepstatin A, leupeptin, and aprotinin) and incubated on 
ice for 30 min. Supernatants were sterilized using 0.22-mmfilters (Corning) and stored 
at -20 degrees Celsius for later analysis.
Cytokine concentrations were measured using cytometric bead array (CBA) in accor-
dance with the recommendations of the manufacturer (BD Biosciences Pharmingen). 
The mouse inflammation kit contains antibodies for tumor necrosis factor (TNF)–α, 
interleukin (IL)-6, IL-10, IL-12p70, and monocyte chemoattractant protein (MCP)–1, 
and the mouse Th1/Th2 kit contains antibodies for interferon (IFN)–γ, IL-2, IL-4, and 
IL-5. The chemokines, cytokine-induced neutrophil chemoattractant
(KC) and macrophage inflammatory protein (MIP)–2 were measured using commer-
cially available ELISA kits in accordance with the recommendations of the manufac-
turer (R&D Systems). Concentrations are given as mean ± standard error (SE) values.
The experiments were repeated using 5 x 10e5 CfU of M. tub H37Rv. Mice intra-
cerebrally injected with saline (n=2) and mice not injected at all (n=2) were used as 
controls.
ResulTs
The experimental mice did not show physical signs of being unwell and no growth 
retardation after infection. Gross pathological analysis of the brains did not show 
exudate or signs of infarction. Tuberculomas however, were present. We also found 
granulomatous inflammation of the lungs and spleen. Meningitis was defined as 
positive CSf or brain tissue culture for M. tub and histopathological evidence of 
meningitis consisting of infiltration of leukocytes in the meninges. All mice devel-
oped meningitis. Cellular infiltration of the meninges is shown in Figure 1A and was 
predominantly perivascular, as shown in Figure 1B. The site of inoculation could be 
identified in 36 of 40 mice and was in or very close to the subarachnoidal space, as 
shown in Figure 1C. This mimics the rupture of a tuberculoma to the CSf. 
The number of CfU of M. tub cultured from tissue homogenates at different time 
points after infection is shown in Figure 2. CSf cultures were negative. After culturing, 
no CSf was left for further biochemical analysis or cytokine measurements. Three 
weeks after infection, we counted 4.3 ± 1.5 x 10e4 CFU/mL of brain homogenate. 
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This decreased to a minimum of 5.2 ± 1.5 x 10e3 CFU/mL of brain homogenate at 12 
weeks. Interestingly, after 24 weeks, the bacterial load increased to 1.0 ± 0.6 x 10e5 
CFU/mL, implicating bacterial reproduction in the mouse brain. Bacterial counts in 
lung homogenates gradually increased from 2.6 ± 1.5 x 10e5 CFU/mL 3 weeks after 
infection to a maximum of 3.0 ± 1.5 x 10e6 CFU/mL 24 weeks after infection. Bacte-
rial counts in spleen homogenates increased from 5.0 ± 0.8 x 10e4 CFU/mL 7 weeks 
after infection to 2.7 ± 0.8 x 10e5 CFU/mL 24 weeks after infection.
In a second experiment, with 5 x 10e5 CfU of M. tub, we were able to reproduce 
these results: all mice developed meningitis with histopathological findings similar 
to those of the first experiment. M. tub could be cultured from all organs throughout 
the experiments. After 24 weeks, we cultured 2.2 ± 0.8 x 10e4 CFU/mL from brain 
homogenates, 4.6 ± 1.8 x 10e5 CFU/mL from lung homogenates, and 2.7 ± 0.5 x 
10e5 CFU/mL from spleen homogenates. No growth of M. tub was found in CSf. 
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Figure 1. Hematoxylin-eosin–stained slides of murine brain with men-
ingitis after infection with cfu of Mycobacterium tuberculosis.51 10
Shown are the infiltration of meninges with leukocytes (A; original mag-
nification, ) and perivascular infiltration (B; original magnification,4 3.3
). Also shown is the site of bacterial inoculation, with iron de-10 3.3
posits due to small hemorrhage (C; original magnification, ).4 3.3
Cytokine concentrations were measured using a cytometric
bead array in accordance with the recommendations of the
manufacturer (BD Biosciences Pharmingen). The mouse in-
flammation kit contains antibodies for tumor necrosis factor
(TNF)–a, interleukin (IL)-6, IL-10, IL-12p70, and monocyte
chemoattractant protein (MCP)–1, and the mouse Th1/Th2 kit
contains antibodies for interferon (IFN)–g, IL-2, IL-4, and IL-
5. The chemokines cytokine-induced neutrophil chemoattrac-
tant (KC) and macrophage inflammatory protein (MIP)–2were
measured using a commercially available ELISA in accordance
with the recommendations of the manufacturer (R&D Sys-
tems). Concentrations are given as values.mean SE
The experiments were repeated using cfu of M. tu-55 10
berculosis H37Rv. Mice intracerebrally injected with saline
( ) and mice not injected at all ( ) were used asnp 2 np 2
controls.
Results. The experimental mice did not show physical signs
of being unwell or of growth retardation. Gross pathological
analysis of the brains did not show exudate or signs of infarc-
tion. Tuberculomas, however, were present. We also found
granulomatous inflammation of the lungs and spleen.
Meningitis was defined as positive CSF or brain tissue culture
for M. tuberculosis and histopathological evidence of meningitis
consisting of infiltration of leukocytes in the meninges. All mice
developed meningitis. Cellular infiltration of the meninges is
shown in figure 1A and was predominantly perivascular, as
shown in figure 1B. The site of inoculation could be identified
in 36 of 40 mice and was in or very close to the subarachnoidal
space, as shown in figure 1C. This mimics the rupture of a
tuberculoma to the CSF.
The number of colony-forming units of M. tuberculosis cul-
tured from tissue homogenates at different time points after
infection is shown in figure 2. CSF cultures were negative. After
culturing, no CSF was left for further biochemical analysis
or cytokine measurements. Three weeks after infection, we
counted cfu/mL of brain homogenate. This de-44.3 1.5 10
creased to a minimum of cfu/mL of brain ho-35.2 1.5 10
mogenate at 12 weeks. Interestingly, after 24 weeks, the bacterial
load increased to cfu/mL, implicating bacterial51.0 0.6 10
reproduction in the mouse brain. Bacterial counts in lung ho-
mogenates gradually increased from cfu/mL 352.6 1.5 10
weeks after infection to a maximum of cfu/mL63.0 1.5 10
24 weeks after infection. Bacterial counts in spleen homogenates
increased from cfu/mL 7 weeks after infection45.0 0.8 10
to cfu/mL 24 weeks after infection.52.7 0.8 10
In a second experiment, with cfu of M. tuberculosis,55 10
we were able to reproduce these results: all mice developed
meningitis, with histopathological findings similar to those of
the first experiment. M. tuberculosis could be cultured from all
organs throughout the experiments. After 24 weeks, we cultured
2.2  0.8  104 cfu/mL from brain homogenates, 4.6 1.8
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tems). Concentrations are given as values.mean SE
The experiments were repeated using cfu of M. tu-55 10
berculosis H37Rv. Mice intracerebrally injected with saline
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of being unwell or of growth retardation. Gross pathological
analysis of the brains did not show exudate or signs of infarc-
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Figure 1. Hematoxylin-eosin–stained slides of murine brain with men-
ingitis after infection with cfu of Mycobacterium tuberculosis.51 10
Shown are the infiltration of meninges with leukocy es (A; riginal mag-
nification, ) and perivascular infiltration (B; original magnification,4 3.3
). Also shown is the site of bacterial inoculation, with iron de-10 3.3
posits due o small hemorrhage (C; original magnification, ).4 3.3
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10 cfu of Mycobacterium tuberculosis.
Shown are the infiltration of me inges with leukocytes (A;  ori al magn fic ion, 
4 x 3.3) and perivasculair infiltration (B; original magnification, 10 x 3.3). Also shown is the site of 
bacterial inoculation, with iron deposits due to small hemorrhage (C; original magnification, 4 x 3.3)
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Tissue homogenates and CSf of control mice injected with saline and of non-injected 
control mice did not contain bacilli.
We measured concentrations of cytokines and chemokines in serum and brain ho-
mogenates. In both compartments, levels of TNf-α, IfN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, 
and IL-12p70 were < 10 pg/mL and were comparable with those of uninfected mice. 
After infection with 5 x 10e5 CfU of M. tub, levels of these inflammatory cytokines 
were also < 10 pg/mL. In contrast, chemokine concentrations in brain homogenates 
and serum were highly elevated in mice infected with M. tub, compared with those 
in non-infected mice. Mean concentrations for MIP-2 after infection with 1 x 10e5 
CFU were 591 ± 84 pg/mL after 3 weeks, 112 ± 32 pg/mL after 7 weeks, 368 ± 112 
pg/mL after 12 weeks, 608 ± 113 pg/mL after 18 weeks, and 695 ± 97 pg/mL after 
24 weeks. Mean concentrations for KC were 123 ± 16 pg/mL after 3 weeks, 37 ± 4 
pg/mL after 7 weeks, 86 ± 15 pg/mL after 12 weeks, 61 ± 11 pg/mL after 18 weeks, 
and 72 ± 6 pg/mL after 24 weeks. Mean concentrations of MCP-1 were 237 ± 19 pg/
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Figure 2. No. of colony-forming units per microliter (on a logarithmic
scale) cultured from brain homogenates (A), lung homogenates (B), and
spleen homogenates (C) 3, 7, 12, 18, and 24 weeks after intracerebral
infection with cfu of Mycobacterium tuberculosis. Data are51 10
mean SE values.
 105 cfu/mL from lung homogenates, and 2.7  0.5  105
cfu/mL from spleen homogenates. No growth of M. tuberculosis
was found in CSF. Tissue homogenates and CSF of control
mice injected with saline and of noninjected control mice did
not contain bacilli.
We measured concentrations of cytokines and chemokines
in serum and brain homogenates. In both compartments, levels
of TNF-a, IFN-g, IL-2, IL-4, IL-5, IL-6, IL-10, and IL-12p70
were !10 pg/mL and were comparable with those of uninfected
mice. After infection with cfu of M. tuberculosis, levels55 10
of these inflammatory cytokines were also !10 pg/mL. In con-
trast, chemokine concentrations in brain homogenates and se-
rum were highly elevated in mice infected with M. tuberculosis,
compared with those in noninfectedmice.Mean concentrations
for MIP-2 after infection with cfu were pg/51 10 591 84
mL after 3 weeks, pg/mL after 7 weeks,112 32 368 112
pg/mL after 12 weeks, pg/mL after 18 weeks, and608 113
pg/mL after 24 weeks. Mean concentrations for KC695 97
were pg/mL after 3 weeks, pg/mL after 7123 16 37 4
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of MCP-1 were pg/mL after 3 weeks, pg/mL237 19 73 8
after 7 weeks, pg/mL after 12 weeks, pg/mL after80 7 52 7
18 weeks, and pg/mL after 24 weeks. Mice infected with43 5
cfu of M. tuberculosis had chemokine concentrations55 10
comparable with those observed in the first experiment (data
not shown). Control mice injected intracerebrally with saline
and naive mice had concentrations !10 pg/mL of all measured
cytokines and chemokines.
Discussion. In this report, we describe a new model of TM
in mice. In our experiments, all mice developed meningitis,
characterized by a positive brain tissue culture and meningeal
inflammation. Meningitis could be diagnosed up to 24 weeks
after infection. The histopathological findings in combination
with elevated levels of chemokines in the brain homogenates
mimic the progression of this disease in untreated human
patients.
We designed our model to study the pathogenesis of TM in
vivo, focusing on the role played by inflammatory mediators
in the central nervous system (CNS). Knowledge of the path-
ogenesis of TM originates from experiments in rabbits and
children postmortem by Rich and McCordock in 1933 [5].
They found that TM results from hematogenous dissemination
of M. tuberculosis to the CNS after primary pulmonary infec-
tion. However, TM develops not directly by hematogenous
spread of bacilli to the meninges but by release of bacilli from
focal lesions, called “Rich foci,” that are typically located subpial
or subependymal.
Infection of mononuclear phagocytes is a critical step in the
immunopathogenesis of TM. Microglial cells, the macrophages
of the brain, are the preferential cells in the CNS to be infected
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mL after 3 weeks, 73 ± 8 pg/mL after 7 weeks, 80 ± 7 pg/mL after 12 weeks, 52 ± 
7 pg/mL after 18 weeks, and 43 ± 5 pg/mL after 24 weeks. Mice infected with 5 x 
10e5 CfU of M. tub had chemokine concentrations comparable with those observed 
in the first experiment (data not shown). Control mice injected intracerebrally with 
saline and naive mice had concentrations < 10 pg/mL of all measured cytokines and 
chemokines.
dIscussIon
In this report, we describe a new model to study TBM in mice. In our experiments, all 
mice developed meningitis, characterized by a positive brain tissue culture and men-
ingeal inflammation. Meningitis could be diagnosed up to 24 weeks after infection. 
The histopathological findings in combination with elevated levels of chemokines 
in the brain homogenates mimic the progression of this disease in untreated human 
patients.
We designed our model to study the pathogenesis of TBM in vivo, focusing on 
the role played by inflammatory mediators in the central nervous system (CNS). 
Knowledge of the pathogenesis of TBM originates from experiments in guinea pigs 
and rabbits and postmortem observations in children by Rich and McCordock in 
1933 [5]. They found that TBM results from hematogenous dissemination of M. tub 
to the CNS after primary pulmonary infection. However, TBM develops not directly 
by hematogenous spread of bacilli to the meninges but by release of bacilli from 
focal lesions, called Rich foci, which are typically located subpial or subependymal. 
Infection of mononuclear phagocytes is a critical step in the immunopathogenesis 
of TBM. Microglial cells, the macrophages of the brain, are the preferential cells 
in the CNS to be infected with M. tub. They also regulate the immune response 
against mycobacteria by secretion of cytokines and chemokines [4, 6, 7]. TNf-α is 
a crucial cytokine of mycobacterial pathogenicity in the CNS [6, 8, 9, 10, 11]. In 
human bacterial meningitis other than TBM, TNf-α levels in CSf correlate with the 
clinical course of meningitis: high levels are associated with more severe disease 
[12, 13]. This correlation could not be proven in human TBM [11]. In vitro data from 
Curto et al. show production of TNf-α by microglia that peaks 2 h after infection and 
lasts up to 48 h. Later, a mechanism of inhibition is triggered, leading to the return 
to basic concentrations of TNf-α [6]. In the rabbit model of TBM, TNf-α in CSf also 
peaks after 2 h and then decreases to 10-fold-lower levels 8 days after infection [8]. In 
human TBM, TNf-α in CSf is also shown to be increased after infection: Mastroianni 
et al. reported moderately elevated levels detectable for several weeks after infec-
tion [10]; Thwaites et al. however, found elevated levels of TNf-α up to 7 days after 
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infection only [11]. In our model, we did not find elevated levels of proinflammatory 
cytokines such as TNf-α, IfN-γ , and IL-6 in serum or brain homogenates, but we 
killed the first mice 3 weeks after infection. However, we did find elevated levels of 
chemokines lasting until up to 24 weeks after infection. Chemokines are small che-
motactic proteins that contribute to leukocyte recruitment. In microglial cells in the 
CNS, chemokine production is upregulated on activation by stimuli such as bacteria 
or proinflammatory mediators (e.g. TNF-α) [14]. Human TBM is characterized by 
increased CSf expression of IL-8, a chemoattractant for neutrophils and a subset of 
T-lymphocytes [10]. Rodent analogues for this chemokine are MIP-2 and KC [14]. 
In our model, concentrations of MIP-2 and KC were increased in infected mice, 
explaining the leukocyte influx in the CNS we found on histologic examination. We 
also found elevated concentrations of MCP-1, a chemokine that attracts mononuclear 
phagocytes, leading to macrophage activation in general or activation of microglial 
cells in the CNS.
Histopathological changes in human TBM consist of cellular response in the CSf as 
well as protein influx (cytokines and chemokines), causing perivascular inflammation 
and occlusion of small vessels, which leads to infarcts and cranial nerve palsies [12]. 
The infected mice in the present study did have infiltration of leukocytes in their me-
ninges, especially perivascular, comparable with that observed in human infection.
conclusIons
In conclusion, we were able to develop a reproducible in vivo model to study the 
inflammatory response in TBM. However, this model has limitations in terms of trans-
lation to human disease: although the route of infection mimics the natural way TBM 
is acquired, mice did not show clinical signs of disease, contrary to human disease, 
and the cytokine profile was different from that of human disease. On the other hand, 
we did find bacterial growth of TB in the CNS that leads to a chronic inflammatory 
response in terms of chemokine production. We intend to use this model to further 
analyze the role played by the innate immunity in TBM, especially the role played by 
Toll-like receptors and other signaling pathways that orchestrate an immunological 
response.
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aBsTRacT
The susceptibility, severity and prognosis of infectious diseases depend on the ability 
of the host immune system to respond to pathogens. Genetic variation of immune 
response genes is associated with susceptibility to and severity of infectious diseases.
Bacterial meningitis (BM) is a serious and life-threatening infectious disease of the 
central nervous system (CNS). Despite adequate antibiotic treatment and immuniza-
tion strategies, mortality remains high, especially in developing countries. Strepto-
coccus pneumoniae and Neisseria meningitidis are the two most common causative 
microorganisms of BM worldwide.
The pathogenesis of BM starts with mucosal bacterial colonization, followed by 
invasion and survival of bacteria in the bloodstream, crossing of the blood–brain bar-
rier, finally causing infection in the CNS, where host defense is less adequate. Host 
defense to BM starts with a complex cascade of pathogen recognition and subsequent 
intracellular signaling causing transcription of genes leading to the production of 
inflammatory mediators. Although this immune reaction is essential for killing mi-
crobes, it is also associated with damage to healthy cells and thus adverse disease 
outcome. 
This review provides an overview of the pathogenesis of invasive pneumococcal 
disease and invasive meningococcal disease related to the influence of genetic varia-
tion in genes involved in innate immunity, focusing on BM.
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InTRoducTIon
Bacterial meningitis (BM) is a life-threatening infectious disease of the central nervous 
system (CNS) accounting for an estimated annual 170 000 deaths worldwide. Despite 
the availability of antibiotics, universal immunization strategies, and continuing 
improvement of supportive care, mortality remains 4 to 10% in children in industrial-
ized countries and is even higher in the developing world [1]. The overall incidence 
of meningitis in developed countries is about 2 to 10 cases per 100 000 people per 
year. In neonates, the attack rate is about 400 per 100 000, in children between 1 
month and 2 years of age the attack rate is 20 per 100 000 and in adults 1 to 2 per 
100 000 [2]. The most common pathogens causing BM beyond the neonatal period 
worldwide are Streptococcus pneumoniae (SP, 53%) and Neisseria meningitidis (NM, 
19%) [2,3]. Survivors of BM have a high risk to develop neurological sequelae, rang-
ing from subtle learning and behavioral disorders in over 20% of cases, to deafness, 
paresis and severe encephalopathy in 10–15% [2,4,5].
Bacterial infections of the CNS are very often preceded by bacteremia [6]. The 
clinical course of BM depends on the causative microorganism, the mode of acquisi-
tion and the immunological response of the affected patient. An acquired pathogen 
may lead to bacterial colonization but may also result in meningitis with severe 
neurological sequelae. for example, genetically determined host–bacteria interac-
tions determine the immune response in case of severe meningococcal disease (MD), 
defined as sepsis and/or meningitis [7,8]. For several infectious diseases it is known 
that genetic variation determines susceptibility to develop disease on acquisition of a 
certain pathogen [9]. Defects of the innate immune system, affecting host susceptibil-
ity, have been described in both pneumococcal and meningococcal infections within 
families [10]. Single-nucleotide polymorphisms (SNPs) in immune response genes 
have been shown to be involved in the susceptibility, severity and outcome of severe 
infections, including BM [11-13]. Several SNPs are associated with susceptibility to 
invasive pneumococcal disease (IPD) and invasive meningococcal disease (IMD) 
[10,14]. for SP, associations are described with genetic variation in genes involved 
in intracellular innate immune cell signaling and complement. for NM, convincing 
association with genetic variation has been found in cell-surface molecule genes, 
surfactant protein (SP) genes, complement genes and cytokine genes [10].
We found no papers that exclusively studied the role of SNPs in the development 
of BM. We recently published a paper on the role of Toll-like receptor (TLR) 9 SNPs 
affecting susceptibility to meningococcal meningitis (MM) [12]. 
Here, we summarize studies that describe associations with SNPs in large cohorts 
of patients with IPD and IMD, including those with BM. The proportion of BM pa-
tients in these cohorts was approximately 10%. for this review, we focus on the 
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essential steps in the development of BM: epithelial colonization and disruption, 
infection of the blood stream, crossing the endothelial blood–brain barrier (BBB) and 
finally infection of the CNS. We review how genetic variation is involved in pathogen 
acquisition and epithelial interactions, mechanisms that predispose for bloodstream 
infection and how genetic variation affects pathogen recognition and the subsequent 
inflammatory response, both in the bloodstream and inside the CNS.
In concordance with a recent systematic review on IPD and IMD, we will summa-
rize studies on genes involved in adhesion to epithelial surfaces, pathogen recogni-
tion, complement and cytokines.
paThoGenesIs of BacTeRIal MenInGITIs
The sequential steps in the pathogenesis of BM from the pathogen’s perspective are: 
(1) nasopharyngeal colonization with bacteria that have the potential to cause BM; 
(2) epithelial disruption by bacterial components, enabling these bacteria to enter 
the bloodstream where they replicate and cause bacteremia [15,16]; (3) pathogen 
specific passage of the BBB and bacterial multiplication inside the subarachnoidal 
space; (4) bacterial recognition inside the CNS by microglia and astrocytes and by 
non-neural structures in direct contact with the cerebrospinal fluid (CSF), such as den-
dritic cells and macrophages, all expressing pathogen recognition receptors (PRRs) 
including TLRs and nucleotide-binding oligomerization domain (NOD) proteins. PRR 
activation triggers an intracellular signaling cascade resulting in (5) the transcription 
of pro-inflammatory cytokines and chemokines inside the CNS. Cytokine induced 
increased permeability of the BBB and chemokine induced influx of inflammatory 
cells from the bloodstream into the CNS result in enhancement of the local inflam-
matory response inside the brain. The clinical consequence is brain edema, raised 
intracranial pressure, infarction and neuronal injury [6]. The ability of a host to sense 
CNS invasion by microbes and to respond appropriately to control the local infection 
is essential for killing microbes but the inflammatory response also results in the 
production of several cytotoxic mediators responsible for damage to healthy neuronal 
cells and thus for adverse disease outcome [6]. Figure 1 summarizes the pathogenesis 
of BM for SP (a) and NM (b).
Next, we will discuss the various steps in the pathogenesis of BM in more detail and 
discuss the SNPs in genes involved in each of these steps.
nasopharyngeal colonization and mucosal invasion
Nasopharyngeal colonization precedes invasion but identifiable disease occurs only 
in a small percentage of persons who are colonized. SP and NM are common inhabit-
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ants of the nasopharyngeal cavity but are also capable of causing invasive disease 
such as meningitis [15,16]. Nasopharyngeal colonization of SP and NM is possible 
because of their ability to inactivate the host’s local antibody defense by produc-
ing immunoglobulin A proteases, which inactivate neutralizing immunoglobulin A 
antibodies in the epithelial cells [2]. Conversion of asymptomatic colonization to 
invasive disease may be enhanced by local generation of inflammatory factors, as 
seen in the presence of viral infections [17].
Surfactant protein (Sp)-A and Sp-D are also implied in the first line of defense 
against nasopharyngeal and respiratory colonization [18,19]. Sp-A and Sp-D belong 
to a family of proteins called collectins. They act as pattern recognition molecules 
and activate phagocytosis and inflammation on binding of bacterial capsular sugars.
SP is a Gram-positive coccus and a prototypic extracellular bacterial pathogen. 
The external polysaccharide capsule determines the antigenic differences and > 90 
serotypes have been described. The pneumococcal cell wall consists of peptidogly-
can and lipoteichoic acid (LTA), which are of particular importance in SP virulence. 
The capsule prevents entrapment in the nasopharyngeal mucus and also inhibits 
effective opsonophagocytosis. Pneumococcal enzymes, such as neuraminidases 
(NanA and B), cleave glycoproteins and oligosaccharides and enhance colonization 
by decreasing the viscosity of the mucus [18,20]. Pneumococcal immunoglobulin 
A1 protease supports nasopharyngeal colonization by inactivating human secretory 
immunoglobulin A and promotes attachment to host cells [21]. Phosphorylcholine 
(ChoP) is an adhesin on the pneumococcal surface that mediates adherence to the 
receptor for platelet activating factor and activates host cell signaling [22]. The ability 
to invade the mucosa correlates with the presence of the polymeric immunoglobulin 
receptor on the human mucosal cell surface and choline-binding protein (CbpA) on 
the pneumococcus [23]. This binding facilitates transcytosis and enhances bacte-
rial traversal of the mucosa. Another important property of the pneumococcus is 
autolysis, which is essential for pneumolysin release. Pneumolysin, a pore-forming 
toxin common for all SP serotypes, is thought to be a multi-effective virulence factor 
following pneumococcal infection. Its role in mucosal colonization and BM remains 
contradictory [24]. Pneumococcal colonization and mucosal invasion are summa-
rized in Figure 1a.
Although variable, carriage of SP shows an increase before the age of 2 years and 
the peak incidence of colonization is 55% at the age of 3 years [15]. Colonization 
rates decline to < 10% in adults [22] and increase during respiratory infections to 
22–45%, which might implicate greater adherence during (viral) infections [15]. Car-
riage is mostly asymptomatic, can be simultaneous and serial by multiple strains and 
lasts for a few weeks to a few months. Nasopharyngeal carriage shows quite similar 
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Figure 1 (a) Schematic representation of the sequential steps in the pathogenesis of pneumococcal meningitis. (1) Colonization: the
pneumococcal polysaccharide capsule prevents entrapment in the mucus and inhibits phagocytosis. Pneumococcal neuraminidases (NanA
and B) cleave glycocproteins and oligosaccharides in mucus enhancing colonization by decreasing the viscosity. Pneumococcal
immunoglobulin A (IgA)1 protease inactivates local secretory IgA and further facilitates colonization. Phosphorylcholine (ChoP) on the
pneumococcal surface binds to the receptor for platelet-activating factor (rPAF) and activates cell signaling. Mucosal invasion is facilitated
by pneumococcal choline-binding proteins (CbpA) to the immunoglobulin receptor (IgR). SP then traverses the mucosa by transcytosis.
(2) Intravascular bacterial survival and multiplication. Pneumococcal ChoP binds to C-reactive protein (CRP) and enhances complement
activation. Pneumococcal surface proteins PspA and PspC inhibit complement activation by interfering binding of SP to complement factor
C3 and H, respectively. (3) Attachment of BMECs by cholin binding surface proteins (Cbpa) to the laminin receptor protein (LRP) and, ChoP
to rPAF followed by transcellular live bacterial traversal of the BBB. (4) Bacterial invasion of the meninges and replication in the CNS. LytA is
responsible for autolysis and release of subcapsular components, recognized by immunocompetent cells that trigger cytokine and chemokine
production leading to increased BBB permeability and pleocytosis, in turn enhancing the local inflammatory response with subsequent
increased intracranial pressure and edema, ultimately resulting in neuronal injury. (b) Schematic representation of the sequential steps in the
pathogenesis of MM. (1) Colonization: the polysaccharide capsule enables attachment to nasopharyngeal mucosal cells of outer membrane
proteins and pili with carcinoembryonic antigen cell adhesion molecules (CEACAMs). Capsular saccharides bind to collectins, and inactivate
IgA by protease. Bacteria then cross the mucosa by transcytosis or probably through phagocytosis in a ‘Trojan horse’ manner. (2) Intravascular
bacterial survival and multiplication; lipooligosaccharide (LOS) contribute to a high-degree of bacteremia, and complement activation.
(3) Attachment of BMECs by bacterial pili to CD46, opacity-associated adhesion protein (Op) binding to fibronectin, and PorA and PilQ
binding to laminin receptor protein (LRP). Attachment of these bacterial epitopes contribute to live bacterial traversal of the BBB by
endoctyosis or transcytosis after disorganizing the cell polarity via binding to type IV pili. (4) Bacterial invasion of the meninges and
replication in the CNS triggering the production of cytokines and chemokines by immunocompetent cells leading to increased BBB
permeability and pleocytosis, in turn enhancing the local inflammatory response with subsequent increased intracranial pressure and edema,
ultimately resulting in neuronal injury.
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figure 1 .  Schematic representation of the sequential steps in the pathogenesis of pneumococcal and 
meningococcal meningitis
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serotype distributions in Europe and the United States. The serotypes 6B, 14, 19F and 
23F are the most common causative types in BM [15].
NM is a Gram-negative bacterium. Most meningococci express a polysaccharide 
capsule, the basis of the serogroup typing system [25]. Virulence determinants in-
clude the polysaccharide capsule, outer membrane proteins including pili, porin A 
and B (PorA and B), opacity-associated adhesion protein (Op), iron sequestration 
mechanisms and endotoxin [26]. Adhesion to epithelial surfaces is a crucial step 
in meningococcal acquisition. NM attaches to the mucosa by pili. Human carcino-
genic embryonic antigen cell adhesion molecules (CEACAMs), also known as CD66, 
are cell-surface molecules in nasopharyngeal epithelial cells and neutrophils that 
(a) schematic representation of the sequential 
steps in the pathogenesis of pneumococcal 
meningitis. 
(1) colonization: the pneumococcal 
polysaccharide capsule prevents entrapment 
in the mucus and inhibits phagocytosis. 
Pneumococcal neuraminidases (NanA and B) 
cleave glycocproteins and oligosaccharides in 
mucus enhancing colonization by decreasing 
the viscosity. Pneumococcal immunoglobulin 
A (IgA)I protease inactivates local secretory 
IgA and further facilitates colonization. 
Phosphorylcholine (ChoP) on the pneumococcal 
surface binds to the receptor for platelet-
activating factor (rPAf) and activates cell 
signaling. Mucosal invasion is facilitated by 
pneumococcal choline-binding proteins (CbpA) 
to the immunoglobulin receptor (IgR). SP then 
traverses the mucosa by transcytosis. 
(2) Intravascular bacterial survival and 
multiplication. Pneumococcal ChoP binds 
to C-reactive protein (CRP) and enhances 
complement activation. Pneumococcal surface 
proteins PspA and PspC inhibit complement 
activation by interfering binding of SP to 
complement factor C3 and H, respectively. 
(3) attachment of BMecs by cholin binding 
surface proteins (Cbpa) to the laminin receptor 
protein (LRP) and, ChoP to rPAf followed by 
transcellular live bacterial traversal of the BBB. 
(4) Bacterial invasion of the meninges and 
replication in the CNS. 
LytA is responsible for autolysis and release 
of subcapsular components, recognized by 
immunocompetent cells that trigger cytokine and 
chemokine production leading to increased BBB 
permeability and pleocytosis, in turn enhancing 
the local inflammatory response with subsequent 
increased intracranial pressure and edema, 
ultimately resulting in neuronal injury 
(b) schematic representation of the sequential 
steps in the pathogenesis of MM. 
(1) colonization: the polysaccharide capsule 
enables attachment to nasopharyngeal mucosal 
cells of outer membrane proteins and pili 
with carcinoembryonic antigen cell adhesion 
molecules (CEACAMs). Capsular saccharides 
bind to collectins, and inactivate IgA by protease. 
Bacteria then cross the mucosa by transcytosis 
or probably through phagocytosis in a ‘Trojan 
horse’ manner.
(2) Intravascular bacterial survival and 
multiplication; lipooligosaccharide (LOS) 
contribute to a high-degree of bacteremia, and 
complement activation. 
(3) attachment of BMecs by bacterial pili to 
CD46, opacity-associated adhesion protein 
(Op) binding to fibronectin, and PorA and 
PilQ binding to laminin receptor protein (LRP). 
Attachment of these bacterial epitopes contribute 
to live bacterial transversal of the BBB by 
endoctyosis or transcytosis after disorganizing the 
cell polarity via binding to type IV pili. 
(4) Bacterial invasion of the meninges 
and replication in  the CNS triggering the 
production of cytokines and chemokines by 
immunocompetent cells leading to increased 
BBB permeability and pleocytosis, in turn 
enhancing the local inflammatory response with 
subsequent increased intracranial pressure and 
edema, ultimately resulting in neuronal injury. 
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interact with Op type a (Opa) of NM [27]. Upregulation of CEACAM expression in 
vitro leads to increased uptake of meningococci [28]. Besides transcytosis, [29,30] 
NM can cross the epithelium directly following damage to the monolayer integrity 
[29]. It has recently been suggested that pairing of Opa and CEACAMs results in 
cellular infiltration by bacteria, which are carried across epithelial and endothelial 
barriers inside phagocytic cells as a Trojan-horse [16,17]. Although the vasculature is 
considered the primary route to the brain, NM has recently shown to be able to pass 
directly from nasopharynx to the meninges via the olfactory nerve [31]. Meningococ-
cal colonization and mucosal invasion are summarized in Figure 1b.
NM colonizes 8–25% of healthy individuals [26]. In approximately 25% of indi-
viduals, meningococcal acquisition in the upper respiratory tract results in prolonged 
carriage during several months. In 35% of individuals carriage is brief (days or weeks) 
and in the remaining 40% carriage is transient or infrequent [32]. Carriage is less 
frequent in children under the age of 10 (< 3%) than in adults (approximately 10%) 
and highest in adolescents (7–37%) [26]. Colonization is an important immunizing 
process, because bactericidal antibodies are acquired through meningococcal car-
riage. Otherwise, colonization is also a prerequisite for invasive disease [32]. Strains 
of NM can be divided in 13 serogroups; invasive meningococcal isolates most often 
express capsules of serogroups A, B, C, Y and sometimes W-135 [26]. Epidemiologi-
cal studies have revealed that only around 50% of colonizing meningococci express 
a capsule, while those of patients are almost always encapsulated [33].
single nucleotide polymorphisms in genes involved in adhesion to epithelial 
surfaces
No SNPs have been reported in genes involved in adhesion to epithelial surfaces in 
relation to SP infection, in contrast to NM infections.
Genetic diversity in the CEACAM genes influences the affinity of epithelial cells 
to adhere to epitopes of the meningococcus. Dose-dependent associations of three 
CEACAM haplotypes with MD were observed. The effect of carrying these haplo-
types is amplified in homozygous individuals. Two haplotypes (in CEACAM3 and 
CEACAM6) were protective while another haplotype in CEACAM6 was associated 
with a twofold increase in disease susceptibility [34].
A SNP resulting in the substitution of glutamine with lysine at residue 223 in the 
carbohydrate recognition domain of Sp-A2 increases susceptibility to MD, as well as 
the risk of death [18].
Table 1 summarizes the clinical relevant SNPs affecting epithelial adhesion, pre-
disposing to MM.
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Invasive disease and complement evasion
Disruption of colonized nasopharyngeal epithelium enables bacteria to enter the 
bloodstream where they can multiply, resulting in bacteremia, often a prerequisite for 
the development of meningitis. Intravascular invasion by traversing the endothelium 
is established in a pathogen-specific way.
The critical stimuli for the inflammatory response on invasion with SP are peptido-
glycan, LTA and pneumolysin, 35 but not the polysaccharide capsule, which lacks 
inflammatory potential but inhibits phagocytosis and complement-mediated bacteri-
cidal activity [22]. A higher incidence of infections with encapsulated bacteria, es-
pecially meningococci, is observed in people with deficiencies in all three pathways 
(the classical, the alternative and the lectin-mediated pathway) of the complement 
system [36-39].
C-reactive protein binds specifically to ChoP of SP and next, interacts with comple-
ment component C1q to activate the classical pathway of complement [22]. Pneumo-
coccal surface protein (Psp) A and PspC are involved in the inhibition of complement 
activation by interfering binding of SP with complement factor C3 (classical pathway) 
and factor H (alternative pathway) respectively [22].
Inside the CNS, complement proteins are important for the innate immune re-
sponse but they are nearly absent under physiological conditions. However, their 
concentration increases during BM but will always remain below blood levels [40]. 
All classical and alternative complement components can be produced in the CNS 
[41]. The critical role of the complement system for innate immune responses in 
case of pneumococcal meningitis (PM) and MM is well illustrated in experimental 
meningitis studies and by case reports in people with specific mutations causing 
deficiencies in complement components, which will both be discussed here.
Rise of complement proteins seems to be essential for limiting pneumococcal 
outgrowth within the CNS. Tuomanen et al. [42] provided the first evidence for a 
functional role of the complement system in limiting PM. In rabbits depleted of C3, 
intracisternal inoculation of SP resulted in higher bacterial titers than in complement 
sufficient controls. Using mice, deficient in the complement components C1q, lack-
ing the classical pathway, or deficient of C3, lacking all three pathways, Rupprecht 
et al. [40] concluded that the complement system limits PM via all three pathways, 
although it is unable to eradicate the pathogen. C3 deficiency led to diminished 
CNS inflammation (higher bacterial titers in the CNS, but reduced CSF leukocyte 
counts) and CNS complications, while survival was decreased, presumably due to 
worse systemic complications. Earlier, our group demonstrated classical complement 
pathway activation in PM in rats. C1 inhibitor reduced outgrowth of pneumococci 
in the brain and resulted in reduced clinical illness, a less pronounced inflammatory 
infiltrate around the meninges, and lower brain levels of pro-inflammatory cytokines 
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and chemokines [43]. Data on 10 children with PM demonstrated that the total he-
molytic activity of both the classical and the alternate pathways were reduced in one 
patient, determination of individual complement components indicated predominant 
activation of the alternate pathways [44]. In four case reports, low C3 levels are 
associated with recurrent PM [45-48].
As NM is a strictly human pathogen, [49] our knowledge on the role of comple-
ment in MM comes from human data, mostly case reports. A study of 35 children 
with MM showed transiently reduced total hemolytic activity of the classical pathway 
in one case [44]. In another study, the functional activity of the classical and alter-
native pathways of the complement system and the levels of C3, C4, and factor B 
were determined in 10 children with MM. It seems that the alternative pathway is 
preferentially activated, probably due to the greater ability of endotoxin to activate 
this pathway in vivo [50]. four case reports associated frequent episodes of MM with 
C5, C6 or C7 deficiency [51-54]. Single episodes of MM were also described in C7 
deficiencies [55,56]. Two mutations causing deficiency of C8 were diagnosed in an 
adult following three episodes of MM [57]. A complement factor D (CFD) deficiency 
was found in one case of MM [36].
single nucleotide polymorphisms in complement genes
Three SNPs in the mannose-binding lectin (MBL)2 gene result in three variant structural 
alleles (protein B, C and D), which are associated with decreased MBL concentrations 
[58]. Roy et al. [59] reported that individuals with homozygote mutants for MBL 
codon variants are at increased risk of IPD. In contrast, Kronborg et al. [60] found 
only a non-significant increased risk between the three MBL structural codon variants 
and IPD. Moens et al. [61] also described a non-significant increased risk of severe 
pneumococcal infection but combined with the data of Kronborg they described a 
small but significantly increased risk to develop IPD. Importantly, pooling the data of 
these three studies revealed a significant increased prevalence of the mutant alleles 
in the patient groups. A small Turkish study found that the +154 C>T SNP in the MBL 
gene may have a role in susceptibly to purulent BM in children (31 patients with CSf 
findings suggestive for BM, 4 positive cultures: 2 SP, 1 NM, 1 Staphylococcus aureus) 
[62].
The role of MBL SNPs in NM infection is assessed in two studies [63,64]. Variant 
alleles were more frequent in patients with MD as compared with healthy controls. 
Three SNPs in the MBL2 gene result in three variant structural alleles and are associ-
ated with low serum MBL levels as compared with the wild types but was not associ-
ated with nosocomial sepsis or infections with NM or SP in neonates [65]. Another 
study suggests that MBL2 variants are significantly associated with susceptibility to 
childhood IMD in an age-dependent manner. The overall frequency of this genotype 
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was significantly higher in patients infected with NM than in controls (31.8 vs 8.2%). 
for children under the age of 1 year this association was even stronger [63].
factor D is an essential factor for C3 convertase complex formation in the alterna-
tive complement pathway. Factor D deficiency was found in several patients with MD 
and factor D-deficient serum appeared to be hyporesponsive to NM in vitro. In two 
reports, SNPs associated with meningococcal infection are found in the CfD gene 
[36,66].
factor H is a complement-regulatory protein in plasma and acts as a co-factor for 
factor I in the classical and alternative pathways. The complement factor H (CFH) 
-496C>T SNP affects its activity: the -496 C/C genotype was associated with higher 
concentrations of factor H and reduced bactericidal activity against NM. The -496 
C/C genotype was significantly associated with meningococcal infection [38]. Re-
cently, Davila et al. [14] performed a genome-wide association study and found in 
a United Kingdom (UK) population SNPs in CFH associated with susceptibility to 
meningococcal disease. They confirmed these results in two independent cohorts 
from Western Europe and Southern Europe. They conclude that host genetic variation 
in these regulators of complement activation play a role in the occurrence of invasive 
disease upon pathogen acquisition.
Table 1 summarizes the clinical relevant SNPs in complement genes, predisposing 
for BM.
crossing the blood-brain barrier and bacterial recognition inside the central 
nervous system
In order to enter the CNS, bacteria must attach to and finally cross the BBB, a 
structural and functional barrier that is formed by the brain microvascular endothe-
lial cells (BMECs). SP and NM have shown to be able to invade the BBB within a 
membrane-bound vacuole [67,68] as live bacteria  [69]. This process is enhanced 
by cytokine release, leading to an increased BBB permeability during meningitis 
[6]. Pneumococci use endothelial cells that express the platelet-activating factor 
and cross the endothelial layer via the platelet-activating factor-recycling pathway 
[68,70]. The binding of pneumococcal ChoP to the platelet-activating factor enables 
this pathway. Pneumococcal CbpA, via the laminin receptor protein [71] and NanA 
[72] has also shown to promote the passage of rodent and human BMECs. Using 
a microvascular endothelial cell culture model it was shown that pneumococci, 
expressing pneumolysin, were able to breach the endothelial cells, whereas mutant 
pneumococci, deficient in pneumolysin, were unable to penetrate the cell barrier 
[24]. Hyaluronidase facilitates pneumococcal invasion by degrading connective tis-
sue. Pneumococcal strains with higher hyaluronidase activity breach the BBB and 
disseminate more effectively [73]. Strains causing meningitis have significantly higher 
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hyaluronidase activity than strains causing otitis media. SP has been shown to be 
nearly twice as efficient at invading cerebral compared with peripheral endothelium. 
Low polysaccharide content of the capsule and high amount of CbpA and LTA in SP 
increases the ability of invasion of the BBB [74].
Meningococci traverse the endothelium of the BBB by transcytosis via endocytosis 
in membrane-bound vacuoles, 67 and recent data also suggest paracelllar penetra-
tion [75]. NM, via type IV pili-mediated adhesion to human BMECs, can disorganize 
cell–cell junctions and polarity, opening the paracellular route to invade the menin-
ges [75]. NM has been shown to use several BBB receptors in order to invade the 
CNS [69,76]. NM pili bind to CD46, a human cell surface protein, richly expressed 
at BMECs [77], promoting passage of the BBB in human CD46 transgenic mice [78]. 
NM contains Opc, binding to endothelial fibronectin and anchoring NM to the integ-
rin a5b1 receptor on BMECs [69]. PorA and PilQ bind to laminin receptor protein and 
contribute to live traversal of the BBB by transcytosis [71] (Figure 1b).
After bacteria have crossed the BBB they are recognized inside the CNS by PRRs 
on residing cells. TLRs are a major group of PRRs and are also expressed by cells in 
the CNS, especially on microglia and astrocytes, endogenous cells in the CNS and 
key players in the immune response in this compartment [79]. Microglia are myeloid 
derived cells, able to recruit and activate peripheral immune cells, such as monocytes 
and T-lymphocytes, leading to cellular influx in the CSF. These recruited cells also 
express TLRs and are able to produce pro-inflammatory cytokines as signaling media-
tors. Studies in mice with deficiencies in TLRs demonstrated that TLR activation is a 
key event in meningeal inflammation and for meningitis-associated tissue damage 
[80].
Many studies showed the importance of TLR2 and TLR4 in PM. TLR activation leads 
to Myeloid differentiation primary response gene (MyD)-88-dependent production 
of IL-1 family cytokines via caspase 1, which in turn forms a positive feedback loop 
that boosts the MyD88-dependent production of inflammatory mediators [80]. NM 
strains showed activation of TLR2, TLR4 and TLR9 by genetic complementation of 
HEK293 cells [81]. When bacterial components inside the CNS trigger the inflam-
matory cascade in the host, various cells like macrophages, (monocyte derived) 
microglia, meningeal and endothelial cells, produce pro-inflammatory cytokines like 
tumor necrosis factor (TNf) and interleukins (ILs) on microbial invasion of the CNS. 
Cytokines and chemokines (proteins inducing migration of inflammatory cells to the 
site of infection) lead to influx of neutrophils from the bloodstream into the CNS [6]. 
This enhances the local inflammatory response, further increases the permeability of 
the BBB and leads to increased intracranial pressure and edema, ultimately resulting 
in neuronal injury.
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Altogether, the CNS is a compartment with suppressed but inducible immune 
reactivity. 
Bacterial recognition and the local inflammatory response cascade are summarized 
in more detail in Figures 2a and b for SP and NM, respectively.
SNPs in cytokine genes
After NFkB is activated on bacterial recognition, pro-
inflammatory cytokines are released (IL-1, IL-6, TNF)
followed by anti-inflammatory cytokines (IL-10 and
soluble cytokine agonists such as IL-1 receptor antago-
nist (IL1RA) and soluble TNF receptors). IL6–174
(ref. 123) IL10–1082, TNFa �308 and lymphotoxin a
(LTA) þ 252 (ref. 124) SNPs were not associated with
susceptibility to pneumococcal infection, but IL6 GG
carriers were less likely to develop extrapulmonary
infection including meningitis.123 An association was
found between a high-expression macrophage migration
inhibitory factor �794 CATT allele and susceptibility to
PM.125 Migration inhibitory factor upregulates TLR4
expression by macrophages.
Several studies on the role of cytokine gene SNPs in
meningococcal infection have been performed, especially
on IL1 genes. Balding et al.126 associated IL1RA variable
number of tandem repeats SNPs with susceptibility to
MD (including one-third meningitis cases), but studies
by Carrol et al.127 and a meta-analysis of Brouwer et al.10
did not confirm this relation. Read et al.128 did not find an
association of two IL1 SNPs with susceptibility to MD,
but patients carrying the common allele at IL1b–511 were
Figure 2 (a) Sequential steps in the local innate immune response inside the CNS in pneumococcal meningitis. SP is able to activate antigen-
presenting cells such as microglia and astrocytes through TLR2, TLR4, TLR9, and nucleotide oligomerization domain protein 2 (NOD2). TLR2
recognizes LTA and pneumococcal peptidoglycan (PGN), TLR4 and its co-receptor CD14 recognize pneumolysin (PLY). TLR4 expression is
upregulated by macrophage migration inhibitory factor (MIF). TLR9 and NOD2 are intracellular receptors recognizing pneumococcal DNA
and internalized muramyl dipeptide, respectively. NOD2 induces RIP2-dependent signaling. Activation of other receptors induces a
signaling cascade via Mal (TIRAP) and MyD88 resulting in NFkB activation in the nucleus and subsequent transcription of proinflammatory
cytokine genes, and in induction of complement factor 3 (C3) expression via IRAK4. C3b enhances phagocytosis, by microglia but also
contributes to the expression of IL-1 family cytokines, promoting neutrophil influx into the CSF. Figure partly adapted from Koedel et al.80
(b) Sequential steps in the local innate immune response inside the CNS in MM. NM is able to activate antigen-presenting cells such as
microglia and astrocytes. TLR2 recognizes porin B (PorB) and Lip with co receptors TLR1 and CD14. TLR4 recognizes lipooligosaccharide
(LOS). TLR9, nucleotide oligomerization domain protein (NOD)1 and NOD2 are intracellular receptors recognizing meningococcal DNA,
internalized muramyl dipeptide, and dipeptide meso-diaminopimelic acid (iE-DDP), respectively. NODs induce RIP2-dependent signaling.
Activation of TLR-1, -2, -4 and -9 induces a signaling cascade via Mal (TIRAP) and MyD88 resulting in NFkB activation in the nucleus and
subsequent transcription of pro- and anti-inflammatory cytokine genes, and induction C3 expression via IRAK4. C3b contributes to
phagocytosis of bacteria by but also contributes to the expression of IL-1 family cytokines, promoting neutrophil influx into the CSF. Figure
partly adapted from Koedel et al.80
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figure 2. Sequential steps in the local innate immune response inside the CNS in case of 
pneumococcal (a) and meningococcal (b) meningitis
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single nucleotide polymorphisms in genes involved in pathogen recognition
For severe infections with SP, defects in innate immunity were first discovered by 
studies on extreme phenotypes, such as recurrent or familial infections. for example, 
studies in family members with recurrent IPD discovered SNPs in the IL-1 receptor-
associated kinase 4 (IRAK4) gene and the nuclear factor kappa B (NfkB) essential 
modulator protein (NEMO) gene [82,83]. MyD88 has an important role in immunity 
against PM as shown by MyD88 KO mice, which displayed diminished inflammatory 
host response in the CNS, as evidenced by reduced CSf pleocytosis, and expression 
of cytokines, chemokines and complement factors, but also a worsening of disease 
that seemed to be attributable to severe bacteremia [84]. Human studies on MyD88, 
show nine children with MyD88 deficiency suffering from recurrent pyogenic infec-
tions including IPD, while they were otherwise healthy with normal resistance to 
microbes [85].
IRAK4 is an important enzyme in TLR-mediated pathogen recognition and its 
downstream signaling to activate the inflammatory response. NEMO is a regulatory 
protein downstream of TLR4 and NOD proteins. SNPs in either of these genes were 
associated with impaired pathogen recognition and in vitro unresponsiveness to LPS 
and clinically associated with recurrent IPD [83,86-88].
(a) Sequential steps in the local innate immune 
respons inside the CNS in pneumococcal 
meningitis SP is able to activate antigen-
presenting cells such as microglia and astrocytes 
through TLR2, TLR4, TLR9, and nucleotide 
oligomerizatioa domain protein 2 (NOD2), 
TLR2 recognizes LTA and pneumococcal 
peptidoglycan (PGN), TLR4 and its co-receptor 
CD14 recognize pneumolysin (PLY). TLR4 
expression is upregulated by macrophage 
migration inhibitory factor (MIf). TLR9 and 
NOD2 are intracellular receptors recognizing 
pneumococcal DNA and internalized muramyl 
dipeptide, respectively. NOD2 induces RIP2-
dependent signaling. Activation of other 
receptors induces a signaling cascade via 
Mal (TIRAP) and MyD88 resulting in NfkB 
activation in the nucleus and subsequent 
transcription of proinflammatory cytokine 
genes, and in induction of complements factor 
3 (C3) expression via IRAK4. C3b enhances 
phagocytosis, by microglia but also contributes 
to the expression of IL-1 family cytokines, 
promoting neutrophil influx into the CSF. 
(b) Sequential steps in the local innate immune 
response inside the CNS in MM. MM is able 
to activate antigen-presenting cells such as 
microglia and astrocytes. TLR2 recognize porin 
B (PorB) and Lip with co-receptors TLR1 and 
CD14. TLR4 recognizes lipooligosaccharide 
(LOS). TLR9, nucleotide oligomerization domain 
protein (NOD)I and NOD2 are intracellular 
receptors recognizing meningococcal 
DNA, internalized muramyl dipeptide, and 
dipeptide meso-diaminopimelic acid (iE-DDP), 
respectively. NODs induce RIP2-dependent 
signaling. Activation of TLR 1, 2 , 4 and 9 
induces a signaling cascade via Mal (TIRAP) 
and MyD88 resulting in NfkB activation in  the 
nucleus and subsequent transcription of pro- and 
anti-inflammatory cytokine genes, and induction 
C3 expression via IRAK4. C3b contributes to 
phagocytosis of bacteria by but also contributes 
to the expression of IL-1 family cytokines, 
promoting neutrophil influx into the CSF. 
Figure adapted from Koedel et al.80
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Another approach to study SNPs is by selection of candidate genes on the basis 
animal models or systems biology and compare them in a case–control design. We 
summarize polymorphism studies on TLR2, TLR4, CD14, Toll IL-1 receptor domain-
containing adaptor protein (TIRAP/Mal) and NFkB inhibitor genes.
SP generally has the potential to activate immune cells through TLR1/2, TLR4, TLR9, 
NOD2, and presumably as yet unidentified PRRs and some of these PRRs appear to 
work synergistically [89]. Moens et al. [90] did not find an association between TLR2 
+1736 G>A, +1892 C>A and +2257 G>A and TLR4 +896 A>G (Asp299Gly) SNPs 
and infection with SP. However, based on murine data they hypothesized that TLR2 
and TLR4 were associated with increased susceptibility to develop SP infections. It 
should, however, be mentioned that neither the controls, nor the patients in their 
study contained homozygous mutant individuals. Yuan et al. [91] compared SNPs in 
pathogen recognition genes between children with IPD and healthy blood donors and 
concluded that genetic variability in the TLR4 +896 A>G and CD14 –260 C>T genes 
is associated with an increased risk of developing invasive disease in patients who are 
infected with SP. They found a lower incidence of the TLR4 +896 A>G polymorphism 
and a higher incidence of the CD14 –260 SNP in patients. No differences were found 
in incidences of the TLR2 +2257 G>A polymorphism.
TIRAP is an essential adaptor protein for the inflammatory signaling cascade down-
stream of TLR2 and TLR4. A recently discovered SNP in TIRAP that changes serine to 
a leucine residue on position 180 (Ser180-Leu; C539T) impairs TLR2-mediated NfkB 
signaling in reconstitution experiments [92]. Moreover, the 180L variant was less 
able to bind TLR2 in comparison with the 180S variant. The heterozygous variant was 
associated with protection to pneumococcal bacteremia [92].
TLR-mediated pathogen recognition induces intracellular signaling leading to the 
activation of NFkB in the nucleus and subsequent transcription of pro-inflammatory 
cytokine genes. NfkB inhibitors, coded in NfKBIA, NfKBIB and NfKBIE inhibit 
this activation. Chapman et al. [93] found two NFKBIA SNPs to be associated with 
protection against infection with SP and a NFKBIE SNP associated with increased 
susceptibility. NFKBIB SNPs were not associated with susceptibility to severe PD.
Meningococcal LOS interacts with TLR4, while Neisserial DNA activates TLR9. 
TLR2 recognizes outer membrane proteins porin B and Lip with its co-receptors 
TLR1 and CD14. In addition to muramyl dipeptide, the cell wall of NM contains di-
peptide meso-diaminopimelic acid, having potentials activating NOD2 and NOD1, 
respectively [80]. Candidate gene studies on innate immunity genes found relevant 
polymorphisms in TLR2 and TLR4 genes.
One study on CD14 -159 C>T polymorphisms in 185 surviving IMD patients, did 
not find an association with susceptibility, neither for TLR4 Asp299Gly SNPs [94]. 
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One study in patients with severe infection with NM studied TLR2 and suggested 
a protective effect of the TLR2 +1892 C>A polymorphism but only a non-significant 
higher frequency of this variant was found in control patients [95].
C3H/HeJ mice have an intrinsic point mutation in TLR4 that abolishes LPS responses. 
These mice are hyporesponsive to gram-negative infections [96]. Arbour et al. [97] 
demonstrated the importance of TLR4 by finding an association of two TLR4 SNPs 
with hyporesponsiveness to inhaled LPS in alveolar macrophages and epithelial cells. 
These two important SNPs of the TLR4 gene (+896 A>G and +1196 C>T) have been 
intensively studied. TLR4 +896 A>G was determined in a study on meningitis exclu-
sively, but there was no association with the susceptibility to group A meningococcus 
during epidemics in the Gambia [98]. Most studies have demonstrated that these two 
TLR4 polymorphisms confer an increased risk to infections, but this finding could 
not be observed consistently [99]. Agnese et al. [100] did find a significantly higher 
incidence of Gram-negative infection among patients with mutations in TLR4 com-
pared with the wild-type population. Several genetic studies have examined whether 
there is an association between TLR4 +896 A>G and bacterial infections. Faber et al. 
[101,102] showed age-dependent associations with susceptibility to IMD in children 
up to 1-year old and mortality in these children up to 2 years old. Smirnova et al. 
[95] investigated rare TLR4 SNPs that are highly variable in humans and animals. 
They found that TLR4 polymorphisms were obviously more present in patients with 
severe meningococcal infections. However, the exact functional consequences of 
these SNPs remain unknown.
The promoter region of the CD14 gene contains a SNP at position -260 C>T that 
affects the binding of transcription factors. The result of a SNP in the CD14 gene is an 
elevated expression of CD14 in membrane form on monocytes and neutrophils and 
in a soluble form in serum (sCD14) [103]. Genetically determined variation in CD14 
serum levels may have functional consequences. Recently, we detected a protective 
SNP in TLR9 +2848 leading to a decreased susceptibility to MM [12].
Table 1 summarizes the clinical relevant SNPs in pathogen recognition genes af-
fecting the susceptibility to develop BM.
Local inflammatory response inside the central nervous system: cytokines and 
chemokines
Once inside the CNS, bacteria multiply in the SAS and are recognized by innate 
immune receptors on microglia and astrocytes. The activation of these receptors 
triggers an intracellular signaling cascade resulting in the nuclear transcription of pro-
inflammatory cytokines and chemokines. These small messenger proteins then en-
hance increased permeability of the BBB (cytokines) and influx of inflammatory cells, 
mainly granulocytes, from the bloodstream into the CNS (chemokines) [104,105].
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Pneumococcal DNA loads are associated with high plasma cytokine concentra-
tions. In children with PM, median CSF cytokine concentrations were significantly 
higher than plasma cytokine concentrations [106].
TNf-α is produced by a wide variety of cells, including microglial cells, in response 
to pneumococcal cell wall in vitro. [107,108] In rats, intracisternal treatment with 
TNf-α alone does only cause minimal inflammatory changes, whereas combined 
with SP components it resulted in a maximal inflammatory response with high in-
tracranial pressure and brain edema [109]. TNf-α has also been suggested to be 
involved in the breakage of the BBB during SP bacteremia in mice [110].
IL-1b is one of the early key inflammation-initiating cytokines during PM. CSF 
bacterial loads in children with PM were associated with CSf IL-1b [106]. Levels of 
IL-1a and IL-1b mRNA and protein levels are upregulated in the brains of mice with 
PM [111]. The absence of an intact IL-1 signal in IL1R   -/- mice was associated with 
a higher susceptibility to PM, impaired bacterial clearance, decreased brain cytokine 
and higher and earlier mortality [111]. Klein et al. [112] intracisternally infected mice 
with PM and observed markedly elevated levels of IL-1b.
IL-6 is produced by microglial cells in response to SP [108] and is elevated in CSf 
during PM [113]. IL-6 enhances immune responses and might have a role in the 
disruption of the BBB but also seems to have anti-inflammatory effects in PM [114]. 
Comparing wild-type mice with IL6 -/- mice, Paul et al. [114] concluded that IL-6 
acts as an anti-inflammatory cytokine by suppressing the migration of leukocytes into 
the SAS but has a major role in the increase in vascular permeability, causing brain 
edema and increase in intracranial pressure. TNf-α and IL-1b levels in brain tissue of 
infected IL-6 -/- mice were increased compared with infected WT controls.
IL-8 has an important role in the recruitment of leukocytes during PM. In rabbits 
infected with SP, intravenous, but not intracisternal treatment with anti-IL-8 attenu-
ated pleocytosis significantly [115].
Microglial cells produce IL-12 in response to SP [108]. This induces the production 
of interferon (IfN)-γ with TNf-α as a co-stimulator.
IL-18 is upregulated during PM in mice and contributes to an unfavorable inflam-
matory response during meningitis. IL-18 does not seem to affect susceptibility to 
PM, yet IL-18 -/- mice showed a suppressed inflammatory response and a prolonged 
survival, as reflected by lower concentrations of cytokines in brain tissue and a less 
profound inflammatory infiltrate around the meninges [116].
A deletion of the TGf-b receptor II on leukocytes is found to enhance recruitment 
of neutrophils to the site of infection and to promote bacterial clearance in mice 
with PM. Moreover, this improved immunity was associated with an almost complete 
prevention of meningitis induced vasculitis and endogenous TGf-b suppressed the 
innate immune response [117].
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IfN-γ is produced by microglia during PM. IfN-γ presence during PM modulated 
the patterns of LPS induced cytokine release in a dose-dependent, potent and com-
plex manner. Although amounts of TNf-α and IL-6 remained nearly unchanged, IfN-γ 
enhanced the production of IL-12 [118].
In vitro studies show that leukocytes stimulated by outer membrane vesicles of NM 
produce TNf-α, IL-1b and IL-8, which was enhanced in the presence of IfN-γ [119].
TNf-α and its soluble receptors are also intrathecally produced in case of MM [120]. 
IL-1b and IL-1 receptor antagonist (IL-1Ra) are increased in CSf of MM patients, as 
is the level of IL-1 soluble receptor type II (IL-1sRII) in CSf. The pattern in plasma is 
different, indicating that the inflammatory response is differentially regulated [121]. 
IL-8 levels are higher in CSf of MM patients compared with controls [122]. IL-10 
inhibits TNf-α, IL-1b and IL-8 production triggered by NM [119]. Mogensen et al. 
[81] observed that different strains of NM differed in their ability to induce cytokine 
expression.
Single nucleotide polymorphisms in cytokine genes
After NFkB is activated on bacterial recognition, proinflammatory cytokines are re-
leased (IL-1, IL-6, TNf-α) followed by anti-inflammatory cytokines (IL-10 and soluble 
cytokine agonists such as IL-1 receptor antagonist (IL1RA) and soluble TNf recep-
tors). IL6 –174 [123] IL10 –1082, TNFA -308 and lymphotoxin a (LTA) +252 [124] 
SNPs were not associated with susceptibility to pneumococcal infection, but IL6 GG 
carriers were less likely to develop extrapulmonary infection including meningitis 
[123]. An association was found between a high-expression macrophage migration 
inhibitory factor (MIF) -794 CATT allele and susceptibility to PM [125]. MIf upregu-
lates TLR4 expression by macrophages.
Several studies on the role of cytokine gene SNPs in meningococcal infection have 
been performed, especially on IL1 genes. Balding et al. [126] associated IL1RA vari-
able number of tandem repeats SNPs with susceptibility to MD (including one-third 
meningitis cases), but studies by Carrol et al. [127] and a meta-analysis of Brouwer 
et al. [10] did not confirm this relation. Read et al. [128] did not find an association 
of two IL1 SNPs with susceptibility to MD, but patients carrying the common allele 
at IL1B –511 were more likely to survive and significantly less likely to survive if 
they also carried the rare allele at the IL-1 receptor antagonist gene IL1RN +2018. In 
another study, this SNP was also associated with susceptibility and mortality of MD, 
[129] while no association was found in five other SNPs in IL1A and IL1B. Severity 
and mortality of MD was associated with IL6 -174 G/G and IL10 -1082 A/A, but not 
with LTA +252, TNF -308, IL10 -592, or IL1B SNPs [126].
Significant associations of cytokine genes with susceptibility to meningococcal 
infections are summarized in Table 1.
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dIscussIon
Only for the TLR9 +2848 and MIF –794 SNPs, specific associations were found with 
meningitis [12,125]. for IPD, the strongest relation with genetic variation was found 
in genes involved in innate immune cell signaling and in complement genes. TLR2 
and TLR4 are important cell surface receptors and animal data have shown their 
subtle role in the response to PM: deficiency leads to reduced bacterial clearing from 
the CNS [130,131]. The recognition by TLR4 of pneumolysin in the pneumococcal 
cell wall is crucial in mounting this response [132]. Although TLR2 and TLR4 SNPs 
have been shown to be associated with human diseases such as tuberculosis, lues 
and Lyme’s disease, [133] no association was found between TLR2 and TLR4 SNPs 
and IPD in a cohort of severely ill patients where SP was cultured from blood, CSf 
or joint fluid [90]. Their cohort did not include any homozygous mutants for TLR2, 
which might have shown larger differences but they concluded that variations in TLR 
genotype is probably a minor cause of increased susceptibility to IPD. Homozygosity 
of the TIRAP Ser180Leu allele, shown to be associated with IPD, leads to defect 
MyD88-dependent signaling downstream of TLR2 and TLR4 [92]. Heterozygosity, 
however, protects against IPD because this leads to attenuated signaling but reduced 
NfkB activation. It seems that there is a delicate balance between pathogen recogni-
tion, inflammation and bacterial clearance: no recognition fails to clear a pathogen 
but too much inflammation damages the host itself [134]. This observation is sup-
ported by the protective role described of the NFKBIA and NFKBIE SNPs and IPD 
[93].
Strong relations were described for susceptibility of severe meningococcal infec-
tions and genetic variation in cell-surface molecule genes, BM genes and cytokine 
genes. Cell surface proteins in the human nasopharyngealepithelium (CEACAMs) 
adhere to meningococcal outer membrane proteins and are important in pathogen 
acquisition. Genetic diversity of these proteins was described to be associated with 
susceptibility to MD [34]. As nasopharyngeal pathogen acquisition is an important 
step in the pathogenesis of BM, we extrapolate this result as important genetic deter-
minant for susceptibility to meningitis as well.
The complement system is important in early pathogen recognition and uses opso-
nization to clear microbes. MBL, a protein belonging to the collectin group, binds to 
MBL serine proteases, which activate the complement cascade and opsonize bacteria 
by means of surface oligosaccharides [59]. MBL deficiency, caused by several SNPs, 
leads to reduced opsonization in early infection, leading to longer initial survival of 
SP, thus enhancing the possibility of invasion and subsequent BM. MBL deficiency is 
not associated with susceptibility for meningococcal infection. CfH is responsible for 
downregulation of complement activation and polymorphisms in CFH are indepen-
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dently associated with MD. Individuals with the C496T CC genotype have increased 
levels of CfH and have reduced bactericidal activity against meningococci, [38] thus 
predisposing for MM.
conclusIons
All together we were able to summarize the literature on SNPs that affect the suscep-
tibility to IPD and IMD. Taken into account the several pathophysiological steps to 
develop BM we focused on SNPs that very likely predispose to the development of 
BM by these microorganisms. We advocate that multidisciplinary efforts are needed 
in order to reveal the exact role of host genetic factors in severe infections includ-
ing meningitis, which will require large numbers of patients and controls, with the 
ultimate goal to invent better effective treatment and prevention strategies for severe 
infections.
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aBsTRacT
Bacterial meningitis (BM) is a severe infection mainly caused by Streptococcus 
pneumoniae and Neisseria meningitidis (NM). However, genetically determined 
susceptibility to develop severe infections by these microorganisms is variable be-
tween individuals. Toll-like receptor 9 (TLR9) recognizes bacterial DNA leading to 
intracellular inflammatory signaling. Single nucleotide polymorphisms (SNPs) within 
the TLR9 gene are associated with susceptibility to several diseases, but no such 
association with meningitis has been described.
We studied the role of TLR9 SNPs in host defense against BM. Two TLR9 SNPs and 
four TLR9 haplotypes were determined in 472 survivors of BM and compared to 392 
healthy controls.
Carriage of the TLR9 +2848-A mutant was significantly decreased in meningococ-
cal meningitis (MM) patients compared with controls (p = 0.0098, OR 0.6, 95% CI 
0.4–0.9). TLR9 haplotype I was associated with an increased susceptibility to MM (p 
= 0.0237, OR 1.3, 95% CI 1.0–1.5). In silico analysis shows a very strong immune-
inhibitory potential for DNA of NM upon recognition by TLR9 (CpG index of -106.8).
We report an association of TLR9 SNPs with susceptibility to BM, specifically MM 
indicating a protective effect for the TLR9 +2848-A allele. We hypothesize that the 
TLR9 +2848-A mutant results in an upregulation of TLR9 induced immune response 
compensating the strong inhibitory potential of NM CpG DNA. 
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BackGRound
Bacterial meningitis (BM) is a serious, life-threatening infectious disease of the cen-
tral nervous system (CNS) that often occurs in young children. Despite adequate 
antibiotic treatment and the use of adjunctive therapy such as corticosteroids, the 
rates of mortality and morbidity remain high [1]. The two most common pathogens 
causing BM in children in the Western world are Streptococcus pneumoniae (SP) and 
Neisseria meningitidis (NM). The incidence of BM, defined as bacteria isolated from 
the cerebrospinal fluid (CSF), was 1.2 per 100 000 inhabitants for pneumococcal 
meningitis (PM) and 0.4 per 100 000 for meningococcal meningitis (MM) in 2008 in 
the Netherlands [2] but is much higher in developing countries [3] where immuniza-
tion rates are low.
A crucial step in the first-line defense against BM is the recognition of bacteria by 
innate immune mechanisms, using pathogen recognition receptors (PRRs) expressed 
on antigen presenting and phagocytic cells present in neural structures and non-
neural structures (including macrophages and dendritic cells) in direct contact with 
the CSf [4]. Toll-like receptors (TLRs) are a key example of those PRRs. Within the 
CNS, TLRs are expressed on antigen presenting astrocytes and monocyte derived 
microglia [5]. TLR9 is an intracellular PRR that recognizes unmethylated Cytosine-
phosphate-Guanine (CpG) motives in bacterial and viral DNA. Binding of TLR9 to 
non-self DNA triggers a cascade of intracellular receptor signaling, finally resulting 
in transcription of nuclear factors and the production of pro- and anti-inflammatory 
cytokines [6].
Single nucleotide polymorphisms (SNPs) have been identified in different TLR genes, 
and they affect the susceptibility to and severity of several inflammatory diseases [7, 
8]. for example, the TLR4 +896 A > G (Asp299Gly) SNP causes hyporesponsiveness 
to lipopolysacharide (LPS), an important content in the membrane of NM and has 
been shown to enhance susceptibility to NM infections [9, 10]. Smirnova et al. exam-
ined a large group (n = 230) of patients with meningococcal sepsis and compared the 
frequency of TLR4 coding changes to those in an ethnically matched control group (n 
= 421). They observed that rare heterozygous missense mutations of TLR4 significantly 
contribute to the risk of developing meningococcal sepsis in a white population (p = 
2.3 10e-6, odds ratio [OR] 27.0) [10]. Yuan et al. compared SNPs in TLR2 and TLR4 
between children with invasive pneumococcal disease and healthy blood donors 
and concluded that the prevalence of the TLR4 +896 A > G/ TLR4 +1196 C > T SNPs 
was significantly lower in patients than in controls (p< 0.05, OR 0.3, 95% CI 0.1 – 1) 
[11]. TLR mediated activation by interleukin-1 receptor-associated kinase 4 (IRAK4) 
is an important enzyme in the functioning of TLRs [12]. Eight different IRAK4 SNPs 
are associated with recurrent pneumococcal disease and some with meningococcal 
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disease, characterized by the absence of fever and unresponsiveness to LPS in in vitro 
whole blood tests [7]. One Gambian study on meningitis exclusively did not show 
an association between TLR4 +896 A > G SNPs and susceptibility to MM during 
epidemics in children (n = 50) [13].
Genetically determined defects in innate immunity have been described in both 
meningococcal and pneumococcal infections within families. A large sibling study in 
UK whites showed that host genetic factors contribute up to one-third to the suscep-
tibility to meningococcal disease [14]. Although many studies on genetic variation 
in TLRs and infections with SP and NM have been described, studies focusing on 
meningitis exclusively are rare.
The aim of this study is to investigate the role of TLR9 SNPs in the susceptibility to 
PM and MM. TLR9 SNPs have been associated with the susceptibility to pouchitis, 
systemic lupus erythematosus, atherosclerosis, and asthma [8, 15], but no association 
of TLR9 SNPs with BM or meningococcal and pneumococcal infections has been 
described. We hypothesized that SNPs in TLR9 genes might change the recognition of 
CpG motifs in bacteria causing BM, leading to a decreased or increased susceptibility 
to PM and MM. To investigate the role of TLR9 SNPs in susceptibility to BM, we 
compared the frequencies of TLR9 SNPs, representing TLR9 +2848 and TLR9 -1237 
and their haplotypes, in survivors of BM (n = 472) with those in healthy controls (n 
= 392) without a known history of BM. To determine the importance of the CpG 
in SP and NM and its immunostimulatory ability, we also performed an in silico 
analysis, a computer-based scan of bacterial genomes for stimulatory and inhibitory 
CpG motives.
MaTeRIals and MeThods
patients
The study population consists of 472 Dutch white school-aged children and ado-
lescents who survived PM or MM. These former patients were selected from data 
on bacterial CSf isolates of the Netherlands Reference Laboratory for Bacterial 
Meningitis. The mean age of infection was 2 years. Of the 472 participating children, 
83 (17.6%) had PM and 389 (82.4%) had MM. In total, 397 children had meningitis 
between January 1990 and December 1995, and this cohort was described in detail 
by Koomen et al. [16–18]. A similar cohort of 75 children had BM between 1997 and 
2001. Children with ‘‘complex onset’ of meningitis (defined as: meningitis secondary 
to immune deficiency states, CNS surgery, cranial trauma or CSF shunt infections or 
relapsing meningitis) were excluded (14 patients [3%]).
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controls
The control group consists of 392 healthy adult Dutch whites without a known his-
tory of BM. Serum samples were taken from healthy employees of the VU University 
Medical Center in Amsterdam and the Erasmus University in Rotterdam, both in The 
Netherlands. Since the SNPs studied are stable over ages, no age-matched controls 
were needed.
Patients were mailed and asked to return a sterile swab after collecting their buccal 
DNA. Of these patients, 472 (71.9% of all patients who were asked to participate) 
returned the swab and an informed consent form. The Medical Ethical Committee of 
the VU University Medical Center approved this study.
dna isolation
DNA was isolated from the buccal swabs using the following procedure: after addition 
of 250 μL 10 mmol/L Tris-HCl (pH 7.4) the sample was heated at 96 degrees Celsius 
for 10 minutes. After mixing for 10 seconds the swabs were removed and the sample 
was centrifuged (14.000 rpm). In controls, venous blood (5–10 mL) was drawn and 
genomic DNA was isolated using standard protocols; 5–100 ng of genomic DNA was 
used each cycle of genotyping.
Genotyping
The polymorphisms were analyzed by TaqMan analysis using the standard TaqMan 
protocol. The AbiPrism 7000 Sequence Detection System (Applied Biosystems) was 
used to obtain data. Primer and probes used for TLR9 -1237 were: forward primer 
5’-GGCCTTGGGATGTGCTGTT-3’ and reverse primer 5’-GGTGACATGGGAG-
CAGAGACA-3’ and dual-labeled fluorogenic hybridization MGB-probes CTGCCT-
GAAAACT-5’ fluor Label (fAM, 6-carboxyfuorescein) and CTGGAAACTCCCC-5’ 
fluor Label (VIC). The primers and probes used for TLR9 +2848 were: forward primer 
5’-CCGCTGTGCAGGTGCTAGAC-3’ and reverse primer 5’-CCAAAGGGCTGGCT-
GTTGTA-3’ and dual labeled fluorgenic hybridization MGB probes AGCTACCGC-
GACTGG-5’ fluor Label (fAM) and AGCTACCACGACTGGA-5’ fluor Label (VIC).
haplotypes
The two TLR9 SNPs we analyzed were chosen on the basis of a study by Lazarus 
et al. [19] in which a set of 4 frequent TLR9 SNPs (TLR9 -1486, TLR9 -1237, TLR9 
+1174, and TLR9 +2848) was described. Genotyping of both TLR9 -1237 T > C (NCBI 
SNP CLUSTER ID: rs5743836) and TLR9 +2848 G > A (NCBI SNP CLUSTER ID: 
rs352140) allows all 4 locus haplotypes to be distinguished. (Haplotype I: -1486T/-
1237T/+1174A/+2848G, Haplotype II: -1486C/-1237T/+1174G/+2848A, Haplotype 
III: -1486T/-1237C/+1174G/+2848A, Haplotype IV: -1486T/-1237C/+1174G/+2848G 
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or -1486C/-1237T/+1174G/+2848G or -1486C/-1237C/+1174G/+2848G or -1486T/-
1237T/+1174G/+2848A. TLR9 haplotypes were inferred using PHASE v2.1.1 [20, 21] 
and SNPHAP [22].)
statistics
Genotypes were compared between cases and controls for the PM and MM group 
separately and for all cases of BM. Hardy-Weinberg tests were used to test for Men-
delian inheritance. fisher exact test and χ2 test were employed where appropriate. P 
values < 0.05 were considered statistically significant.
In silico analysis
To determine the immunostimulatory ability of the CpG DNA in SP and NM we 
performed an in silico analysis as described by Lundberg et al. [23]. To determine 
the relative prevalence of canonical stimulatory and inhibitory CpG motifs in the 
genomic sequences of the various bacteria, we employed a two-step approach. 
Genbank-retrieved FASTA formatted text files were uploaded to http://insilico.ehu.
es/ and the frequency of all 4096 possible hexamers were determined as described 
by Bikandi et al. [24]. This information and the general composition of each genome 
was then entered into Microsoft Excel, and common place formulas were used to 
count the occurrence of specific CpG motifs. As a measure of SP and NM genome’s 
potential for TLR9 stimulation, the CpG index is used to facilitate comparison of 
immunostimulatory potentials regardless of genome size, G + C content and overall 
CpG suppression and was calculated by comparing the frequency of stimulatory and 
inhibitory CpG motifs [23].
Table 1a. TLR9+2848 Genotype Distribution in Cases and Controls
TLR9+2848 N GG Wild type 
(%)
GA Heterozygous (%) AA mutant (%)
Total BMa 460 110 (23.9) 214 (46.5) 136 (29.6)
S. pneumoniae 80 17 (21.3) 36 (45.0) 27 (33.8)
N. meningitidisb 380 93 (24.5) 178 (46.8) 109 (28.7)
Controls* 392 66 (16.8) 192 (49.0) 134 (34.2)
a TLR9+2848 mutant allele (genotypes GA or AA) was significantly decreased in BM patients 
compared to controls (p: .0110, OR .6, 95% Cl .5 - .9).
b TLR9+2848 mutant allele was most significantly decreased in MM patients compared to healthy 
controls (p: .0098, OR: .6, 95% Cl: .4 - .9).
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Table 1B. TLR9-1237 Genotype Distribution in Cases and Controls
TLR9-1237 N TT Wildtype (%) TC Heterozygous (%) CC mutant (%)
Total BM 464 341 (73.5) 113 (24.4) 10 (2.2)
S. pneumoniae 82 61 (74.4) 20 (24.4) 1 (1.2)
N. meningitidis 382 280 (24.5) 93 (24.4) 9 (2.4)
Controls 392 274 (69.9) 112 (28.6) 6 (1.5)
ResulTs
susceptibility analysis
Single nucleotide polymorphisms analysis
for susceptibility analysis, BM patients were compared to the control group. The PM 
and MM groups were also separately compared to the controls. PM and MM patients 
were also compared to each other to discover associations between SNPs and sus-
ceptibility to a specific pathogen. The results are summarized in Table 1A and 1B. 
Because concentrations and quality of DNA varied among samples, some samples 
that could not be genotyped after 3 or more TaqMan analyses were excluded. This 
explains the difference in numbers of included patients and numbers of genotyped 
patients in the tables. Carriage of the TLR9 +2848 mutant allele (genotypes GA or AA) 
was significantly decreased in BM patients compared with controls (p = 0.011, OR 
0.6, 95% CI 0.5–0.9).
Carriage of the TLR9 +2848 mutant allele was also significantly decreased in MM 
patients compared with healthy controls (p = 0.0098, OR 0.6, 95% CI 0.4—0.9), 
but the genotype distribution in PM patients did not differ significantly from healthy 
controls. There were no significant differences between PM and MM patients. The 
TLR9 -1237 SNP was not significantly associated with the susceptibility to BM.
Haplotype analysis
Genotyping of both TLR9 -1237 and TLR9 +2848 allows all four locus haplotypes 
to be distinguished. The results are summarized in Table 2. TLR9 haplotype I was 
significantly increased in BM patients compared with the control group; (p = 0.0348, 
OR 1.2, 95% CI 1.0—1.5). TLR9 haplotype I was significantly increased in the MM 
patients compared to healthy controls; (p = 0.0237, OR 1.3, 95% CI 1.0—1.5). There 
were no significant differences in haplotype I distribution between the PM group and 
controls, neither between the PM and the MM group. for the distribution of other 
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haplotypes we found no significant differences between the control group and the 
total group of BM patients, nor between the PM and MM patients separately.
Table 2. frequencies of TLR9 Haplotypes in Cases and Controls
TLR9 haplotypes
(2n) Ia (%) IIb (%) IIIc (%) IVd (%)
Total BM* 914 419 (45.8) 363 (39.7) 124 (13.6) 8 (0.9)
S. pneumoniae 160 69 (43.1) 69 (43.1) 21 (13.1) 1 (0.6)
N. meningitidis* 754 350 (46.4) 294 (39.0) 103 (13.7) 7 (0.9)
Controls* 784 319 (40.7) 341 (43.5) 118 (15.1) 6 (0.8)
a-d Haplotypes as defined by Lazarus et al. [19]
*TLR9 haplotypes I was significantly increased in BM patients compared to the 
control group; (p: .0348, OR 1.2, 95% Cl 1.0 – 1.5). TLR9 haplotype I was 
significantly increased in the MM patients compared to healthy controls; (p: .0237, OR 1.3, 95% C;: 
1.0 – 1.5). 
In silico analysis
In Table 3 we summarized CpG indices for causative agents of BM. Positive CpG 
indices indicate immunostimuatory properties, whereas negative values indicate im-
munoinhibitory properties. Increasing values for the CpG indices indicate stronger ef-
fects. SP showed a mildly immunostimulatory potential with a CpG index of 8.6. This 
was comparable to another causative agent of meningitis, Haemophilus Influenzae. 
Interestingly, for NM we found a very strong immunoinhibitory CpG index of -106.8. 
Table 3. Results of the In Silico Analysis
CpG motif deviationa
Genome Consensus motifsb
Bacterium Size (Mb) G 1 C (%) CPG/kbc Total CpGd Stimulatorye Inhibitoryf CpG indexg
Streptococcus pneumoniae 2.22 39.5 78.0 69.5 82.4 66.5 8.6
Neisseria meningitidis 2.27 51.5 132.7 130.6 78.4 140.0 -106.8
Haemophillus influenzae 1.91 38.2 72.8 109.1 105.5 96.4 7.2
a  Deviations in specified motif occurrences relative to those expected based on genomic G 1 C content.
b  Consensus stimulatory and inhibitory CpG hexamer motifs are based on published analysis. They are 
used in this table as indicators of the general frequencies of stimulatory and inhibitory CpG hexamer 
motifs in each genome.
c Number of CpG hexamer motifs (NNCGNN) occurring in each genome normalized to 100 kb.
d  Total frequency of CpG hexamer motifs (NNCGNN); expected number based on nucleotide 
composition of the genome.
e frequency of consensus stimulatory hexamer motifs (RRCGYY).
f frequency of consensus inhibitory hexamer motifs (NCCGNN and NNCGRN).
g  Calculated from frequencies of stimulatory less inhibitory consensus hexamer motifs as an indicator 
of stimulation versus inhibition multiplied by total CpG number (normalized to 1 kb) and the overall 
frequency of CpG (NNCGNN).
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dIscussIon
This study describes a strong association between TLR9 SNPs and BM in a large 
cohort of BM survivors. Based on our findings we propose that TLR9 genetic varia-
tion can compensate for the inhibitory effects of Neisserial CpG DNA resulting in a 
reduced susceptibility for MM.
Carriage of the TLR9 +2848-A mutant decreases the susceptibility to BM, specifi-
cally MM (p = 0.0098). Carriage of TLR9 haplotype I was associated with an increased 
risk to develop MM. This can be explained for the greatest part by the fact that this 
haplotype does not contain the protective TLR9 +2848-A allele. Knockout (KO) mice 
data showed that the presence of the TLR9 gene is essential to combat meningococcal 
infection [25]. The in silico analysis showed a very strong immunoinhibitory potential 
(CpG index of -106.8) for the DNA from NM. Combining the SNP, haplotype, KO-
mice data, and in silico analyses, one might hypothesize that the TLR9 +2848-A 
mutant results in an upregulation of TLR9 induced immune response, compensating 
for the strong inhibitory potential of NM CpG DNA.
Besides activation of microglia and astrocytes [5, 26] and complement mediated 
bacterial lysis [27] also antibacterial responses like antimicrobial peptides and reac-
tive nitrogen and oxygen radicals are relevant in the pathogenesis of BM. A recent 
study using human embryonic kidney cells reported TLR9 activation by NM [28]. 
Sjolinder et al. reported that TLR9 -/- mice displayed reduced survival, elevated levels 
of bacteremia, and reduced bactericidal activity in vivo compared with wild type 
mice during meningococcal bacteremia [25]. They also found that antigen-presenting 
cells relied entirely on TLR9 to induce activation of signal transduction and induc-
tion of proinflammatory cytokine gene expression. Together, these studies show the 
importance of TLR9 upon bacteremia with NM. We propose that the TLR9 SNPs we 
described are able to enhance TLR9 function and prevent high levels of bacteremia, 
an important step in the pathophysiology of BM.
Once inside the CNS, bacteria are recognized by antigen presenting astrocytes 
and microglia. Intracellular recognition of (bacterial) CpG motifs leads to immune 
activation inside the CNS by the proinflammatory cytokines tumor necrosis factor 
alpha (TNf-α) and interleukin 6 (IL-6) and the granulocytic chemoattracktant IL-8 
[29]. Tauber et al. studies the effects of continuous intrathecal CpG DNA exposure 
to the brain of TLR9 -/- mice in the CNS. Microglia from TLR9 -/- mice could not be 
activated by CpG DNA. Brains of wild-type mice showed more pronounced neuronal 
damage with microglial activation and reactive astrogliosis. These results suggest that 
the unfavorable effects of CpG DNA in the brain are dependent on TLR9 and may 
contribute to neuroinflammation [30]. Very recently, Ribes et al. reported increased 
phagocytic activity by murine microglia activated with agonists for TLR2, -4, and -9 
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upon exposure by SP [31]. We speculate that this might also happen in MM and that 
the TLR9 SNPs we described result in enhanced phagocytosis by microglia inside 
the CNS. In contrast, by using mice with single- or combined deficiencies of TLR2, 
TLR4, or TLR9, Klein et al. demonstrated that TLR2 and TLR4 play an essential role in 
PM, whereas additional TLR9 deficiency did not result in further attenuation of the 
inflammatory reaction observed TLR2-TLR4-double deficient mice [32]. We did not 
find this protective TLR9 effect in our SP cohort either.
The strength of this study is that we focused exclusively on meningitis patients to 
find the host genetic determinant of this specific disease. We recruited a large group 
of MM survivors and found very significant results. Our cohort of PM survivors was 
relatively small however, and we could not find significant results for this group. In 
our study we used a healthy adult control group, but we have no specific information 
on a history of BM. However, since the maximum incidence of BM in the Netherlands 
was low (incidence per 100.000 inhabitants varied between 4.8 and 1.6 during the 
period 1999–2008 in the Netherlands) [2], we considered it a representative control 
group for immunogenetic research on BM. DNA from children with fatal BM who suf-
fered the most severe infections was not available. We expect, however, that includ-
ing DNA of fulminant cases will only make the association we found for susceptibility 
to BM stronger, although future studies focusing on the severity of BM specifically 
would be of interest in this respect but these cases are rare and collecting 400 cases 
would be near to impossible.
The results we found in this study will guide future research on genetic studies in 
susceptibility to and severity of BM in our cohort. Genetic studies can reveal relevant 
SNPs in immune response genes influencing the pathogenesis of BM. This might also 
identify potential drug targets. for example, TLR activation leads to cytokine produc-
tion mostly via nuclear factor kappa B (NfκB) and the mitogen-activated proteins 
kinase (MAPK) family. Clinical trials are prepared to block NfκB and MAPK transcrip-
tion [33, 34]. However, none of such potential drugs are used for clinical practice 
yet. Identification of specific SNPs could be used to develop a customized treatment 
fitting the patient´s genetic profile and decreasing side effects. Patients carrying 
SNPs known to influence the immune response might receive medication to either 
stimulate or inhibit this response. Better understanding of the role of immunogenetics 
in the pathogenesis of BM may allow the prediction of individual risk to develop 
BM, enabling a tailored approach to follow up. Besides clinical factors, host-genetic 
factors (SNPs) may be valuable markers for the prediction of long term consequences 
of BM including hearing loss, and neuropsychological complications [17, 18, 35] in 
an early stage of disease. Multiple associations have already been described between 
SNPs in innate immunity genes and the outcome of SP and NM infections [36–38].
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Three important steps have to be made to translate these findings into patient man-
agement: (1) the study has to be confirmed and additional SNPs in other genes have 
to be added in a genetic trait to obtain synergy in the prediction of susceptibility or 
protection to BM, (2) this genetic trait has to be added to potentially strengthen cur-
rent clinical prediction rules on complication rates after BM which include hearing 
loss and academic and behavioral limitation [16–18], and (3) strategies to promote 
a faster path for genetic knowledge from bench to bedside have to be implemented. 
The various stakeholders in public health play a key role in translating the implica-
tions of genomics such as deriving from molecular epidemiology and host-pathogen 
genomics. This knowledge will not only enable clinical interventions but also health 
promotion messages and disease prevention programs to be targeted at susceptible 
individuals as well as subgroups of the population based on their genomic profile 
(personalized healthcare) [39, 40]. The field involved in this translation is called 
Public Health Genomics, which has as major task in ‘‘the responsible and effective 
translation of genome-based knowledge and technologies into public policy and 
health services for the benefit of population health’’ (Bellagio statement, 2005: see 
www.graphint.org for details).
conclusIons
In summary, our findings provide another step toward the use of SNPs in immune 
response genes as valuable markers to assess the risk to develop BM. Additional immu-
nogenetic studies with larger sample sizes, validation cohorts, and genotyping includ-
ing multiple synergistic genes and more complete haplotype information will help to 
elucidate the pathophysiology of meningitis and to explain the inter-patient variability 
in BM, largely depending on the ability of the (innate) immune system to clear the 
infection, with as an ultimate goal to predict the course and outcome of infection.
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Men mijde de serieuzen, want zij missen de ernst. 
Zij zijn zo lichtzinnig, dat zij hun mening voor de enige 
waarheid houden. 
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aBsTRacT
Background
Genetic variation in immune response genes is associated with susceptibility and se-
verity of infectious diseases. Toll-like receptor (TLR) 9 polymorphisms are associated 
with susceptibility to develop meningococcal meningitis (MM). The aim of this study 
is to compare genotype distributions of two TLR9 polymorphisms between clinical 
severity variables in MM survivors.
Methods
We used DNA samples of a cohort of 390 children who survived MM. Next, we 
determined the genotype frequencies of TLR9 -1237 and TLR9 +2848 polymorphisms 
and compared these between thirteen clinical variables associated with prognostic 
factors predicting adverse outcome of bacterial meningitis in children.
Results
The TLR9 -1237 TC and CC genotypes were associated with a decreased incidence 
of a positive blood culture for Neisseria (N.) meningitidis (p = 0.014, odds ratio 
(OR) 0.5. 95% confidence interval (CI) 0.3 – 0.9). The TLR9 +2848 AA mutant was 
associated with a decreased incidence of a positive blood culture for N. meningitidis 
(p = 0.017, OR 0.6, 95% CI 0.3 – 0.9). Cerebrospinal fluid (CSF) leukocytes per μL 
were higher in patients carrying the TLR9 -1237 TC or CC genotypes compared to 
carriers of the TT wild type (WT) (p = 0.024,medians: 2117, interquartile range (IQR) 
4987 versus 955, IQR 3938). CSF blood/glucose ratios were lower in TLR9 -1237 TC 
or CC carriers than in carriers of the TT WT (p = 0.017, medians: 0.20, IQR 0.4 versus 
0.35, IQR 0.5). CSF leukocytes/μL were higher in patients carrying the TLR9 +2848 
AA mutant compared to carriers of GG or GA (p = 0.0067, medians: 1907, IQR 5221 
versus 891, IQR 3952).
conclusions
We identified TLR9 genotypes associated with protection against meningococcemia 
and enhanced local inflammatory responses inside the central nervous system, im-
portant steps in MM pathogenesis and defense.
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BackGRound
The susceptibility, severity and prognosis of infectious diseases depend on the ability 
of the host immune system to respond to pathogens. Genetic variation of immune 
response genes is associated with susceptibility to and severity of infectious diseases 
(1). Bacterial meningitis (BM) is a serious and life-threatening infectious disease of 
the central nervous system (CNS). Despite adequate antibiotic treatment and im-
munization strategies, mortality remains high, especially in developing countries 
(2;3). Neisseria (N.) meningitidis is a common causing pathogen of BM, both in the 
Western world as in developing countries. The clinical course of meningococcal 
meningitis (MM) is highly diverse and depends both on pathogen characteristics as 
on the individual immune response of the affected patient. Host-bacteria interac-
tions are crucial in defense against MM (4). Acquisition of N. meningitidis may lead 
to bacterial colonization in one patient and to fatal MM or meningococcal septic 
shock in the other. Survivors of BM have a high risk to develop neurological se-
quelae, ranging from subtle learning and behavioral disorders to deafness, paresis, 
and severe encephalopathy (5-7). Innate immunity is of particular importance as first 
line of defense since it quickly senses pathogen invasion by pattern recognition and 
subsequently initiates the immune response. Toll-like receptors (TLRs) are a class of 
pathogen recognition receptors (PRRs) that are key players of innate immunity. It 
becomes increasingly clear that TLR mediated meningeal inflammation is a pivotal 
factor for meningitis associated tissue damage (8). TLR9 is an intracellular PRR, which 
recognizes unmethylated Cytosine-phosphate-Guanine (CpG) motives in pathogen 
DNA (9). Meningococcal CpG DNA enters TLR9 expressing cells by endocytosis and 
then binds to TLR9. A cascade of intracellular receptor signaling via myeloid dif-
ferentiation protein 88 (MyD88) induces activation of transcription of nuclear factor 
kappa B (NfkB) resulting in the production of cytokines and chemokines (10). TLR9 
is present in phagocytosing microglia and antigen presenting astrocytes inside the 
CNS, cells responsible for adequate immune responses in this compartment (11). 
In a previous study we demonstrated that the TLR9 +2848 SNP is associated with a 
decreased susceptibility to MM (12). Recent studies showed that carriage of the TLR9 
-1237 C variant allele creates a potential nuclear factor kappa B (NfκB) binding site 
that increases the transcriptional activity of TLR9 and enhances cellular production 
of pro-inflammatory cytokines (13).
The purpose of this study is to compare the genotype distributions of TLR9 -1237 
and TLR9 +2848 single nucleotide polymorphisms (SNPs) between thirteen clinical 
severity variables in order to identify patients at risk for severe disease and sequelae.
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MeThods
 The study population consists of 390 Dutch Caucasian children who survived MM. 
These patients were identified by the Dutch Reference Laboratory for Bacterial Men-
ingitis. The diagnosis of MM was based on a positive cerebrospinal fluid (CSF) culture 
with N. meningitidis or meningococcal antigens in the CSf. A total of 560 children 
were asked to participate in the study and to return a sterile swab after collecting 
their buccal DNA, of whom 390 patients (70%) returned a buccal swab and informed 
consent form. Patients were diagnosed between January 1990 and December 1995 
and this cohort was previously described in detail by Koomen et al. (6;7). A similar 
validation cohort of 76 children developed BM between 1997 and 2001 (14). Data 
for our study were collected in the period from 2006 till 2010. Median age at infec-
tion was 2,5 (range 0.1 – 9.5) years, 46.5% were female, 53.5% were male. Data on 
medical history, physical examination, clinical course during hospitalization, and 
laboratory results were gathered from the medical records of all patients.
Children with ‘complex onset’ of meningitis (defined as meningitis secondary to 
immune deficiency states, cranial trauma, CNS surgery, and CSF shunt infections), 
relapsing meningitis, or meningitis in the neonatal period were excluded. 
The Medical Ethical Committee of the VU University Medical Center, Amsterdam, 
The Netherlands approved this study. 
TLR9 -1237 (rs5743836) and TLR9 +2848 (rs352140) SNPs were analyzed in buc-
cal DNA by TaqMan analysis using the standard TaqMan protocol. The AbiPrism® 
7000 Sequence Detection System (Applied Biosystems, UK) was used to obtain data. 
Primers and probes we used have been described previously (12). The two TLR9 SNPs 
were chosen based on a study by Lazarus et al. In three ethnic groups they found 20 
TLR9 SNPs. A set of four frequent TLR9 SNPs (TLR9 -1486, TLR9 -1237, TLR9 +1174 
and TLR9 +2848) accounted for more than 75% of all chromosomes in all three 
populations. Genotyping of both TLR9 -1237 T>C and TLR9 +2848 G>A allows all 
four locus haplotypes to be distinguished (15).
We performed a literature search to identify severity variables. We used clinical 
variables: duration of clinical illness before admission, rectal temperature, convul-
sions, level of consciousness at admission, ICU admission, main clinical diagnosis 
at discharge (meningitis or meningitis with sepsis), and post meningitis hearing loss. 
Convulsions were defined as convulsions reported before or at admission or dur-
ing hospitalization. Post meningitis hearing loss was defined as > 25 dB perceptive 
hearing loss that was not present before meningitis occurred. Laboratory variables 
at admission included: blood culture results, CSF leukocyte numbers, CSF/blood 
glucose ratios, CSf protein concentrations, blood leukocyte numbers, and C-reactive 
protein (CRP) concentrations in serum. The selected variables were in accordance 
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with a recent systematic review summarizing the evidence regarding prognostic fac-
tors predicting death or sequelae after BM in children (16). We distinguish continuous 
and dichotomous variables. Continuous variables were dichotomized according to 
clinical relevant cut off points known from the literature i.e. duration of clinical ill-
ness before admission > 2 days, rectal temperature ≥ 38°C, CSF leukocyte numbers > 
600 and > 1000 (17;18), CSF blood/glucose ratio ≤ 0.4, CSF protein concentration > 
0.7 g/L, blood leukocytes > 20x10e9 g/L, and serum CRP concentration > 100 mg/L 
(16).
Within selected severity groups, we compared the distribution of TLR9 -1237 and 
+2848 genotypes. for statistical analysis, SPSS for Windows 17.0 and Graphpad 
Prism 5 were used. Genotype distributions were checked for deviations of the Hardy-
Weinberg equilibrium (HWE). Recessive and dominant models were used to model 
the relations between genotype distributions and clinical variables. Histograms were 
used to assess normality of the clinical variables. T-tests, Mann-Whitney U tests, and 
χ2 test or fisher’s exact tests were used where appropriate. Outliers (< 4%) were 
excluded by the Grubbs’ test (p< 0.01) before continuous testing. P values < 0.05 
were considered statistically significant. 
ResulTs
Table 1 shows the distribution and characteristics of the severity variables in the study 
population. Differences in numbers of patients are due to missing or non-determined 
data in patient records.
Continuous variables i.e. duration of clinical illness, rectal temperature, CSf 
leukocyte numbers, CSF/blood glucose ratios, CSF protein concentrations, blood 
leukocytes, and serum CRP concentrations were compared between carriers of wild 
type (WT) alleles and mutant alleles in MM patients for TLR9 -1237 and TLR9 +2848 
respectively. Figure 1A shows that CSF leukocyte numbers were significantly higher 
in MM patients carrying the TLR9 -1237 TC or CC genotypes compared to carriers 
of the TT WT genotype (median 2117, interquartile range (IQR) 4987 versus median 
955, IQR 3938). 
CSF/blood glucose ratios were significantly lower in TLR9 -1237 TC or CC carriers 
than in carriers of the TT WT (p = 0.017, median 0.20, IQR 0.4 versus median 0.35, 
IQR 0.5) (Figure 1B). CSF leukocytes/μL were significantly higher in patients carrying 
the TLR9 +2848 AA mutant compared to children with genotype GG or GA. (p = 
0.0067, median 1907, IQR 5221 versus median 891, IQR 3952) (Figure 1C). There 
was no significant difference in CSF/blood glucose ratios for TLR9 +2848 genotypes 
(results not shown).
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No significant differences in genotype distributions of -1237 and +2848 SNPs were 
found for the other continuous variables (data not shown). 
Dichotomous variables, i.e. blood culture, convulsions in patient history, level of con-
sciousness at admission, ICU admission, sepsis and hearing loss and the dichotomized 
continuous variables (as described above) were compared between WT carriers and 
mutant carriers. TLR9 -1237 TC or CC mutant carriers were compared to the TT WT carri-
ers. Significant associations are shown in Table 2A. The TLR9 -1237 TC and CC genotypes 
were associated with a decreased incidence of a positive blood culture for N. meningitidis 
(p = 0.014, odds ratio (OR) 0.5, 95% confidence interval (CI) 0.3 – 0.9). These genotypes 
were also associated with CSF leukocyte levels > 1000 per μL (p= 0.029, OR 1.7, 95% CI 
1.1 – 2.8), and with a CSF/blood glucose ratio ≤ 0.4 (p = 0.015, OR 2.0; 95% CI 1.1 – 3.6). 
No significant differences in TLR9 -1237 genotype distribution were observed 
between the groups classified by the other severity variables (data not shown). 
Table 1. Distribution and characteristics of 13 severity variables in children with meningococcal 
meningitis
Severity variable Total
 Continuous variable Median Range N
Duration of clinical illness before 
admission (days) 
1.7 0.5 – 13.0 324
Rectal temperature (°C) 39.1 35.0 – 41.8 358
CSf leukocytes (μL) 1 227 0.0 – 12 081 354
CSF/blood glucose ratio 0.34 0 – 1.77 280
CSF protein concentrations (g/L) 1.4 0.01 – 9.33 317
Blood leukocytes (x10^9 g/L) 16.2 0.8 – 57.2 382
C-reactive protein (CRP) (mg/L) 129 0 – 768 229
Dichotomous variable N N    (%) N   (%) N
N. meningitidis in blood culture No  187 (54) Yes 161 (46) 348
Convulsions No 355 (91) Yes 35 (9) 390
Level of consciousness at admission Normal 133 (35) Disturbed 242 (65) 375
ICU-admission No 302 (78) Yes 87 (22) 389
Main clinical diagnosis at discharge:
(MM without/with sepsis)
No sepsis 219 (56) Sepsis 171 (44) 390
Post meningitis hearing loss No 375 (96) Yes 15 (4) 390
Academic and behavioural limitations No 90 (61) Yes 57 (39) 147
Abbreviations: CSF: cerebrospinal fluid,  ICU: intensive care unit,MM: meningococcal meningitis. 
Different numbers within groups are due to missing or non-determined data in patient records.
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figure 1a. Comparison of CSf leukocytes per μL in TLR9 -1237 TC/CC cariers versus wild type (WT) 
carriers. Carriers of TLR9 -1237 TC/CC  had significantly higher CSF leukocyte numbers compared to 
carriers of the TT WT (medians: 2117, interquartile range (IQR) 4987 versus 955, IQR 3938). Mann-
Whitney U test, * p = 0.024.
Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide polymorphism, CSF: cerebrospinal fluid, 
ul: microliter.
 
figure 1B. Comparison of CSF/blood glucose ratios in TLR9 -1237 TC/CC carriers versus WT carriers.
Carriers of TLR9 -1237  TC/CC  alleles display significant lower ratios compared to carriers of the TT 
WT (medians: 0.20, IQR 0.4 versus 0.35, IQR 0.5). Mann-Whitney U test, * p = 0.017.
Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide polymorphism, CSF: cerebrospinal fluid, 
ul: microliter.
 
figure 1c. Comparison of CSf leukocytes per μL in TLR9 +2848 AA mutant carriers versus GG/GA 
carriers. Carriers of the TLR9AA  mutant  display significantly higher CSF leukocyte levels compared 
to GG/GA carriers (medians: 1907, IQR 5221 versus 891, IQR 3952). Mann-Whitney U test, ** p = 
0.0067.
Abbreviatons: TLR: Toll-like receptor, SNP: single nucleotide polymorphism, CSF: cerebrospinal fluid, 
ul: microliter.
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Table 2a. TLR9 -1237 SNPs and severity variables in meningococcal meningitis patients (p < 0.05)
 Severity variable TLR9 -1237 P OR 95% CI
N (%)
 TT TC CC Total
N. meningitidis in blood culture 
Positive 127 (80) 29  (18)* 3 (2)* 159 0.014 0.5 0.3 – 0.9
Not detected 124 (68) 52 (29)* 6 (3)* 182
Total 251 81 9 341
CSf leukocytes per μL  
≤ 1000 129 (78) 34 (21)* 2 (1)* 165 0.029 1.7 1.1 – 2.8
> 1000 127 (68) 52 (29)* 6 (3)* 183
Total 253 87 8 348
CSF/blood glucose ratio
≤ 0.4 114 (69) 46 (28)* 6 (4)* 166 0.015 2.0 1.1 – 3.6
> 0.4 90 (82) 18 (16)* 2 (2)* 110
Total 204 64 8 276
*  = Significance p < 0.05.
Abbreviations: TLR: Toll-like receptor, OR: Odds ratio, 95% CI: 95% confidence interval, CSF: 
cerebrospinal fluid. Different numbers within groups are due to missing or non-determined data in 
patient records.
Table 2B. TLR9 +2848 SNPs and severity variables in meningococcal meningitis patients (p < 0.05)
Severity variable TLR9 +2848 P OR 95% CI
N (%)
 GG GA AA Total
N. meningitidis in blood culture 
Positive 42 (27) 80 (51) 36 (23)* 158 0.017 0.6 0.3 – 0.9
Negative 40 (22) 79 (43) 63 (35)* 182
Total 82 159 99 340
CSF leukocytes/μL
≤ 600 36 (27) 66 (50) 30 (23)* 132 0.028 1.7 1.1 – 2.9
> 600 50 (24) 91 (43) 72 (34)* 213
Total 86 157 102 345
≤ 1000 41 (25) 85 (53) 36 (22)* 162 0.005 2.0 1.2 – 3.2
> 1000 45 (25) 72 (39) 66 (36)* 183
Total 86 157 102 345
* = Significance p < 0.05
Abbreviations: TLR: Toll-like receptor, OR: Odds ratio, 95% CI: 95% confidence interval, CSF: 
cerebrospinal fluid. Different numbers within groups are due to missing or non determined data in 
patient records.
Table 3. TLR9 haplotypes and severity variables in meningococcal meningitis patients (p < 0.05)
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TLR9 +2848 mutant carriers were compared with WT carriers. Significant asso-
ciations are shown in Table 2B. TLR9 +2848 AA was associated with a decreased 
incidence of a positive blood culture (p = 0.017, OR 0.6, 95% CI 0.3 – 0.9). The TLR9 
+2848 AA mutant was also significantly more present in children with > 600 and > 
1000 leukocytes per μL (p = 0.028, OR 1.7, 95% CI 1.1 – 2.9 and p = 0.005, OR 2.0, 
95% CI 1.2 – 3.2 respectively). 
No significant differences for TLR9 +2848 genotype distribution were observed 
between the groups classified by the other severity variables (data not shown). 
Table 3 shows that TLR9 haplotype I was very significantly associated with blood 
cultures positive for N. meningitidis (p = 0.001, OR 1.5, 95% CI 1.1 – 2.0). Haplotype 
I was also significantly associated with decreased CSF leukocytes (less than 1000/μL: 
p = 0.03; OR 0.7 95% CI 0.5-1.0). No significant differences in haplotype distribution 
were observed for other severity variables (data not shown). 
dIscussIon
We demonstrate that the TLR9 -1237 and +2848 SNPs are associated with severity 
variables in a cohort of MM survivors. In order to assess the biological consequence 
of this statistical association we focus on the essential steps in BM pathogenesis and 
Severity variable TLR9 
haplotype¹
N (%)
P OR 95% CI
TLR9-1237
TLR9+2848
I
T
G
II
T
A
III
C
A
IV
C
G
Total 2N
N. meningitidis in blood culture
Positive 162 (51)** 119 (38) 33 (10) 2 (1) 316 0.001 1.5 (1.1 – 2.0)
Negative 148 (41)** 147 (41) 59 (16) 4 (1) 358
Total 310 266 92 6 674
CSf leukocytes per μL
≤ 1000 164 (50)* 122 (38) 36 (11) 2 (1) 324 0.03 0.7 (0.5 – 1.0)
>1000 154 (42)* 144 (40) 60 (17) 4 (1) 362
Total 318 266 96 6 686
¹ haplotypes as defined by Lazarus et al, ref 15.
* =  Significance p < 0.05
Abbreviations: TLR: Toll-like receptor CSF: cerebrospinal fluid, OR: odds ratio.
Different numbers within groups are due to missing or non-determined data in patient records.
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the recognition of N. meningitidis by TLR9. Meningococci colonize the nasopharynx 
and may penetrate the mucosal barrier of the upper respiratory tract by transcellular 
passage of epithelial cells (19). During this process meningococci are recognized by 
intracellular TLR9 of sinonasal epithelial cells (20). After passage of this epithelial 
barrier meningococci are able to pass directly from the nasopharynx to meninges 
through the olfactory nerve system but more frequently they will enter the blood-
stream (21). Survival of bacteria within the circulation is a prerequisite for meningeal 
invasion. Complement-mediated opsonophagocytosis of N. meningitidis leads to 
activation of phagocytosing cells via TLR9 (22). Upon survival in the bloodstream 
meningococci may attach to and traverse the blood-brain barrier by endocytosis, 
they will multiply in the subarachnoidal space and are recognized by astrocytes and 
microglia, dendritic cells and macrophages of the brain respectively and in direct 
contact with the CSf (23). After being phagocytosed, meningococcal DNA motifs 
activate endosomal TLR9 and subsequent signal transduction occurs, stimulating the 
production of cytokines inside the CNS and chemokines leading to leukocyte recruit-
ment towards the CNS (24;25). 
We associated TLR9 SNPs with protection against meningococcemia, a prerequi-
site for meningeal invasion, and with elevated CSf leukocyte levels during MM. A 
decreased incidence of positive blood cultures in children carrying TLR9 -1237 C 
allele and TLR9 +2848 AA genotypes may represent a reduction in the occurrence 
of secondary bacteremia due to more pronounced host immune response in the CSf. 
A possible mechanistic explanation and biological consequence is increased NfκB 
binding to the TLR9 promotor region, leading to increased transcriptional regulation 
of TLR9 (13). We confirmed this mechanism in our study population using a novel in 
silico regulatory SNP detection method as described by McIntyre et al. (26): The TLR9 
-1237 “C” variant was associated with significantly increased binding of NFκB, avian 
reticuloendotheliosis viral oncogene homolog A (RelA) and signal transducer and 
activator of transcription (STAT3) to the TLR9 -1237 C variant (Figure 2). According 
to these predictions, the TLR9-1237 C allele creates an increased affinity for NFκB 
which in its turn increases the transcriptional activity of the gene, leading to enhanced 
production of cytokines and chemokines. This effect was present in stimulated cells, 
but not under basal conditions, which may explain an association of TLR9-1237 
with severity, but not susceptibility to MM. Carvalho et al. reported that the C allele 
of TLR9-1237 introduced a new IL-6-dependent transcription factor-binding site in 
the TLR9 promoter. Peripheral blood mononuclear cells (PBMCs) harbouring the 
TC genotype show higher expression of both TLR9 and IL-6 and increased B-cell 
proliferation in response to CpG (27). Another study showed higher serum Interferon 
gamma levels in children carrying the TLR9-1237-C allele with cerebral malaria, 
indicating that enhanced TLR9 mediated immune responses are also relevant inside 
TLR9 SNPs and severity of BM 127
C
H
A
PT
ER
 7
the CNS (28). The +2848 SNP does neither result in an amino acid change nor to the 
modification of a regulatory site, implying linkage of a functional relevant SNP in the 
vicinity of this SNP.
In a mouse meningococcal bacteremia model the role of TLR9 in preventing bac-
teremia was also confirmed. TLR9 KO mice displayed reduced survival and elevated 
levels of bacteremia compared to WT mice (22). We associated TLR9 polymorphisms 
with prevention of bacteremia and higher levels of leukocytes in the CSf. The link 
between systemic inflammation and pleocytosis was previously studied. Intravenous 
injection of LPS prior to intracisternal LPS injection in rabbits led to impaired pleocy-
tosis, reduced levels of TNf-α, and impaired leukocyte influx into the CNS reflecting 
an impaired inflammatory response in the CNS (29). 
Clinical studies show that the most severely affected patients with MM or septic 
shock with a rapidly evolving septic shock associated with high mortality have sig-
nificant lower levels of pleocytosis (30). Although we found an association of TLR9 
SNPs with bacteremia, no association was found with clinical sepsis. We propose 
that TLR9 -1237 and +2848 polymorphisms have a beneficial effect on preventing 
bacteremia and increase the leukocyte influx in the CNS, reflecting an enhanced 
immune response inside the CNS.
 
figure 2. Schematic diagram of Toll-like receptor-9 (TLR9) -1237 and +2848 SNP positions and 
transcription factor (Tf) binding sites in the TLR9promotor region.In silicoanalyses show that the 
C allele at position -1237 creates extra putative binding sites for Nuclear factor kappa B (NfκB), 
avian reticuloendotheliosis viral oncogene homolog A (RelA) and signal transducer and activator 
of transcription (STAT3). RelA is able to bind to NFkB to form the NFkB complex. STAT3 is able to 
activate transcription in the nucleus in response to cytokines. These processes may upregulate the 
expression of TLR9, altering the TLR9 initiated innate immune response to meningococcal DNA, 
affecting the clinical severity of meningococcal meningitis (partly adapted from Ng et al, ref. 13). 
Abbreviations: TF: transcription factor, R: A/G, N: any base, Y: C/T, W: A/T,  D: A/T/G.
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Although CNS inflammation is necessary to guarantee sterility of the CNS, its injuri-
ous properties are also evident. An adequate but balanced inflammatory response 
inside the CNS is essential in limiting adverse outcome of disease. We concluded 
that TLR9 polymorphisms have a small but possibly important contribution to warrant 
balance between beneficiary and injurious effects of inflammation in the CNS. For 
exact consequences of these SNPs, future studies focussing on TLR9 SNPs and long 
term consequences of BM should be performed.
This study does have certain aspects that limit the interpretations. Survivors of MM 
were retrospectively included in our study. DNA from children with fatal meningitis 
were not a focus of our study because including survivors of MM allows us to obtain 
detailed information on follow-up and long term consequences of the disease which 
are of particular clinical relevance. In addition, the number of patients with fatal 
meningitis is very low in The Netherlands. The effect of treatment of BM was not 
incorporated in this study. This effect may not be of great influence since comparable 
protocols for treatment of BM were used nationwide in the period these children have 
been admitted to Dutch hospitals, and timing of treatment is divided equally between 
groups and independent of genotype distribution. 
Multidisciplinary efforts are needed in order to bundle and translate genetic studies 
into beneficial interventions (personalized medicine, risk profiling, disease treatments 
with better specificity and innovative drug therapies) enforced by the field called 
Public Health Genomics (31). 
We have performed several statistical analyses and therefore also performed cor-
rections for multiple testing. Using the rough false discovery rate (rfDR) would shift 
the threshold for statistical significance from <0.05 to <0.026, reducing the number 
of significant associations described in this paper. Using the more conservative Holm-
Bonferroni corrections, shifts the threshold to <0.002, resulting in one remaining 
significant association (TLR9 haplotype I and N. meningitidis). Although the multiple 
testing corrections reduce the number of statistically significant associations of the 
exploratory study, the trends that remain give indications for potential roles of the 
studied variables in the severity of bacterial meninigitis.
More association and functional studies on TLR9 SNPs, functional consequences 
and long term effects in the CNS are needed to reveal the exact mechanism causing 
the differences in clinical course of MM and to obtain genetic traits which can be 
used for patient profiling and management of meningitis patients. 
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conclusIons
In this study, TLR9 -1237 and TLR9 +2824 mutant genotypes were associated with 
protection against meningococcemia, an essential prerequisite for meningeal inva-
sion. We also associated these SNPs with enhanced local inflammatory responses 
inside the CNS. Carriers of the TLR9+2848 mutant genotype have a lower chance of 
developing meningitis when colonized with N. meningitidis. When they eventually 
do so, they will have more efficient bacterial killing inside the CNS but may also 
result in a higher chance of developing neurological sequelae. 
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aBsTRacT
Bacterial meningitis (BM) is a serious central nervous system infection, frequently 
occurring in childhood often resulting in hearing loss, learning disabilities and en-
cephalopathy. Genetic variation in pathogen recognizing genes affects susceptibility, 
severity, and outcome of BM. The aim of this study is to describe the effect of single 
nucleotide polymorphisms (SNPs) in pathogen recognizing genes on susceptibility to 
develop BM.
Genotype frequencies of eight SNPs, in five immune response genes, in 391 menin-
gococcal post-meningitis (MM) and 82 pneumococcal post-meningitis (PM) children 
were compared with 1141 ethnically matched healthy controls.
TLR4 +896 GG predisposed to susceptibility to develop MM (p=1.1 x 10e-5, 
OR=9.4, 95% CI=3.0-29.2). The NOD2 SNP8 mutant was significantly more frequent 
in MM patients compared to controls (p=0.0004, OR=12.2, 95% CI=2.6-57.8). Com-
bined carriage of TLR2 +2477 and TLR4 +896 mutants was strongly associated with 
MM (p=4.2 x 10e-5, OR=8.6, 95% CI=2.7-27.3). A second carrier trait of TLR4 +896 
and NOD2 SNP8 mutants was also strongly associated with susceptibility to develop 
MM (p=4.2 x 10e-5, OR=10.6, 95% CI=2.9-38.6).
This is the first study associating SNPs and genetic traits of immune response genes 
with susceptibility to develop MM, enabling the identification of patients at risk.
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BackGRound
Susceptibility to infections is determined by genetic variation in human populations 
as can be concluded from genetic epidemiology studies. An important challenge is 
identifying the responsible genes and translating these findings into biological mecha-
nistic explanations [1, 2]. Bacterial meningitis (BM) is a severe infectious disease of 
the central nervous system (CNS). It occurs relatively frequent in childhood and often 
affects hearing and learning abilities [3, 4]. Immune responses to pathogens which 
cause BM are primarily aimed at eliminating bacteria from the CNS by recognition of 
microbial ligands and subsequent triggering of production of specific cytokines, but 
also contribute to collateral damage to healthy neuronal tissue and adverse outcome 
[5]. Genetic variation in genes encoding for pathogen recognizing receptors (PRRs), 
such as Toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD) like 
receptors (NLRs), leads to enhanced or decreased inflammatory responses in several 
cell types such as macrophages and epithelial cells [6]. Microglia, the resident mac-
rophages inside the CNS, and neuro-epithelial cells also express TLRs and NLRs. So, 
genetic variation of these receptors might influence susceptibility, severity and out-
come of BM. It was recently shown that two TLR9 single nucleotide polymorphisms 
(SNPs) were associated with increased serum levels of IfN-γ in children with cerebral 
malaria [7]. Several other genetic association studies have shown that SNPs in innate 
immunity genes were associated with susceptibility to meningococcal and pneumo-
coccal disease, including cases of meningitis [8-10]. We previously described that 
carriage of the TLR9 +2848 SNP protects against BM [11].
In this study we focused on genetic variation of innate immune response genes in 
BM caused by Neisseria meningitidis and Streptococcus pneumoniae, the two most 
common causing pathogens of BM in the world [3]. We selected eight SNPs in five 
immune response genes based on BM pathogenesis which usually starts with na-
sopharyngeal colonization, epithelial disruption by bacterial components, enabling 
these bacteria to enter the bloodstream where they replicate and cause bacteremia, 
might cross the blood-brain barrier (BBB) and multiply in the subarachnoid space [8]. 
The immune response inside the CNS upon bacterial entrance starts with pathogen 
recognition by microglia and astrocytes and by non-neural structures in direct con-
tact with the cerebrospinal fluid (CSF), such as dendritic cells and macrophages, all 
expressing PRRs including TLRs and NLRs. PRR activation triggers an intracellular 
signaling cascade resulting in the transcription of pro-inflammatory cytokines and 
chemokines, also inside the CNS [6]. Cytokine induced increased permeability of the 
BBB and chemokine induced influx of inflammatory cells from the bloodstream into 
the CNS result in enhancement of the local inflammatory response inside the brain. 
The clinical consequence is brain edema, raised intracranial pressure, infarction and 
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neuronal injury [12]. The ability of a host to sense CNS invasion by microbes and 
to respond appropriately to control the local infection is essential for killing these 
microbes but the inflammatory response also results in the production of several 
cytotoxic mediators responsible for damage to healthy neuronal cells and thus for 
adverse disease outcome [12]. 
TLR2 and TLR4 are PRRs located on the surface of immune cells and recognize 
cell wall components of both Gram-positive and Gram-negative bacteria. Animal 
data have shown that deficiency of TLR2 and TLR4 leads to reduced bacterial clear-
ance from the CNS in response to S. pneumoniae infection [13]. NOD1 and NOD2 
recognize degradation products of petidoglycan (PGN), an essential component of 
the cell wall of almost every bacterium. Isolated cultures of murine astrocytes and 
microglia constitutively express robust levels of NOD2 after exposure to both N. 
meningitidis [14] and S. pneumoniae [15]. Cysteine-dependent aspartate-directed 
protease (Caspase) plays an essential role in apoptosis. Activation of intracellular 
caspase-1 (CASP1) upon pathogen recognition by TLRs and NODs defends the host 
against infection by secretion of the pro-inflammatory cytokines IL-1β and IL-18 via 
the IL-1 receptor, and by the induction of apoptosis of infected cells [16]. CASP1 
levels are up regulated in the CSf of patients with BM and correlate with clinical 
outcome, assessed by the Glasgow Coma Scale and CASP1 -/- mice intracerebrally 
infected with S. pneumoniae show a significantly attenuated increase of IL-1β, lower 
CSf leukocytes and an improved clinical status [17].
The aim of this study was to identify the effect of genetic variation in the aforemen-
tioned five genes on susceptibility to BM by comparing gene frequencies in post-
meningitis children with healthy controls.  Genetic association studies frequently 
focus on a single gene or SNP. We also studied the potential synergistic effects of 
SNPs by defining traits in biological relevant SNP combinations.
MeThods
patients
Figure 1 shows a flow chart of patient inclusion in this study. The cohort of school age 
survivors of meningitis is composed of two independent, comparable cohorts, de-
scribed by Koomen et al. and a validation cohort [18, 19]. All patients were selected 
from data on bacterial CSf isolates of the Netherlands Reference Laboratory for 
Bacterial Meningitis. Only Dutch-Caucasian survivors of meningococcal meningitis 
(MM) and pneumococcal meningitis (PM) were asked to participate in this study. The 
original cohort consists of children born between January 1986 and December 1994 
who survived BM between January 1990 and December 1995. The validation cohort 
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from BM between January 1997 and December 2001. Clinical characteristics of both 
cohorts were comparable and no significant differences in genotype distributions 
were observed between both cohorts.
Six hundred seventy one (671) eligible patients were asked to return a sterile swab 
after collecting their buccal DNA. Of these patients a total of 473 (70%) gave informed 
consent and returned a buccal swab. The cohort consisted of 391 former MM patients 
and 82 former PM patients. The median age of all patients at the time of infection was 
2.2 years of age (range 0.1 – 9.5) and 56 % were male. Children with ‘complex onset’ 
of meningitis (defined as meningitis secondary to immune deficiency states, cranial 
trauma, CNS surgery, and CSf shunt infections, meningitis in the neonatal period) or 
Cohort 1
677 non- Hib
Meningitis pt
38 other
causative 
organisms
639
522 MM
117 PM
45 non-Dutch-
Caucasian
594 Dutch 
Caucasians
671 eligible
473 included/
genotyped
Cohort 2
116 non-Hib
meningitis pt
2 other
causative
organisms
114
92 MM
22 PM
37 non-Dutch-
Caucasians
77 Dutch 
Caucasians
figure 1. flow chart of patient inclusion in this study
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relapsing meningitis were not included. The Medical Ethical Committee of the VU 
University Medical Center approved this study.
controls
Controls were unselected blood donors and population controls, drawn from volun-
teers at the University Medical Centers of Utrecht and Groningen. Written informed 
consent was obtained from all subjects, with Ethics Committee approval of both in-
stitutions. Genotype data for 1141 control samples were extracted from Immunochip 
platforms using PLINKv1.07 [20, 21]. 
dna isolation
DNA was isolated from the buccal swabs using the following procedure: after ad-
dition of 250 ml 10 mM Tris-HCl (pH 7.4) the sample was heated at 96 °C for 10 
minutes. After mixing for 10 seconds the swabs were removed and the sample was 
centrifuged few seconds (14000 rpm). In controls, venous blood (5-10 ml) was drawn 
and genomic DNA was isolated using standard protocols and 5-100 ng of genomic 
DNA was used each cycle of genotyping.
Genotyping
All samples were genotyped for the TLR2 +2477 G>A (rs5743708), TLR4 +896 A>G 
(rs4986790), CARD4/NOD1 +32656 C>A (rs6958571),CARD15/NOD2 +2209 A>T 
(rs2066844), CARD15/NOD2 +2722 G>T (rs2066845) CARD15/NOD2 +3020 ins 
C (rs2066847) and CASP1-8404 A>G (rs2282659) SNPs by real-time polymerase 
chain reactions (RT-PCR) using the TaqMan AbiPrism® 7000 Sequence Detection 
System (Applied Biosystems, UK) and the the LightCycler® 480 System (Roche Ap-
plied Science, US),using standard manufacturer’s protocols. Twice two independent 
researchers checked results. 
statistics
Genotypes were compared between cases and controls for MM and PM separately 
and for all cases of BM together using Graphpad Instat. Hardy-Weinberg tests were 
used to check the observed genotype distributions in the control population. fisher’s 
exact tests were used to calculate statistical significance of differences in genotype 
frequencies between cases and controls. P-values < 0.05 were considered statisti-
cally significant in single gene analyses.  Subsequently, the single genotypes were 
used to define carrier traits. After correction for multiple testing according to Holm-
Bonferroni, p-values < 0.0006 turned out to be statistically significant in the trait 
analyses.
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ResulTs
hardy-Weinberg tests
Genotype distributions of all SNPs in the controls were in Hardy-Weinberg Equilib-
rium (HWE). 
single gene analysis
Genotype frequencies of BM patients were compared to those in controls and MM 
and PM patients were also separately compared to controls in order to discover as-
sociations between SNPs and susceptibility to a specific pathogen. The results are 
summarized in Table 1. Differences in numbers of cases and controls were due to 
differences in quality of DNA in the samples. SNPs that could not be genotyped after 
three PCR test were excluded.
Carriage of homozygous mutant alleles for TLR4 +896 predisposed to susceptibility 
to develop BM. Significantly more BM patients than controls were affected (p=1.1 
x 10e-5, odds ratio (OR) 9.0, 95% confidence interval (CI) 2.9-27.5). This was even 
stronger for MM patients compared to controls (p=1.2 x 10e-5, OR 9.4, 95% CI 
3.0-29.2). For PM patients the difference was not statistical significant.
Differences in genotype frequencies were also found for NOD2 SNP 8 when com-
paring carriage of homozygous mutant alleles with heterozygous or homozygous 
wild types in the total group of BM patients (p=0.001, OR=10.0, 95% CI=2.1-47.4). 
MM patients also carried more often homozygous mutant alleles of NOD2 SNP8 
than controls (p=0.0004, OR=12.2, 95% CI=2.6-57.8). The difference between PM 
patients and controls was not statistically significant.
For the other tested SNPs we did not find differences in genotype frequencies 
comparing patients to controls.
carrier trait analysis
With carrier trait analyses we investigated combinations of SNPs. We studied the 
implication of the combined effect of individual SNPs on susceptibility to BM. Based 
on associated biological pathways and guided by the results of the single gene as-
sociations we tested which combinations of two SNPs showed an enhanced statistical 
association implying synergistic effects of combined gene functions. Table 2 shows 
the traits significantly associated with susceptibility to BM.
Combined carriage of homozygous mutant alleles TLR2 +2477 and TLR4 +896 
strongly enhanced the predisposition to develop BM (p=3.4 x 10e-5, OR=8.4, 95% 
CI=2.7-25.9). This effect was even stronger for MM patients compared to controls 
(p=4.2 x 10e-5, OR=8.6, 95% CI=2.7-27.3), however for PM it did not reach statisti-
cal significance.
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Table 1. Genotype distributions in bacterial meningitis survivors versus controls
SNP Total BM N (%) 473 MM N (%) 391 PM N (%) 82 Controls N (%) 1141
TLR2 +2477
GG
GA
AA
P-value*
OR (95% CI)
466
418 (89.6)
46 (9.9)
2 (0.5)
1
1.2 (0.2-6.7)
384
345 (89.8)
37 (9.6)
2 (0.6)
0.6
1.5 (0.3-8.1)
82
73 (89.1)
9 (10.9)
0 (0.0)
1
1.5 (0.1-29.0)
1141
1041 (91.2)
96 (8.4)
4 (0.4)
TLR4 +896
AA
AG
GG
P-value*
OR (95% CI)
456
401 (87.9)
41 (9.0)
14 (3.1)
< 0.0001
9.0 (2.9-27.5)
376
328 (87.2)
36 (9.6)
12 (3.2)
< 0.0001
9.4 (3.0-29.2)
80
73 (91.2)
5 (6.3)
2 (2.5)
0.05
7.3 (1.3-40.4)
1141
1001 (87.7)
136 (11.9)
4 (0.4)
NOD1 +32656
AA
AC
CC
P-value*
OR (95% CI)
450
260 (57.8)
161 (35.8)
29 (6.4)
0.5
1.2 (0.7-1.8)
372
210 (56.5)
136 (36.6)
26 (6.9)
0.3
1.3 (0.8-2.1)
78
50 (64.1)
25 (32.1)
3 (3.8)
0.8
0.7 (0.2-2.2)
1141
663 (58.1)
414 (36.3)
64 (5.6)
NOD2 SNP8
CC
CT
TT
P-value*
OR (95% CI)
463
414 (89.4)
41 (8.9)
8 (1.7)
0.001
10.0 (2.1-47.4)
381
341 (89.5)
32 (8.4)
8 (2.1)
0.0004
12.2 (2.6-57.8)
82
73 (89.0)
9 (11.0)
0 (0.0)
0.2
1.7 (0.8-3.5)
1141
1063 (93.2)
76 (6.7)
2 (0.1)
NOD2 SNP12
GG
GC
CC
P-value*
OR (95% CI)
454
443 (97.6)
8 (1.8)
3 (0.6)
0.02
17.7 (0.9-344.0)
379
369 (97.4)
8 (2.1)
2 (0.5)
0.06
15.1 (0.7-316.0)
75
74 (98.7)
0 (0.0)
1 (1.3)
0.06
46.0 (1.9-1139.0)
1141
1096 (96.1)
45 (3.9)
0 (0.0)
NOD2 SNP13
-/-
-/C
C/C
P-value*
OR (95% CI)
461
442 (95.9)
18 (3.9)
1 (0.2)
0.3
7.4 (0.3-183.0)
381
365 (95.8)
15 (3.9)
1 (0.3)
0.2
9.0 (0.4-222)
80
77 (96.2)
3 (3.8)
0 (0.0)
NA
NA
1141
1079 (94.6)
62 (5.4)
0 (0.0)
CASP1 -8404
AA
AG
GG
P-value*
OR (95% CI)
469
281 (59.9)
156 (33.3)
32 (6.8)
0.9
1.0 (0.7-1.6)
388
231 (59.5)
132 (34.0)
25 (6.5)
1
1.0 (0.6-1.5)
81
50 (61.7)
24 (29.6)
7 (8.7)
0.5
1.3 (0.6-3.0)
1140
650 (57.0)
414 (36.3)
76 (6.7)
SNP: single nucleotide polymorphism, BM: bacterial meningitis, MM: meningococcal meningitis, PM: 
pneumococcal meningitis, OR: Odds Ratio, 95% CI: 95% confidence interval, NA: not applicable
Different numbers in cases are due to different quality of DNA. 
P-values and ORs were calculated for homozygous mutant alleles versus WT and heterozygous 
alleles. 
Genotype frequencies of BM survivors were compared to those in controls and MM and PM patients 
were also separately compared to controls.
* fisher’s exact test.
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We also found a significant trait with TLR4 +896 and NOD2 SNP8. The combina-
tion of these SNPs when carrying both homozygous mutant alleles showed a strong 
association with BM, most pronounced for MM (for BM p=2.8 x 10e-5, OR=10.4, 
95% CI=2.9-37.1 and for MM p=4.2 x 10e-5, OR=10.6, 95% CI=2.9-38.6 and not 
significant for PM).
Other traits with TLR4 or NOD2 SNPs did not show a combined effect. We also 
could not identify significant associations when combining the other SNPs.
dIscussIon
Comparing genotype frequencies between BM survivors and healthy controls we 
showed that TLR4 +896 and NOD2 SNP 8 were significantly associated with sus-
ceptibility to develop MM. The combined carriage of TLR2 +2477 and TLR4 +896 
mutants as well as the combination of TLR4 +896 and NOD2 SNP8 mutants were 
identified as genetic traits significantly associated with susceptibility to develop MM. 
Our results were highly statistical significant and were robust after correction for 
multiple testing. Associations in the PM patient group showed trends in concordance 
with the results for the MM patients but the number of patients in the pneumococcal 
cohort was not large enough to be statistical significant for any SNP. 
Our study is the first to associate NOD2 with susceptibility to MM, both in 
single gene as in genetic trait analyses. NOD2 is an intracellular PRR containing a 
caspase-recruitment domain (CARD) that recognizes bacterial PGN, also present in 
N. meningitidis. NOD2 SNPs are associated with inflammatory bowel disease and 
share a signaling defect in response to both the Gram-negative cell wall component 
Table 2. Significant results of carrier trait analyses
snp combination Genotype
Total BM
n (%)
MM
n (%)
pM
n (%)
controls
n (%)
TLR4 A>G / TLR2 G>A GG/AA
All other alleles
P-value*
OR 
95% CI
13 (2.9)
440 (97.1)
3.38x10e-5
8.4 
2.7-25.9
11 (2.9)
362 (97.1)
4.17x10e-5
8.6 
2.7-27.3
2 (2.5)
78 (97.5)
0.05
7.3
1.4-40.4
4 (0.4)
1137 (99.6)
TLR4 A>G / NOD2 C>T GG/TT
All other alleles
P-value*
OR 
95% CI
12 (2.7)
437 (97.3)
2.84x10e-5
10.4
2.9-37.1
10 (2.7)
359 (97.3)
4.15x10e-5
10.6
2.9-38.6
2 (2.5)
78 (97.5)
0.04
9.7
1.6-59.1
3 (0.3)
1138 (99.7)
Abbreviations: SNP: single nucleotide polymorphism, BM: bacterial meningitis, MM: meningococcal 
meningitis, PM: pneumococcal meningitis, OR: Odds ratio, 95% CI: 95% confidence interval.
* fisher’s exact test.
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lipopolysaccharide (LPS) as PGN in human experimental studies [22]. Mutant al-
leles of NOD2 were associated with decreased activation of NfkB [23]. A genetic 
susceptibility study in a cohort of pediatric Crohn’s disease (Cd) patients showed sev-
eral genes involved in microbial processing to be associated with Cd development. 
TLR4 and NOD2 were significantly associated with Cd at the individual level and in 
gene-gene interactions [24]. In vitro studies have shown that NOD2 is expressed by 
murine microglia and astrocytes and up regulated after exposure to N. meningitidis 
[25, 26]. Experimental studies in murine glial cells have generated hypotheses on 
the role of these cells in the initiation and progression of inflammation following 
CNS infection. These experiments have shown that inflammatory responses of both 
murine astrocytes and microglia are significantly reduced in the absence of NOD2 
after stimulation with N. meningitidis and that NOD2 plays an important role in 
astrogliosis, demyelinisation and increased murine locomotor activity after menin-
gococcal infection [14]. These findings are absent in NOD2 deficient mice. These 
studies indicate that NOD2 represents an important component in the generation of 
damaging CNS inflammation following meningococcal infection [14]. 
The role of TLRs in CNS infection is well recognized and consists of a combination 
of specific responses to the causative pathogen and also of non-specific activation of 
the innate immune system [27]. Although synergistic effects for TLR2 and TLR4 have 
been described for tuberculosis, malaria and lupus, our study is the first to associate 
a genetic trait for TLR2 and TLR4 SNPs with susceptibility to MM [28]. Although TLR2 
and TLR4 share the downstream MyD88 pathway resulting in NfkB transcription, it is 
also known that TLR2 and TLR4 trigger results in differential patterns of gene expres-
sion [29]. Toll-interleukin 1-domain-containing adaptor-inducing interferon-β (TRIf) 
is another class of adapter proteins involved in TLR signaling. TLR4 activation results 
in the recruitment of both MyD88 and TRIf, whereas TLR2 activation results in the 
recruitment of MyD88 and not TRIf. MyD88 and TRIf are thought to orchestrate 
separate gene arms because of temporal differences in how they activate NfkB [29]. 
Synergy between TLR2 and TLR4 activation has already been described previously 
in murine macrophages upon stimulation with LPS in the production of TNf-α [30, 
31]. Experiments in mice deficient for several redundant PRR showed that TLR2 was 
the most important receptor to sense Gram-positive cell wall components in a model 
of pulmonary inflammation. Surprisingly, TLR4 -/- mice also showed significantly 
decreased signs of pulmonary inflammation, upon Gram-positive infection indicating 
a synergistic effect in vivo [32]. 
The combination of TLR4 and NOD2 SNPs was also strongly associated with 
susceptibility to develop MM. At first sight, this combination might not seem very 
comprehensive considering that TLR4 is a plasma membrane PRR and NOD2 is a 
cytosolic PRR. Recently, however, the combined effect of these receptors was stud-
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ied in a murine macrophage cell line [33]. TLR4 activation with muramyldipeptide 
increased NOD2 mRNA expression and up regulated NOD2 upon activation. On 
the other hand, the study proposed that unstimulated NOD2 might play a negative 
regulatory role in the action of TLR4. The authors concluded that NOD2 has dual 
effects on TLR4 signaling and exert a novel ligand independent action [33]. Besides, 
TLR4 and NOD2 were significantly associated with Cd in gene-gene interactions 
in pediatric cohort of Cd patients [24]. The role of TLR4 and NOD2 was studied in 
microglia and showed enhanced expression of TLR4 and NOD2 after stimulation 
with LPS in vitro [34].
Carriage of TLR4 +896 mutants enhances the susceptibility to develop MM in the 
single gene analysis of our study. TLR4 recognizes LPS in the outer membrane of N. 
meningitidis [35]. TLR4 triggering in combination with LPS binding protein and CD14 
leads to an intracellular signaling cascade via MyD88 resulting in the transcription of 
NFkB and the subsequent production of pro-inflammatory cytokines [36]. TLR4 +896 
mutant alleles are responsible for hyporesponsiveness to LPS in mice and humans in 
experimental studies [37, 38]. The same TLR4 SNP has been associated with enhanced 
susceptibility to Gram-negative infections in adult surgical ICU patients compared to 
healthy volunteers [39]. In a cohort of children with invasive meningococcal infec-
tions TLR4 +896 was correlated with mortality, increased frequencies of ventilation 
support, application of inotropic substances, skin grafting, and limb loss [40]. The 
proposed mechanism in both studies is immune paralysis due to impaired TLR4 medi-
ated LPS responses with decreased pro-inflammatory cell signaling. An experimental 
study using chimerical TLR4 mutant mice showed that TLR4 on CNS resident cells 
such as microglia is critically required for sustained inflammation in the brain after 
systemic LPS administration independent of systemic cytokines produced upon TLR4 
triggering in hematopoietic cells [41].However, in a cohort of 252 Gambian children 
with serogroup A meningococcal meningitis (of which 120 were culture proven), 
using a retrospective case-control design, no association was found with TLR4 +896 
and susceptibility to MM [42].
We previously described that TLR9 +2848 was associated with protection to develop 
MM. We showed that N. meningitidis has a strong immune inhibitory potential upon 
intracellular recognition by TLR9. The TLR9 +2848 SNP enhances immune responses 
upon triggering by Neisserial CpG motifs, thereby compensating for the inhibitory 
potential [11]. We did not involve TLR9 in our carrier trait analysis since TLR9 SNPs 
were associated with protection against MM instead of enhanced susceptibility. 
A limitation of this study is the retrospective design. We did not include DNA 
analysis of the most severe cases of BM in which a child died. However, includ-
ing the most severe cases probably enhances the associations between SNPs and 
meningitis susceptibility. Although we used large case and control cohorts, TLR4 and 
144 Chapter 8
NOD2 mutant alleles are rare, as seen by large confidence intervals. This may be 
due to selection pressure because of the possible adverse effect of these SNPs. Bigger 
cohorts should be tested and combined with other studies, also in different ethnical 
populations.
The relevance of identifying genetic variation predisposing for MM development is 
that it provides better understanding of the details of MM pathogenesis. It also enables 
the prediction of the individual risk to develop BM and identifies high-risk patients for 
follow up. In order to be applicable in clinical practice this study has to be confirmed 
in a second, independent cohort of MM patients. Secondly, this knowledge has to 
be implemented in clinical practice, for example in existing prediction models and 
has to be clinically validated. The field of Public Health Genomics is involved in this 
translation and embraces the Belaggio statement which says that ‘‘the responsible and 
effective translation of genome-based knowledge and technologies into public policy 
and health services for the benefit of population health’’ (Bellagio statement, 2005: 
see www.graphint.org for details) [43, 44]. 
conclusIons
In this study we show for the first time that TLR4 +896 and NOD2 SNP8 were strongly 
associated with susceptibility to develop MM in a single SNP analysis. Besides, we 
identified two genetic carrier traits. Simultaneous carriage of TLR2 and TLR4 SNPs 
and of TLR4 and NOD2 SNPs showed an even more pronounced and synergistic as-
sociation with susceptibility to develop MM. These data may enable the identification 
of people at risk to develop severe infectious diseases such as MM. 
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The most important thing in communication, 
Is to hear what isn’t being said. 
 
(Drucker)
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aBsTRacT
Genetic variation in innate immune response genes contributes to inter-individual 
differences in disease manifestation and degree of complications upon infection. We 
recently described an association of single nucleotide polymorphisms (SNPs) in TLR9 
with susceptibility to meningococcal meningitis (MM). In this study, we investigate 
the association of SNPs in multiple pathogen recognition and immune response 
genes with clinical features that determine severity and outcome, (especially hearing 
loss) of childhood MM and pneumococcal meningitis (PM). 
Eleven SNPs in seven genes (TLR2, TLR4, TLR9, NOD1, NOD2, CASP1, and TRAIL) 
were genotyped in 393 survivors of childhood bacterial meningitis (BM) (327 MM 
patients and 66 PM patients). Genotype distributions of single SNPs and combination 
of SNPs were compared between thirteen clinical characteristics associated with 
severity of BM. 
After correction for multiple testing, TLR4 +896 mutant alleles were highly associ-
ated with post-meningitis hearing loss, especially MM (p=0.001, OR 4.0 for BM, 
p=0.0004, OR 6.2 for MM). In a multigene analysis, combined carriership of the 
TLR2 +2477 wild type (WT) with TLR4 +896 mutant alleles increases the risk of hear-
ing loss (p < 0.0001, OR 5.7 in BM and p = 0.0001, OR 7.6 in MM). Carriage of one 
or both mutant alleles in TLR4 +896 and TLR9 -1237 increases the risk for hearing 
loss (p = 0.0006, OR 4.1 in BM). 
SNPs in immune response genes contribute to differences in clinical severity and 
outcome of BM. The TLR system seems to play an important role in the immune 
response to BM and subsequent neuronal damage as well as in cochlear inflamma-
tion. Genetic markers may be used for identification of high-risk patients by creating 
prediction rules for post-meningitis hearing loss and other sequelae, and provide 
more insight in the complex immune response in the CNS possibly resulting in new 
therapeutic interventions.
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InTRoducTIon
Bacterial meningitis (BM) is a serious infectious disease of the central nervous system 
(CNS). Despite worldwide immunization programs and improvement of antimicrobial 
and anti-inflammatory therapy, BM is still responsible for substantial mortality in both 
developing and developed countries. The clinical presentation, severity and outcome 
of BM are highly diverse. Mortality is four to ten percent [1] and 20% of survivors 
develop neurological sequelae, ranging from learning and behavioral disorders to 
deafness, seizures, and motor deficits in 13% of cases [2]. Considerable evidence 
implicates that genetic variation in microbial recognition genes is associated with 
altered host responses to infection and the degree of post-infectious complications 
[3].
Pathogen recognition receptors (PRRs), present on various cells, including microg-
lia and astrocytes inside the CNS [4], recognize pathogen-associated molecular pat-
terns (PAMPs). High affinity binding activates nuclear factor kappa B (NFκB) and the 
subsequent genetic transcription of pro-inflammatory cytokines. Toll-like receptors 
(TLRs) and nucleotide-binding oligomerisation domain-containing proteins (NODs) 
are two major groups of PRRs. 
We recently reported an association of single nucleotide polymorphisms (SNPs) in 
TLR9 with susceptibility to meningococcal meningitis (MM) [5]. Several studies have 
shown that SNPs in innate immune response genes affect the clinical course of both 
meningococcal and pneumococcal infections [6]. Three papers focused on genetic 
variation in innate immune response genes and BM specifically [5,7,8]. 
This study aims to assess associations of single SNPs as well as combinations of 
SNPs with severity and clinical outcome in post-meningitis children. The distributions 
of eleven SNPs in seven genes involved in pathogen recognition were related to 
thirteen clinical or laboratory variables of BM severity as described in literature. 
We studied TLR2, an extracellular receptor that recognizes lipoteichoic acid 
(LTA), present in the cell wall of Streptococcus pneumoniae(S. pneumoniae) [9], 
and meningococcal porin [10]. TLR2 activation triggers intracellular signaling via 
myeloid differentiation protein 88 (MyD88), resulting in pro-inflammatory cytokine 
production. TLR2 -/- mice, intracerebrally infected with pneumococci, showed 
higher mortality, aggravated brain bacterial loads, higher tumor necrosis factor alpha 
(TNf-α) concentrations in brain homogenates, and more damage to the blood-brain 
barrier (BBB) [11]. TLR2 -16934 SNPs are associated with higher risk of sepsis caused 
by Gram-positive bacteria [12]. TLR2 +2477 mutants have been associated with a 
reduced responsiveness to Staphylococcus aureus infections [13]. 
TLR4 recognizes lipopolysacharide (LPS) in the outer membrane of Neisseria 
meningitidis (N. meningitidis). TLR4 triggering activates intracellular signaling via 
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MyD88, resulting in NfkB transcription and subsequent cytokine production. TLR4 
+896 mutants cause hypo-responsiveness to LPS [14] and enhance susceptibility 
to invasive meningococcal [15–17] and pneumococcal infections [18]. TLR4 +896 
mutants are also associated with an increased risk of developing invasive disease in 
patients with pneumococcal infections [18]. 
TLR9 is an intracellular PRR, which recognizes unmethylated Cytosine-phosphate-
Guanine (CpG) motives in bacterial DNA [19]. Meningococcal [5] and pneumococ-
cal [20] CpG DNA enters the cell by endocytosis and binds to TLR9. TLR9 activation 
triggers the MyD88 dependant pro-inflammatory pathway. We recently demonstrated 
that the TLR9 +2848 SNP is associated with decreased susceptibility to MM [5]. 
NODs are intracellular pattern recognition receptors containing a Caspase-
recruitment domain (CARD). NOD1 and NOD2 recognize degradation products of 
peptidoglycan (PGN) [21], a unique and essential component of the cell wall of the 
vast majority of bacteria. NOD1 -/- mice are more susceptible than wild type (WT) 
mice to early sepsis after intranasal administration of pneumococci[22]. Isolated 
cultures of murine astrocytes and microglia constitutively express robust levels of 
NOD2 after exposure to both N. meningitidis[23] and S. pneumoniae[24]. NOD1 
+32556 and NOD2 +2209, NOD2 +2722, and NOD2 +3020 SNPs are associated 
with inflammatory bowel disease [25,26] and share a signaling defect in response to 
LPS and PGN [27].
Caspases play an essential role in apoptosis. Activation of intracellular caspase-1 
(CASP1)upon pathogen recognition by TLRs and NODs defends the host against 
infection by secretion of the pro-inflammatory cytokines IL-1β and IL-18 via the IL-1 
receptor, and by the induction of apoptosis of infected cells inside the cell in a mo-
lecular structure called the inflammasome [28]. CASP1 levels are up regulated in CSF 
of patients with BM and correlate with clinical outcome, assessed by the Glasgow 
Coma Scale. CASP1 -/- mice intracerebrally infected with S. pneumoniae show a 
significantly attenuated increase of IL-1β, lower CSf leukocytes and an improved 
clinical status [29]. CASP1 haplotypes are associated with decreased serum IL-18 
levels [30].  
TNf-related apoptosis-inducing ligand (TRAIL) is a protein that induces caspase 
driven apoptosis upon activation. TRAIL limits granulocyte driven inflammation in 
BM. TRAIL levels are elevated in CSf of patients with BM. TRAIL -/- mice show pro-
longed inflammation, augmented clinical impairment, and increased apoptosis in the 
hippocampus following intrathecal application of pneumococcal cell wall solution 
[31]. A highly polymorphic region in TRAIL, including the TRAIL -692 SNP, has been 
identified but not yet linked to human disease [32].
This study aims to describe significant associations of SNPs in innate immune 
response genes with severity and outcome in survivors of childhood BM by compar-
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ing genotype distributions between thirteen clinical severity parameters, including 
hearing loss.
ResulTs
Table 1 shows the patient characteristics and the distribution of the severity variables 
in our study population. Thirteen clinical severity variables were studied, including 
duration of clinical illness before admission, rectal temperature at admission, and 
Table 1.  Patient characteristics and distribution of 13 clinical severity variables in 393 children with 
bacterial meningitis
continuous variables 
Clinical characteristic/
Severity variable
Median (range) total 
BM group 
Median MM 
group
Median pM 
group
Total BM 
(MM/pM)
n
Age at admission (years) 2,2  (0 – 9,5) 2.5 1.0 393 (327/66)
Duration clinical illness 
before admission (days) 
1,0 (0,5 – 11,0) 1.0 2.0 387 (321/66)
Rectal temperature (°C) 39,4 (35,0 – 41,8) 39.2 39.8 362 (299/63)
CSF leukocytes (n/mL) 1013 (0 – 120810) 1243 600 353 (297/56)
CSf blood-glucose ratio 0,30 (0 – 1,77) 0.29 0.18 278 (236/42)
CSf protein concentration  
(g/l)
1,4 (0,01 – 9,33) 1.7 2.1 324 (58/266)
Blood leukocytes (nx10^9 /l) 16,8 (1,3 – 93,5) 16.7 20.3 384 (319/65)
 CRP concentration (mg/L) 137 (0 – 768) 135 158 234 (190/44)
dichotomous variables
Clinical characteristic/
Severity variable
Total BM 
Group 
n
% MM 
n 
% pM 
n
Total 
determined 
n
Male gender 219 56 174 53 45 68 393 (327/66)
Blood culture positive 188 55 143 44 45 68 345 (286/59)
Convulsions 52 13 30 9 22 33 393 (327/66)
Consciousness disturbed 261 69 215 66 46 70 379 (316/63)
ICU-admission 77 20 69 21 8 12 392 (326/66)
Hearing loss 27 7 13 4 14 21 393 (327/66)
Meningitis with sepsis 170 43 147 45 23 35 393
(327/66)
Different numbers within groups are due to missing data in patient records. 
Abbreviations: SD: standard deviation, CSF: cerebrospinal fluid, CRP: C-reactive protein, NM: 
Neisseria meningitidis, SP: Streptococcus pneumoniae, ICU: intensive care unit
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the laboratory variables CSF leukocyte number, CSF/blood glucose ratio, CSF protein 
concentration, blood leukocyte number, C-reactive protein (CRP) concentrations, 
blood culture (positive for meningitis causing organism),  convulsions, disturbed 
consciousness at admission, ICU-admission, hearing loss, and clinical diagnosis at 
Table 2. Genotypes of 11 studied polymorphisms in patients with meningococcal and pneumococcal 
meningitis
SNP Genotype Total BM (n = 393) % MM (n = 327) % PM (n = 66) %
TLR2-16934 
T>A
(rs4696480)
TT
TA 
AA
107
184
102
27
47
26
89
150
88
27
46
27
18
34
14
27
52
21
TLR2+2477 
G>A
(rs5743708)
GG
GA
AA
357
34
2
91
9
1
298
27
2
91
8
1
59
7
0
89
11
0
TLR4+896 
A>G
(rs4986790)
AA
AG
GG
343
37
13
87
9
3
283
33
11
87
10
3
60
4
2
91
6
3
TLR9-1237 
T>C
(rs5743836)
TT
TC
CC
291
95
7
74
24
2
244
76
7
75
23
2
47
18
0
71
29
0
TLR9+2848 
G>A
(rs352140) 
GG
GA
AA
90
193
110
23
49
28
79
162
86
24
50
26
11
31
24
17
47
36
NOD1 +32556 
T- > GG 
(rs6958571)
T-T-
T-GG
GGGG
225
148
20
57
38
5
183
126
18
56
39
6
42
22
2
64
33
3
NOD2 +2209 
C>T
(rs2066844)
CC
CT
TT
349
37
7
89
9
2
290
30
7
89
9
2
59
7
0
89
11
0
NOD2+2722 
G>C
(rs2066845)
GG
GC
CC
384
7
2
98
2
1
318
7
2
97
2
1
66
0
0
100
0
0
NOD2+3020 
ins C 
(rs5743293)
-/-
-/C
C/C
380
12
1
97
3
0
316
10
1
97
3
0
64
2
0
97
3
0
CASP1+8404 
A>G
(rs2282659)
AA
AG
GG
234
132
27
60
34
7
195
112
20
60
34
6
39
20
7
59
30
11
TRAIL-692 
T>C
(rs365238)
TT
TC
CC
317
69
7
81
18
2
266
56
5
81
17
2
51
13
2
77
20
3
Abbreviations: BM: bacterial meningitis, MM: meningococcal meningitis, PM: pneumococcal 
meningitis, TLR: Toll-like receptor, NOD: nucleotide oligomerization domain protein, SNP: single 
nucleotide polymorphism, CASP: caspase, TRAIL: TNf-related apoptosis inducing ligand.
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discharge (meningitis with or without sepsis). Different numbers within groups are 
due to missing or non-determined data in patient records. 
Table 2 shows the genotype distributions of eleven studied SNPs in our study popu-
lation, for MM and PM patients. No significant differences in genotype distributions 
were observed between MM and PM patients. 
power analyses
A priori power analyses show that we have sufficient power at the 80% threshold in 
BM patients. However, for the rare SNPs we were not able to reach the 80% threshold 
in the PM and MM subgroups. Since BM is relatively rare it is hard to obtain large 
numbers of clinically well-defined patients. 
Genotype and allele frequencies 
Continuous variables were compared by T-tests or Mann-Whitney U tests. Duration 
of clinical illness before admission was shorter in TLR2 -16934-AA carriers compared 
to TT and TA carriers (mean 1.3 ± 1.4 days in AA carriers versus 1.8 ± 0.1 days in TT/
TA carriers; p = 0.0042). The other continuous variables did not show differences in 
genotype distributions (data not shown).
Table 3 shows genotype distributions divided by dichotomous severity variables 
with a p-value <0.05 for MM and PM patients separately and combined. TLR4 +896 
AG or GG alleles were associated with significantly increased risk of hearing loss (p 
= 0.001, OR 4.0, 95% CI 1.7 – 9.4) especially in MM patients (p = 0.0004, OR 6.2 
95% CI 2.0 – 19.5), but was not significant for PM patients. Carriage of TLR9 -1237 
TC or CC mutant alleles was associated with an increased risk for hearing loss in BM, 
especially in PM patients (p = 0.023, OR 2,5, 95% CI 1.1-5.4 and p = 0.017, OR 
5.0, 95% CI 1.4 – 17.4, respectively). CASP1 +8404 GG alleles were associated with 
a decreased incidence of fever in BM and MM patients (p = 0.01, OR 0.3, 95% CI 
0.1 – 0.8 and p = 0.018 OR 0.3, 95% CI 0.1 - 0.9). These associations showed a trend, 
but appeared not statistically significant after stringent correction for multiple testing 
according to Holm-Bonferroni (p < 0.003). No differences in genotype distributions 
were observed for other SNPs classified by severity variables. 
Multigene analysis
Combined carriership of TLR2 +2477 GG WT and TLR4 +896 AG mutant alleles 
significantly increases the risk to develop hearing loss in BM (p < 0.0001, OR 5.7, 
95% CI 2.3 – 14.4, in MM patients: p = 0.0001, OR 7.6, 95% CI 2.3 – 24, in PM 
patients: p = 0.03, OR 13.9, 95% CI 1.3 – 147). Carriage of one or more mutant 
alleles in combined carriership of TLR4 +896 and TLR9 -1237 increases the risk for 
hearing loss in BM patients (p = 0.0006, OR 4.1, 95% CI 1.8 – 9.4, in MM patients: 
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p = 0.02, OR 4.3 95% CI 1.3 – 14.2, in PM patients: p = 0.003, OR 6.0, 95% CI 
1.7 – 21.3). No significant results were observed for combined carriership of TLR2 
-16934 and TLR2 +2477, neither for multiple SNPs in all three NOD2 SNPs, with 
regard to the other severity variables (data not shown).
Multiple regression analyses 
Backward stepwise logistic regression with hearing loss as dependent variable 
resulted in a model containing blood culture, TLR2, TLR4, TLR9, CASP1, age at 
diagnosis, rectal temperature, CSf glucose levels, and gender. All other variables 
were excluded from the model during analyses. These variables accurately (97,8%) 
predicted BM patients with hearing loss (p = 0.017). Analyses were repeated for MM 
and PM patients separately. The same set of variables predicts hearing loss (98,2%) in 
PM patients (p = 0.043), but not in MM patients. 
dIscussIon
In this study we demonstrate for the first time that polymorphisms in pathogen rec-
ognition receptor genes affect the clinical course of BM. After correction for multiple 
testing, we conclude that duration of clinical illness before admission was shorter 
in TLR2- 16934-AA carriers compared to TT or TA carriers. TLR4 +896 mutants are 
highly associated with post-meningitis hearing loss and combined carriership of 
the TLR2 +2477 WT with TLR4 +896 mutant alleles as well as the combination of 
TLR4 +896 mutant alleles with TLR9 -1237 mutant alleles significantly increases this 
risk. In multivariable regression analysis, the same genes are identified to predict 
hearing loss. In order to explain these findings, we focus on the pathogenesis of post-
meningitis hearing loss. Since hearing loss occurs in more than 11% of PM survivors 
and 5% of MM survivors [2] most studies focus on PM. Bacteria spread from the 
infected subarachnoid space to the inner ear through the cochlear aqueduct, along 
the eighth cranial nerve or the blood vessels of the blood-labyrinth barrier [33]. In the 
peri-lymphatic spaces they induce a suppurative labyrinthitis. As a result, the blood-
labyrinth barrier and hair cells are damaged and neurons in the spiral ganglion show 
apoptosis. The inner ear is, similar to the brain, a so-called immune privileged site: 
the number of immune competent cells is small and opsonizing agents are virtually 
absent under normal conditions [34]. Once bacteria have reached the inner ear, they 
multiply uncontrolled and bacterial autolysis occurs, leading to the release of bacte-
rial components. The host innate immune response will be induced by recognition 
of these components by PRRs and lead to the transcription of cytokines by resident 
immunocompetent cells, the local endothelial cells and fibrocytes [34]. There is 
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increasing evidence for a role of TLRs in mediating cochlear damage in meningitis 
[33]. Pneumolysin, recognized by TLR4, has been identified as a mediator of cochlear 
damage by its direct cytotoxic effects and via activation of the immune response 
[35]. Experimental meningitis due to pneumolysin-deficient pneumococci causes 
less hearing loss than meningitis due to WT pneumococci [36]. The innate immune 
response of TLR2/TLR4 double-knockout mice to intracisternal pneumococcal infec-
tion was more severely impaired than that of mice lacking only TLR2 or TLR4 [37]. 
Inside the cochlea these receptors are also present. Activation of these local TLRs then 
activates MyD88, which in turn activates NfκB. MyD88 -/- mice with experimental 
PM show less cochlear inflammation than infected WT mice [38]. All together, these 
findings show that an intact pathogen recognition system via MyD88 is important 
for bacterial clearance from the CNS but also responsible for inflammatory damage. 
TLR2, 4 and 9 are all involved in this pathway, explaining the significance of our trait 
analysis.
No experimental studies on the mechanisms of hearing loss in MM are published. 
However, since TLR2, 4 and 9 are also activated by meningococcal PAMPs [10,21] 
we suggest that the mechanism of TLR induced MyD88-dependant cochlear dam-
age might be similar to those in PM. Hyporesponsiveness to LPS leading to higher 
bacterial loads in TLR4 SNP carriers might enhance MyD88-dependant inflam-
mation and subsequent damage [14]. Upregulation of detrimental TLR4-mediated 
immune responses might be an alternative explanation for hearing loss in MM [39]. 
The TLR4 +896 polymorphism is shown to change the ligand-binding site of the 
receptor and results in a LPS hypo-responsive phenotype [14]. In gene association 
studies, increased susceptibility to Gram-negative infections has been demonstrated 
[15,16], but results from meningococcal infections did not consistently show this 
effect [7,40]. We suspect that other SNPs might compensate for the TLR4 mediated 
hyporesponsiveness to LPS, as we show in the carrier trait analysis. Combined car-
riership of TLR2 +2477 GG (WT) and TLR4 +896 AG (mutants) increased the risk 
to develop post-meningitis hearing loss, indicating that TLR2 SNPs compensate for 
TLR4 mutant hyporesponsiveness.  Carriage of one or more mutants in combined 
carriership of TLR4 +896 and TLR9 -1237 increases the risk for hearing loss in BM 
patients. The link between TLR4 and TLR9 was also shown in a murine in vitro study 
on macrophage cytokine production upon TLR9 mediated CpG DNA stimulation. 
Pretreatment of these macrophages with TLR4 mediated LPS heightened the TNf-α 
and IL-6 production [41]. Recent evidence indicates that the TLR9 -1237 C allele 
results in an increased TLR9 initiated immune response via an extra putative binding 
site for NfκB [42], which may lead to increased immune-mediated cochlear damage. 
Another study on TLR9 -1237 SNPs showed higher serum Interferon gamma levels 
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in children with cerebral malaria, indicating that enhanced TLR9 mediated immune 
responses are also relevant inside the CNS [43]. 
This study consists of a unique large cohort of survivors of BM in childhood includ-
ing genetic as well as clinical data. Since we used two independent cohorts, internal 
validation has been applied.  However, interpretation of the results of this study has 
some limitations. Sample sizes were small for the pneumococcus- and for the hearing 
loss- groups. Different results were found for S. pneumoniae and N. meningitidis. This 
may either be due to an increased incidence of hearing loss in the PM group (21%) 
compared to 4% in the MM group, or to differences in pathogenesis and recognition 
of these two different pathogens by TLR9. TLR9 is shown to recognize both menin-
gococci and pneumococci, but the ability to activate TLR9 was severely attenuated 
when bacteria had been heat-inactivated prior to stimulation in vitro [44]. Since S. 
pneumoniae is associated with higher bacterial loads in the CSf compared to N. 
meningitidis, the presence of a higher bacterial load in PM in the cochlea may also 
explain the stronger association in PM with hearing loss.
In order to assess the influence of clinical as well as genetic factors on the course 
of disease, larger numbers of patients and SNPs are needed preferably with prospec-
tive data and an association study should be repeated in a third, large preferable 
ethnically different cohort in the future to confirm the associations we found. Other 
SNPs involved in the bacterial infection might be relevant in BM e.g. macrophage 
migration inhibitory factor (MIF) Toll-interleukin 1 receptor domain containing adap-
tor protein (TIRAP) and complement mediated inflammation. 
Our study provides evidence that SNPs in pathogen recognition receptor genes 
affect the severity of disease in a specific way. It should be mentioned that this type of 
study is hypothesis generating, but does not prove causation. The exact mechanisms 
how these SNPs affect the course of disease and hearing loss in particular are an 
interesting focus of further research in experimental models. 
Determination of SNPs in an early stage of BM may be useful to identify children at 
risk to develop sequelae and to add host genetic markers to current clinical prediction 
rules on complications after BM such as hearing loss and academic and behavioral 
limitations [45,46].
Indentifying high-risk patients may also provide opportunities for specific individual 
therapeutic modifications to prevent the damage that occurs during the necessary im-
mune response aimed at bacterial clearance from the CNS. Unraveling the molecular 
basis of the inflammatory responses inside the CNS might facilitate the development 
of specific and targeted anti-inflammatory therapy in high-risk patients.
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MaTeRIals and MeThods
patients
Figure 1 shows a flow chart of patient inclusion in this study. The cohort of school age 
children in part with post-meningitis hearing loss is composed of two independent 
cohorts. Both cohorts were described in detail in other studies [45,46]. Both cohorts 
appeared to be rather similar [47] and no significant differences in genotype distribu-
tions were observed between both cohorts. Only Dutch Caucasian survivors of PM 
and MM were selected for this study.
669 eligible
Cohort 1 
877 non-Hib
meningitis patients
38 other causative 
Organisms
639
522 MM
117 PM
45 non-Dutch-
Caucasian
594 Dutch-
Caucasians
471
Included/ 
genotyped
393
327 MM
66 PM
78 - not all
SNPS could be
genotyped
Cohort 2
116 non- hib
meningitis patiens
2 other causative
organisms
114
92 MM
22 PM
37 non-Dutch 
Caucasian
77 Dutch
Caucasians
figure 1. flow chart of patient inclusion in this study
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Six hundred sixty nine (669) patients were eligible for our study and were asked 
to participate in the study and to return a sterile swab after collecting their buccal 
DNA. Of these patients a total of 471 (70%) returned a buccal swab and an informed 
consent form. Only samples with high quality DNA in which all eleven SNPs could 
be genotyped after three distinct Taqman and/or Lightcyler analyses were included 
in this study (n = 393 including 327 MM patients and 66 PM patients). The median 
age of all patients at the time of infection was 2.2 years (range 0.1 – 9.5), 56 % were 
male and 44 % were female. All patients were selected from data on bacterial CSf 
isolates of the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM). 
The NRLBM receives approximately 90% of the isolates of Dutch meningitis patients. 
The diagnosis meningitis was based on the demonstration of pathogens or antigens 
against PM or MM in the CSf by culture. Children with ‘complex onset’ of meningitis 
(defined as meningitis secondary to immune deficiency states, cranial trauma, CNS 
surgery, and CSf shunt infections, meningitis in the neonatal period) or relapsing 
meningitis were not included. The Medical Ethical Committee of the VU University 
Medical Center approved this study.
clinical variables
Data on medical history, physical examination, clinical course during hospitaliza-
tion, and laboratory results were gathered retrospectively from the medical records 
of all patients. Detailed information on CSf culture results was collected from the 
NRLBM. We used clinical factors with regard to severity and outcome of BM in 
children that could potentially be linked to genetic variation as currently accepted 
in literature. These variables were in concordance with a recent systematic review 
summarizing the evidence regarding prognostic factors predicting death or sequelae 
after BM in children [48]. Only variables with a reasonable incidence (>5% cases) 
were included. Continuous clinical severity variables include: duration of clinical 
illness before admission and rectal temperature at admission. Rectal temperature was 
dichotomized to the presence of fever, i.e. rectal temperature ≥ 38°C. Continuous 
laboratory values at admission include: CSF leukocyte number, CSF/blood glucose ra-
tio, CSf protein concentration, blood leukocyte number, and CRP concentration. The 
dichotomous severity variables include: causing pathogen in CSf culture, meningitis 
causing pathogen in blood culture, convulsions present, disturbed consciousness 
at admission, ICU-admission, post-meningitis hearing loss, and meningitis with or 
without sepsis. 
Convulsions were defined as convulsions reported before or at admission or during 
hospitalization. Hearing loss was defined as an unilateral or bilateral perceptive hear-
ing loss > 25 dB that was not present before meningitis occurred and was based on 
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information from medical records and parental information provided from question-
naires about the children’s health [45]. Conductive hearing loss was not included. 
Missing data
Patients in which not all 11 SNPs could be genotyped after 3 PCR assays were ex-
cluded in order to increase the continuity of our data (see figure 1). Missing clinical 
data (Table 1) range from 0% in most cases to 40% in CRP. 
DNA Isolation
DNA was isolated from the buccal swabs using the following procedure: after addi-
tion of 250ml 10mM Tris-HCl (pH 7.4) the sample was heated at 96 degrees Celsius 
for 10 minutes. After mixing for 10 seconds the swabs were removed and the sample 
was centrifuged (14.000 rpm). 
Genotyping
All samples were genotyped for the TLR2 -16934 T>A (NCBI SNP CLUSTER ID: 
rs4696480), TLR2 +2477 G>A (rs5743708), TLR4 +896 A>G (rs4986790), NOD1 
+32556 (T->GG) (rs6958571),NOD2 +2209 C>T (rs2066844), NOD2 +2722 G>C 
(rs2066845), NOD2 +3020 ins C (rs5743293), CASP1 +8404 A>G (rs2282659), and 
TRAIL -692 T>C (rs365238) SNPs by real-time PCR using the TaqMan AbiPrism® 7000 
Sequence Detection System (Applied Biosystems, UK) with the standard TaqMan 
protocol and the the LightCycler® 480 System (Roche Applied Science, US). Two 
independent researchers analyzed the results. TLR9 -1237 T>C (rs5743836) and TLR9 
+2848 G>A (rs352140) were genotyped in a previous study [5] and were used in this 
multigene study. 
statistics
Prior to this study power analyses were performed using G*Power 3.1. Since no prior 
SNP frequencies in BM patients with hearing loss were available, we had to estimate 
the distribution in cases on similar studies and experience.
Within selected severity groups, we compared the distribution of SNP alleles. for 
statistical analysis, SPSS for Windows 17.0 (IBM Corporation, Somers, New York) and 
Graphpad Instat Prism® 5 were used. Genotype frequencies of all 11 SNPs were com-
pared between the aforementioned severity groups. Genotypic models of inheritance 
were used to assess the relation between genetic and clinical variables. Significant as-
sociations were further explored for recessive or dominant models. Histograms were 
used to assess normality. T-tests, Mann-Whitney U tests, and χ2 test or fisher’s exact 
tests were used where appropriate. Outliers were excluded (< 4%) by the Grubbs’ test 
(p < 0.01) before continuous testing. Next, continuous variables were dichotomized 
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based on clinical relevant cut-off points as described in literature [45,46] or as used 
in clinical practice. After Holm-Bonferroni correction for multiple testing, p-values < 
0.003 were considered to be statistically significant.
Multigene analysis
Combinations of SNPs within the same gene or in the same biological pathway 
were studied in variables that showed a significant or trend association in one of the 
SNPs. Studied combinations of SNPs are: TLR2 -16934, TLR2 +2477, and TLR4 +896 
(stimulating MyD88 via TIRAP and triggering the intracellular signaling cascade), 
TLR4+896, TLR9-1237 and TLR9+2848[49] (activating the MyD88 pathway) and the 
three NOD2 SNPs (+2209, +2722 and +3020). 
Clinical and genetic variables were modeled using backward stepwise logistic 
regression.
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hosT-paThoGen InTeRacTIons
This thesis consists of studies on innate immune reponses in (myco) bacterial menin-
gitis and focuses on pathogenesis and outcome of disease. Interactions between host 
and pathogen determine these phenomena. On the one hand, outcome of bacterial 
meningitis (BM) depends on the infecting organism and the timing of antimicrobial 
therapy. On the other hand, aggravating knowledge on host factors has proven to 
be unequivocally important [1]. In other words, the pathogen determines the host 
response but not every host responds identical. Differences in host immune responses 
are largely driven by genetic variation [2,3]. Immune responses are aimed at killing 
or silencing pathogens, but the armamentarium of the host consists of recognizing 
receptors, signaling proteins, phagocytosing cells, and ultimately, reactive oxygen 
radicals and proteolytic enzymes which also frequently result in collateral damage of 
healthy cells and tissues, thereby influencing outcome of disease [4, 5].
paThoGenesIs of (Myco) BacTeRIal MenInGITIs
Tuberculous meningitis
The pathogenesis of tuberculosis (TB) and the development of tuberculous meningitis 
(TBM) is a complicated interplay between mycobacteria and the specific host im-
mune response. Granuloma formation is a very characteristic hallmark of mycobacte-
rial infection [6]. TBM results from hematogenous dissemination of Mycobacterium 
tuberculosis (M. tub) to the central nervous system (CNS) after primary pulmonary 
infection. However, TBM develops not directly by hematogenous spread of bacilli to 
the meninges but by release of bacilli into the cerebrospinal fluid (CSF) from focal 
granulomatous lesions, called Rich foci, which are typically located subpial or sub-
ependymal [7]. Recent studies show the dynamic interactions between mycobacteria 
and granuloma: infected macrophages attract uninfected macrophages and aggregate 
in an organized way to form granuloma, the hallmark of mycobacterial infection [8].
Animal models designed to study the pathogenesis and immune response in TBM 
are reviewed in Chapter 3. Evaluating the available animal models to study TBM, the 
rabbit model seems to most closely mimic human TBM. The mouse model however, 
is superior in terms of studying the immunological response. We developed a new 
mouse model to study the pathogenesis of TBM (Chapter 4). We were able to develop 
a reproducible in vivo model to study the inflammatory response in TBM. However, 
this model has limitations in terms of translation to human disease: although the route 
of infection mimics the natural way, mice did not show clinical signs of disease, con-
trary to human disease, and also the cytokine profile was different from that of human 
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disease. On the other hand, we did find bacterial growth of TB in the CNS that leads 
to a chronic inflammatory response in terms of chemokine production. We intend 
to use this model to further analyze the role played by the innate immunity in TBM, 
especially the role played by Toll-like receptors (TLRs) and other signaling pathways 
that orchestrate the immunological response. Other authors have used the mouse 
model since then for detailed studies of TBM pathogenesis. Be et al. focused on the 
crucial step in the pathogenesis of TBM, which is entering the CNS after primary 
pulmonary infection upon bacteremia. Using the mouse model after intravenous 
infection with M. tub they were able to identify genetic determinants for CNS inva-
sion by pooled infection with genotypically defined M. tub mutants. They were able 
to identify five bacterial genes required for invasion or survival in the CNS [9]. Lee 
et al. described the specific immune response in the CNS after direct intracerebral 
infection of mice with Mycobacterium bovis BCG strain and found specific T-cells in 
the brain, similar as in peripheral blood but also a subset of activated T-cells unique 
to the CNS. These cells originate from microglial and dendritic sources indicating a 
specific local inflammatory response inside the CNS [10]. 
The ultimate goal of these kind of experimental studies is to translate the results 
into disease modifying strategies in humans and apply them to prevention, early 
recognition, targeted therapy and guided follow up. Against this background we ret-
rospectively studied a large cohort of 554 children with TBM in South Africa (Chapter 
2) and found that TBM starts with non-specific symptoms and is often only diagnosed 
when brain damage has already occurred. Recent poor weight gain, low-grade fever, 
vomiting, and recent contact with a TB patient are important clues for early diagnosis 
of TBM and outcome is directly associated with stage of disease. Ethnicity, progressed 
stage of disease, headache, convulsions, affected motor functions, brainstem dys-
function, and cerebral infarctions were independently associated with poor outcome 
in multivariate logistic regression analysis.
We are currently studying the inflammatory response in a prospective cohort of 
children with TBM in South Africa to further unravel the cells, proteins and genes 
involved in human TBM pathogenesis. 
Bacterial meningitis
The sequential steps in the pathogenesis of non-mycobacterial BM from the patho-
gen’s perspective are: (a) nasopharyngeal colonization with bacteria that have the 
potential to cause BM; (b) epithelial disruption by bacterial components, enabling 
these bacteria to enter the bloodstream where they replicate and cause bacteremia 
[11, 12]; (c) pathogen specific passage of the BBB and bacterial multiplication inside 
the subarachnoidal space; (d) bacterial recognition inside the CNS by microglia and 
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astrocytes and by non-neuronal structures in direct contact with the cerebrospinal 
fluid (CSF), such as dendritic cells and macrophages, all expressing pathogen 
recognition receptors (PRRs) including TLRs and nucleotide-binding oligomeriza-
tion domain (NOD) proteins. Activation of PRRs triggers an intracellular signaling 
cascade resulting in (e) transcription of pro-inflammatory cytokines and chemokines 
inside the CNS. Cytokine induced increased permeability of the BBB and chemokine 
induced influx of inflammatory cells from the bloodstream into the CNS then results 
in enhancement of the local inflammatory response inside the brain. The clinical 
consequence of these events is brain edema, raised intracranial pressure, infarction 
and neuronal injury. The ability of a host to sense CNS invasion by microbes and to 
respond appropriately to control the local infection is essential for killing microbes 
but the inflammatory response also results in the production of several cytotoxic 
mediators responsible for damage to healthy neuronal cells and thus for adverse 
disease outcome [13]. 
GeneTIc VaRIaTIon In IMMune Response Genes
Immune response genes have been found to be polymorphic. This genetic variation 
allows for a more sophisticated repertoire and enables the host to better withstand 
microbial challenges. While this is most probable advantageous on a population level 
and acts as evolutionary drive, there may be less favorable outcomes for individuals 
in terms of suppressed or aggravated immune responses affecting susceptibility and 
severity of infectious diseases.
In Chapter 5 we have discussed the stages of BM pathogenesis in detail and have 
reviewed studies on SNPs in genes involved in pathogen acquisition, epithelial 
interactions, and mechanisms that predispose for bloodstream infection. Next, we 
focused on the effect of genetic variation in pathogen recognition and the subsequent 
inflammatory response, both in the bloodstream and inside the CNS. Although we did 
not find studies that exclusively focused on BM, we identified several SNPs predis-
posing to invasive pneumococcal and meningococcal disease.
In order to specifically study the role of genetic variation in immune response genes 
on susceptibility to pneumococcal and meningococcal meningitis we designed a 
case-control study with 472 survivors of childhood BM (83 patients with pneumococ-
cal meningitis [PM; 18%] and 389 patients with meningococcal meningitis [MM; 
82%]). We found a significant effect of genetic variation in the gene encoding for 
Toll-like receptor 9 (TLR9) (Chapter 6). Genotype frequencies of two TLR9 SNPs were 
compared with healthy ethnically matched adults and TLR9 +2848-A alleles occured 
significantly more frequent in controls than in survivors of MM, implying a protective 
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effect. A functional biological explanation of this phenomenon, which we studied in 
silico, is that meningococci have a strong immune inhibitory potential upon trigger-
ing of TLR9, an intracellular endomosal receptor, and that the polymorphism affects 
this potential in favor of the immune response. 
In a second experiment in the same cohort we studied eight SNPs in five immune 
response genes and compared the genotype frequencies with healthy ethnically 
matched controls that were genotyped for the same genes. In the single gene analysis 
we found that TLR4 +896 and NOD2 SNP8 were significantly associated with sus-
ceptibility to develop MM. In a genetic trait analysis we found that the combinations 
of TLR2 with TLR4 SNPs and TLR4 with NOD2 SNPs were strongly associated with 
susceptibility to MM (Chapter 8). 
After genotyping our cohort of BM survivors we also analyzed the effect of the SNPs 
in immune response genes on the severity of BM. We clustered our patients accord-
ing to thirteen clinical and laboratory severity parameters described in the literature 
and compared genotype frequencies in order to relate SNPs to severity parameters. In 
Chapter 7 we described that two TLR9 SNPs were associated with protection against 
bacteremia. Carriers of the mutant alleles of these SNPs also showed enhanced local 
inflammatory responses inside the CNS reflected by higher leukocytes and lower glu-
cose levels in CSf. In other words, carriage of mutant alleles for TLR9 protect against 
bloodstream infection upon nasopharyngeal carriage; in the unanticipated case that 
meningococci eventually reach the bloodstream and cross the blood-brain barrier, 
carriers of the mutant alleles have a better immune response inside the CNS aimed 
at effective removal of the pathogen from the CNS. The immune response attempts 
to achievie bacterial clearance but neuronal and cochlear damage does also occur, 
as described in Chapter 9. In the latter study we used a multigene approach to study 
the relation between genetic variation of immune response genes and severity of BM. 
The single gene analysis showed that TLR4 +896 was associated with post-meningitis 
hearing loss. In a trait analysis, we found that combined carriage of this SNP with 
TLR9 -1237 mutant alleles or TLR2 wild type enhanced this association.
The most relevant SNPs we found in our BM susceptibility and severity studies were 
in TLR2, TLR4, TLR9, and NOD2. Besides the identification of statistically significant 
differences in genotype frequencies in a case-control comparison, the challenge is to 
identify the functional relation between genetic variation in individuals and the effec-
tive response in case of pathogen acquisition. Animal models are very suitable in this 
perspective as are in vitro studies, and in an era of swiftly developing computational 
possibilities, in silico analyses are also of added value.
TLR2, an extracellular receptor on immune cells, recognizes lipoteichoic acid 
(LTA), present in the cell wall of pneumococci, and in meningococcal porin [14,15]. 
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TLR2 activation triggers intracellular signaling via myeloid differentiation protein 88 
(MyD88), resulting in pro-inflammatory cytokine production. TLR2 -/- mice, intrace-
rebrally infected with SP, showed higher mortality, aggravated brain bacterial loads, 
higher tumor necrosis factor alpha (TNf-a) concentrations in brain homogenates, 
and more damage to the blood-brain barrier (BBB) [16]. Variation in TLR2 has been 
reported to alter the susceptibility to various inflammatory and infectious diseases 
and has been suggested to cause impaired function of the intracellular domain of the 
TLR2 protein [17]. The impaired intracellular domain fails to interact with MyD88, 
which subsequently lowers the production of inflammatory cytokines especially 
IL-2. The polymorphism in TLR2 +2477 has been reported to increase the risk of 
Gram-negative sepsis in a Caucasian population and is associated with susceptibility 
to mycobacterial infection [17,18]. In genetic trait analysis we linked this SNP to 
susceptibility and severity of MM in our studies. 
TLR4 recognizes lipopolysacharide (LPS) in the outer membrane of Gram-negative 
bacteria. TLR4 triggering activates intracellular signaling via MyD88, resulting in 
NfkB transcription and subsequent cytokine production. TLR4 SNPs are present in 
10% of Caucasian populations and are reported to have a positive correlation with 
susceptibility to several infectious diseases, including Gram-negative sepsis. The 
SNPs disrupt the normal structure of the extracellular region of TLR4 and are therefore 
hypothesized to decrease responsiveness to LPS through alterations in binding. fur-
thermore, mutant TLR4-transfected cell lines have been shown to elicit a decreased 
LPS-induced immune response, resulting in lower levels of cytokine production [3]. 
TLR4 +896 mutants cause hypo-responsiveness to LPS in mice and humans and are 
associated with human invasive meningococcal and pneumococcal disease [19-22]. 
We found that carriage of TLR4 +896 was associated with susceptibility to MM, even 
stronger in a trait with TLR2 +2477 or NOD2. furthermore, we found that carriage of 
TLR4 +896 was significantly associated with post-meningitis hearing loss. Traits with 
TLR2 +2477 or with TLR9 -1237 made the associations even stronger.
TLR9 is an intracellular PRR, which recognizes unmethylated Cytosine-phosphate-
Guanine (CpG) motifs in bacterial DNA and TLR9 activation triggers the MyD88 
dependant pro-inflammatory pathway [23]. Polymorphisms in TLR9 have been 
described in association with asthma in a European-American population and with 
Crohn’s disease [24, 25].  Lange et al. used an in vitro luciferase assay on a human 
cell-line to show that the CC genotype of the TLR9 -1237 SNP resulted in a higher 
TLR9 promoter activity [26]. Another study showed in silico that carriage of the variant 
C-allele creates a putative NfkB binding site. This extra binding site was postulated to 
enhance the transcriptional activation of TLR9 and potentially affects activation upon 
triggering by bacterial DNA motifs [27]. We also used this method in our study on 
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genetically determined MM severity that was described in detail by Macintyre et al. 
as a new technique for in silico regulatory SNP detection (is-rSNP) [28]. 
Clinical application of genetic susceptibility and severity associations we found is 
the next step. The rapidly evolving field of Public Health Genomics (PHG) translates 
immunogenetic knowledge into health care policies in order to enhance population 
health. PGH activities are, amongst others, represented by large EU funded consortia 
such as PHGEN-II and the international GRaPH-Int consortium. The European Center 
of PHG (ECPHG) promotes translational research on the integration of genome-based 
knowledge and technologies into policies and practices, applying methods such as 
health needs assessment (HNA) and policy impact assement (PIA). Together, these 
efforts should improve health care on national, European and international levels, 
establishing a knowledge database for evidence-based policy-making. ECPHG orga-
nizes meetings, which are open to the scientific community, policy-makers, relevant 
stakeholders and the general public.
fuTuRe peRspecTIVes
With the experience from studying genetic variation in BM susceptibility and sever-
ity, we plan to apply this to TBM as well. Many investigations have confirmed that 
genetic factors are involved in developing disease upon infection with TB and these 
include adoption studies, twin studies, genome-wide linkage, and population-based 
case–control association studies [29]. Additional evidence confirming that TB suscep-
tibility is genetically determined was the discovery that individuals with mutations in 
genes of the interleukin (IL)-12/IL-23/interferon-gamma (IFN-γ) axis have an increased 
susceptibility to even non-pathogenic mycobacteria [30]. An extensive review of TB 
susceptibility genes summarizes polymorhisms in genes involved in cellular receptors 
such as TLRs, cytokines and chemokines, vitamin D and its receptor (VDR), intracel-
lular transporters, antigen presentation, opsonization, bacterial killing by nitric oxide 
(NO), T-cell regulation, and apoptosis. The authors concluded that SNPs in IfNG, 
NRAMP1, and NOS2A have been validated in several ethnically different cohorts. 
SNPs with equivocal associations with TB susceptibility that have been described 
are those in TLR2, TLR9, IL10, CCL2, DC-SIGN, P2RX7, VDR, and SP110 [29]. The 
recently described TNfRSf1B SNP might also be associated with TB susceptibility but 
remains to be validated in replication cohorts [31]. Recently, a SNP on chromosome 
18 (rs4331426) was strongly associated with susceptibility to TB in a genome wide 
association study in three cohorts from the Gambia, Ghana, and Malawi. Although 
it seems a susceptibility locus not associated with major histocompatibility complex 
genes, which is rare in infectious diseases, the functional consequence has not been 
discussion 177
C
H
A
PT
ER
 1
0
clarified yet [32]. In a hypothesis generating study, genetic variation of IL1B, VDR, and 
TLR2 was associated with an increased risk of extrapulmonary disease but the authors 
state that additional studies of the underlying mechanism of these genetic variants 
are warranted [33]. In a large Vietnamese cohort of TBM patients Thuong et al. found 
that a polymorphism in human TLR2 is associated with increased susceptibility to 
TBM [34]. In two ethnically different cohorts in South Africa, Levin et al. found that 
genetic variation of TIRAP, a gene encoding for a signaling receptor downstream of 
TLR2 and TLR4, both associated with mycobacterial recognition, does not appear 
to be involved in childhood TB susceptibility, but might play a role in determining 
occurrence of TBM in specific ethnic populations [35]. All these studies show enough 
leads to perform a prospective genetic search in a cohort of TBM patients. Figure 1 
illustrates human genes and immune response pathways involved in susceptibility 
and severity of TB in general, which we intend to study in TBM specifically.
concludInG ReMaRks
Studying the pathogenesis of BM consists of several strategies. Disease may be 
studied in human cases or case series. A more structured approach is studying well 
Mycobacterium tuberculosis 
Immature T cell 
H+ 
Fe2+ 
NO 
Opsonization Cytokines Antigen presentation 
Apoptosis and T-cell downregulation 
Receptors Chemokines Transporters 
Bacterial killing 
Antigen presenting cell 
Infected cell 
Monocyte 
Endosome TLR1  
TLR2 
 
TLR4 
 
TLR8 
 
TLR9 
 
TIRAP 
CCL2 
 
 
NRAMP1 
 
NOS2A 
 
MBL2 DC-SIGN 
 
IFNG 
 
IL12 
 
IL23 
 
 
IL1 
 
IL8 
 
IL10 
SP110 
 
IFNGR 
 
IL12R
 
 
TNFRSF1B  
 
VDR  
 
P2RX7 
 
 
Macrophage 
figure 1. Human genes and immune response pathways potentially involved in susceptibility and 
severity of TBM
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defined cohorts and compare characteristics between groups. This may be done using 
a retrospective but preferably a prospective approach. Another method is to develop 
a disease model in which specific elements of disease pathogenesis might be studied 
in detail. Animal models are widely used but also in vitro techniques such as cell 
cultures, or in silico techniques, are valuable tools. These kind of studies are very 
suitable for testing hypotheses and therapeutic interventions.
SNPs in immune response genes contribute to differences in susceptibility and clini-
cal severity as well as outcome of BM. Innate immune responses plays an important 
role in host defense to BM and subsequent neuronal and cochlear damage. Genetic 
markers may be used for identification of high-risk patients by creating prediction 
rules for post-meningitis hearing loss and other sequelae, and provide more insight in 
the complex immune response inside the CNS, possibly resulting in new therapeutic 
interventions.
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To achieve great things, 
Two things are needed: 
A plan, and not quite enough time. 
 
(Bernstein)
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suMMaRy
Human beings are in constant interaction with microbial pathogens and evolution 
has mostly selected for peaceful coexistence. Successful survival is determined by 
host-pathogen interactions at a cellular level: coexistence with mutual advantages on 
the one hand and protective immune responses on the other hand. Human immune 
responses to infectious diseases are aimed at removal of the causative pathogen but 
are also frequently responsible for damage to the host cells and tissues. Variation of 
genes encoding for immune receptors and signaling proteins affect the susceptibility 
to and severity of infectious diseases such as bacterial meningitis (BM).
The studies described in this thesis aim to unravel the details of the pathogenesis 
and host immune response to BM and how genetic variation affects these processes 
and thereby the outcome of disease.
paRT I focuses on meningitis caused by Mycobacterium tuberculosis (M. tub). 
Chapter 2 describes a retrospective cohort study of 554 children with tuberculous 
meningitis (TBM) in South Africa, a country with incidence figures of this disease 
ranging among the highest worldwide. In this study the relationship between present-
ing clinical characteristics and outcome of pediatric TBM was described. Variables 
independently associated with poor clinical outcome were ethnicity, stage of disease, 
headache, convulsions, motor function, brainstem dysfunction, and cerebral infarc-
tions. TBM starts with nonspecific symptoms and is mostly diagnosed when brain 
damage has already occurred, so the focus should be on early diagnosis.
In order to better understand the details of TBM pathogenesis and subsequent 
inflammatory responses, animal studies are of eminent importance. Chapter 3 sum-
marizes animal models that have studied TBM pathogenesis, especially granuloma 
formation, and local immune responses inside the central nervous system (CNS). 
Animal models are crucial to our understanding of both host and bacterial factors in 
TBM. The non-human primates are irreplaceable for drug and vaccine testing. The 
rabbit model seems to most closely mimic human TBM. The murine model however, 
is superior in terms of studying the immunological response and is ideal to study the 
genetics of host defense. 
Chapter 4 describes the development of a new murine model to study the patho-
genesis of TBM focusing on inflammatory mediators in the CNS. Direct intracerebral 
inoculation with M. tub induced development of granuloma in the mouse brain 
and mimics human TBM pathogenesis with secondary subependymal Rich foci after 
primary pulmonary infection. Although the cytokine and chemokine patterns differ 
from human disease, this model may well be used to study detailed inflammatory 
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responses inside the brain, identifying the receptors and proteins involved and the 
genetic basis it depends on.
paRT II focuses on meningitis caused by Neisseria meningitidis (NM) and Strepto-
coccus pneumoniae (SP) and how genetic variation influences the innate immune 
responses upon BM, thereby affecting susceptibility, course of disease and prognosis. 
In Chapter 5, studies that describe associations with single nucleotide polymorphisms 
(SNPs) in large cohorts of patients with invasive pneumococcal and meningococcal 
disease, including meningitis, were summarized and applied to the pathogenesis of 
BM. Studies on genes involved in adhesion to epithelial surfaces, pathogen recogni-
tion, complement and cytokine responses, important steps in meningitis pathogen-
esis, were the focus of this review. Although several SNPs with a significant effect on 
susceptibility to pneumococcal and meningococcal disease have been described, no 
study focused exclusively on BM.
In Chapter 6 the discovery of a significant association with variation in the Toll-like 
receptor 9 (TLR9) gene and the susceptibility to develop meningococcal meningitis is 
described. The TLR9 +2848-A allele was significantly more frequent in 392 controls 
than in 389 survivors of meningococcal meningitis indicating a protective effect of 
this SNP. The biological consequence of this SNP seemed that it alters the ability 
of TLR9 to respond to molecular motifs of meningococci, resulting in upregulated 
immune responses and thus protecting against severe disease upon meningococcal 
infection.
Chapter 7 describes a study that compares TLR9 genotypes amongst BM survivors 
clustered according to variables determining severity of disease. Both TLR9 -1237 
and TLR9 +2848 SNPs are associated with a decreased incidence of bacteremia with 
NM and also with a more pronounced inflammatory response inside the CNS in terms 
of significantly higher levels of pleocytosis and significantly more decreased glucose 
levels in cerebrospinal fluid. Thus, people carrying either of these SNPs will be rela-
tively protected to develop meningococcemia upon infection with N. meningitidis. 
However, in case of unanticipated bacteremia and possible subsequent meningitis, 
they are able to develop more pronounced TLR9 induced inflammatory responses 
inside their brain immune cells, resulting in more efficient removal of meningococci 
from the CNS but also more neuronal damage, reflected by an increased chance to 
develop post meningitis hearing loss.
In Chapter 8 a study on BM susceptibility using a multigene approach is described. 
Genotype frequencies of SNPs in TLR2, TLR4, NOD1, NOD2, and CASP1 in 473 
survivors of childhood BM were compared to healthy ethnically matched controls. 
TLR4 +896 and NOD2 SNP8 were significantly associated with susceptibility to 
develop MM. Besides, we identified two genetic traits consisting of the combinations 
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of TLR2 and TLR4 SNPs as well as TLR4 and NOD2 SNPs, both strongly associated 
with susceptibility to meningococcal meningitis.
Chapter 9 describes a study that compares genotypes of 11 SNPs in seven immune 
response genes (TLR2, TLR4, TLR9, NOD1, NOD2, CASP1 and TRAIL) amongst 393 
BM survivors clustered according to 13 clinical validated severity variables. TLR4 
+896 mutant alleles are highly associated with post-meningitis hearing loss. In a 
multigene analysis, combined carriage of the TLR2 +2477 wild type with TLR4 +896 
mutant alleles increases the risk of hearing loss. Carriage of one or both mutant alleles 
in TLR4 +896 and TLR9 -1237 also increases the risk of post-meningitis hearing loss.
SNPs in immune response genes contribute to differences in susceptibility and clini-
cal severities as well as outcome of BM. Innate immune responses play an important 
role in host defense to BM and subsequent neuronal and cochlear damage. Genetic 
markers may be used for identification of high-risk patients by creating prediction 
rules for post-meningitis hearing loss and other sequelae, and provide more insight 
in the complex immune response in the CNS, possibly resulting in new therapeutic 
interventions.
Parijs is nog ver… 
 
(Zoetemelk)
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saMenVaTTInG
De mensheid is in voortdurende interactie met al dan niet pathogene micro-organis-
men en de evolutie heeft vooral geselecteerd op vreedzame co-existentie van beide. 
Succesvolle overleving voor de mens als soort wordt bepaald door de interacties tus-
sen gastheer en pathogeen, vooral op cellulair niveau: co-existentie met wederzijds 
voordeel aan de ene kant en beschermende afweerreacties aan de andere kant. De 
menselijke afweerreacties tegen infectieziekten zijn gericht op het elimineren van 
het veroorzakende pathogeen maar zijn vaak ook verantwoordelijk voor schade aan 
gezonde cellen en weefsels van de gastheer. Variatie in genen die coderen voor bij 
de afweer betrokken receptoren en signaaleiwitten beïnvloeden de vatbaarheid voor, 
en de ernst van, infectieziekten zoals bacteriële meningitis (BM). 
De studies in dit proefschrift hebben als doel de details van de pathofysiologie en 
de gastheerrespons in geval van BM te ontrafelen en te achterhalen hoe genetische 
variatie bovengenoemde processen beïnvloedt en daarmee de uitkomst van ziekte.
In deel I wordt ingegaan op meningitis veroorzaakt door Mycobacterium tuberculosis 
(M. tub). In hoofdstuk 2 wordt een retrospectief cohort van 554 kinderen met tuber-
culeuze meningitis (TBM) in Zuid-Afrika beschreven, een land met incidentiecijfers 
voor deze ziekte die tot de hoogste wereldwijd behoren. In deze studie wordt de rela-
tie tussen presenterende symptomen in relatie tot de uitkomst na het doormaken van 
TBM beschreven. Variabelen die onafhankelijk geassocieerd waren met een slechte 
prognose waren etniciteit, verder gevorderd ziektestadium, hoofdpijn, convulsies, 
aangedane motorische functies, hersenstamstoornissen en cerebrale infarcering. TBM 
begint met aspecifieke symptomen en de diagnose wordt meestal pas gesteld als er al 
irreversibele neurologische schade is optreden. Alle inspanningen zijn gericht op het 
eerder stellen van de diagnose. 
Om de details van de pathofysiologie en de inflammatoire reacties in geval van 
TBM beter te onderzoeken en te begrijpen zijn proefdierstudies van eminent belang. 
In hoofdstuk 3 wordt een overzicht gepresenteerd van proefdiermodellen die ontwik-
keld zijn om de pathofysiologie, en dan met name granuloomvorming en de lokale 
afweerreactie, in het centraal zenuwstelsel (CZS) in geval van TBM te bestuderen. Het 
bestuderen van TBM in proefdiermodellen is essentieel voor het begrip van zowel 
de gastheerfactoren als de pathogeen geassocieerde factoren. Studies met mensapen 
zijn onvervangbaar voor de laatste testfase van geneesmiddelen en vaccin onderzoek. 
Het konijnenmodel lijkt menselijke ziekte het meest nauwgezet na te bootsen. Het 
muizenmodel is echter superieur in het bestuderen van de details van de immunolo-
gische respons en is tevens zeer geschikt om de genetica van de afweer te bestuderen.
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In hoofdstuk 4 wordt een nieuw muizenmodel beschreven om de pathofysiologie 
van TBM te bestuderen en vooral de inflammatoire mediatoren in het CZS. Recht-
streekse intracerebrale inoculatie van M. tub genereert granuloomvorming in de 
muizenhersenen en bootst menselijke TBM pathogenese na waarbij subependymale 
Rich foci ontstaan na primaire pulmonale infectie. Hoewel de patronen van cytokine 
en chemokine responsen verschillen van de menselijke situatie, lijkt het wel een 
geschikt model om de inflammatoire respons in de hersenen te bestuderen en de 
receptoren en eiwitten die daarbij betrokken zijn te identificeren.
deel II beschouwt meningitis veroorzaakt door Neisseria meningitidis (NM) en 
Streptococcus pneumoniae (SP) en gaat in op de invloed van genetische variatie op 
de primaire aangeboren afweerreacties in geval van BM en hoe dit de prognose beïn-
vloedt. In hoofdstuk 5 wordt een overzicht gegeven van bestudeerde polymorfismen 
(SNPs) in patiëntencohorten met invasieve pneumokokken of invasieve meningokok-
ken ziekte, inclusief meningitis. De SNPs worden beschreven in het kader van de 
essentiële stappen in de pathogenese van BM. Studies met betrekking tot genen die 
de epitheliale adhesie beïnvloeden, de aangeboren herkenning van pathogenen, en 
genen die coderen voor complement en cytokinen, worden samengevat. Hoewel er 
verscheidende SNPs zijn beschreven met een duidelijke invloed op de gevoeligheid 
voor het ontwikkelen van ernstige infecties met pneumokokken of meningokokken, 
zijn er nauwelijks studies die zich specifiek gericht hebben op BM.
In hoofdstuk 6 wordt de ontdekking van een significante associatie beschreven 
met variatie in het gen dat codeert voor Toll-like receptor 9 (TLR9) en de gevoelig-
heid voor het krijgen van meningokokkenmeningitis. Het TLR9 +2824-A allel werd 
significant vaker gevonden bij 392 controles in vergelijking met 389 overlevers van 
meningokokkenmeningitis op de kinderleeftijd hetgeen een beschermend effect van 
deze SNP impliceert. De biologische consequentie van deze genetische variatie lijkt 
gelegen in het feit dat het de mogelijkheid van TLR9, om moleculaire motieven op 
het oppervlak van meningokokken te herkennen, beïnvloedt. Het heeft tot gevolg dat 
de afweerreactie ten gunste wordt beïnvloed, waarmee het beschermt tegen ernstige 
ziekte in het geval van kolonisatie met meningokokken.
In hoofdstuk 7 wordt een studie beschreven die TLR9 genotypen vergelijkt bin-
nen de groep van meningitis overlevers die geclusterd zijn op grond van variabelen 
die de ernst van ziekte bepalen. Zowel TLR9 -1237 als TLR9 +2848 SNPs waren 
geassocieerd met een verlaagde incidentie van bacteriëmie  met NM maar ook met 
een meer uitgesproken lokale inflammatoire respons in het CZS, weerspiegeld door 
een hoger celgetal in de liquor en lagere glucosewaardes in liquor in vergelijking 
met die in het bloed. Het lijkt er dus op dat dragers van een van deze SNPs relatief 
beschermd zijn tegen het krijgen van bacteriëmie of sepsis met meningokokken. In 
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geval van onverhoopte aquisitie van een dergelijk pathogeen in de bloedbaan en 
daarop volgende meningitis zijn zij beter in staat het micro-organisme te klaren uit de 
liquor, echter wel tegen de prijs van neuronale schade, weerspiegeld door een hogere 
incidentie van gehoorsverlies na het doormaken van meningitis.
Hoofdstuk 8 beschrijft een studie naar de vatbaarheid voor BM waarbij naar 
meerdere bij de afweer betrokken genen wordt gekeken. Genotype frequenties van 
SNPs in TLR2, TLR4,  NOD1, NOD2, and CASP1 van 473 overlevers van BM op de 
kinderleeftijd werden vergeleken met gezonde en etnisch vergelijkbare controles. 
TLR4 +896 en NOD2 SNP8 waren significant geassocieerd met vatbaarheid voor 
meningokokkenmeningitis. Daarnaast konden we twee combinaties van aan elkaar 
gerelateerde genen onderscheiden, namelijk TLR2 en TLR4 SNPs alsmede TLR4 en 
NOD2 SNPs, die beiden sterk geassocieerd waren met vatbaarheid voor meningo-
kokkenmeningitis.
Hoofdstuk 9 beschrijft een de genotypeverdeling van 11 SNPs in 7 immuunrespons-
genen (TLR2, TLR4, TLR9, NOD1, NOD2, CASP1 and TRAIL) over 393 overlevers van 
BM die geclusterd waren op grond van 13 klinisch gevalideerde variabelen voor ernst 
van ziekte. TLR4 +896 mutante allelen waren sterk geassocieerd met gehoorsverlies 
na het doormaken van meningitis. In een multigenanalyse bleek het gecombineerde 
dragerschap van TLR2 +2477 wild type met TLR4 +896 mutante allelen het risico op 
gehoorsverlies te vergoten. Dragerschap van een of meer mutante allelen van TLR4 
+896 of TLR9 -1237 vergrootte ook het risico op gehoorsverlies na het doormaken 
van meningitis.
SNPs in immuunresponsgenen dragen bij aan de vatbaarheid en de klinische ernst 
alsmede de prognose  van BM. De aangeboren eerstelijns afweer speelt een belang-
rijke rol in de afweer tegen BM en daaraan gerelateerde neuronale en cochleaire 
schade. Genetische markers kunnen gebruikt worden om hoog risico patiënten te 
identificeren door voorspelregels te ontwikkelen om het patiëntspecifieke risico op 
gehoorsverlies en andere lange termijn gevolgen van BM te inventariseren. Daarnaast 
geeft het meer inzicht in de ingewikkelde immuunrespons in het CZS, hetgeen moge-
lijk weer resulteert in nieuwe therapeutische strategieën.
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aBBReVIaTIons
A Adenine
Asp Asparagin
AUC area under the curve
BMEC brain microvascular endothelial cell
BBB blood-brain barrier
BCG BacilleCalmette-Guerin
BM bacterial meningitis
C Cytosine
CARD caspase-recruitment domain
Cbp choline-binding protein
CCL chemokine (C-C motif) ligand
CD cluster of differentiation
Cd Crohn’s disease
CEACAM human carcinogenic embryonic antigen cell adhesion molecules
Cf complement factor
CfU colony forming unit
CH communicating hydrocephalus
ChoP phosphorycholine
CI confidence interval
CNS central nervous system
CpG Cytosine-phosphate-Guanine
CRP C-reactive protein
CSF cerebrospinal fluid
CT computed tomography
DC-SIGN  dendritic cell-specific intercellular adhesion molecule-3-grabbing 
non-integrin
DNA deoxyribonucleic acid
ECPHG European Center of PHG
G Guanine
GCS Glasgow Coma Scale
Gly Glycin
Hib Haemophilus influenzae type b
HNA health needs assessment
HIV human immunodeficiency virus
hsp heat shock protein
HWE Hardy-Weinberg equilibrium
IfN-g interferon-gamma
204 addendum
IL interleukin
IMD invasive meningococcal disease
IPD invasive pneumococcal disease
IQR interquartile range
IRAK4 IL-1 receptor-associated kinase 4
is-rSNP in silico regulatory SNP detection
KC murine neutrophil chemoattracktant
KO knock-out
LPS lipopolysaccharide
LTA lipoteichoic acid
MAPK mitogen-activated protein kinase
MBL mannose-binding lectin
MCP monocyte chemoattracktant protein
MDR multi-drug resistant
MIf macrophage inhibitory factor
MIP macrophage inflammatory protein
MM meningococcal meningitis
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
M. tub Mycobacterium tuberculosis
MyD88 myeloid differentiation primary response gene (88)
Nan neuraminidase
NCH non-communicating hydrocephalus
NEMO NfkB essential modulator protein
NfkB nuclear factor kappa B
NLR NOD like receptor
NM Neisseria meningitidis
NO nitric oxide
NOD nucleotide-binding oligomerization domain
Nramp1 natural resistance-associated protein 1
Op opacity-associated adhesion protein
OR odds ratio
P2RX7 P2X purinoceptor 7
PAMP pathogen-associated molecular pattern
PCR polymerase chain reaction
PGN peptidoglycan
PHG public health genomics
PIA policy impact assessment
PM pneumococcal meningitis
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Por porin
PRR pathogen recognition receptor
Psp pneumococcal surface protein
RelA avian reticuloendotheliosis viral oncogene homolog A
rfDR rough false discovery rate
rs reference SNP (unique number in SNP database)
SAS subarachnoid space
SNP single nucleotide polymorphism
SP Streptococcus pneumoniae
Sp surfactant protein
SP110 Sp110 nuclear body protein
STAT signal transducer and activator of transcription
T Thymine
TB tuberculosis
TBM tuberculous meningitis
TIR Toll-interleukin 1
TIRAP TIR-domain-containing adaptor protein
TNf-a tumour necrosis factor-alpha
TNfRSf1B TNf-receptor superfamily member 1B
TLR Toll-like receptor
TRAIL TNf-related apoptosis-inducing ligand
TRIf TIR-domain-containing adaptor-inducing interferon-b
VDR vitamin D receptor
VPS ventriculoperitoneal shunt
WT wild type
XDR extensive drug resistant
Als een boek begint te leven, 
Moet de schrijver zwijgen. 
 
(Nietzsche)
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